var title_f16_20_16704="Gram stain sputum 12A answer";
var content_f16_20_16704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and poorly- staining, large, septate hyphae which tend to branch at acute angles. Filamentous fungi are usually better seen by wet mount or silver stain. Aspergillus fumigatus grew from this specimen on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16704=[""].join("\n");
var outline_f16_20_16704=null;
var title_f16_20_16705="Neobladder PI";
var content_f16_20_16705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Orthotopic neobladder (also called Studer neobladder or pouch)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts one option for people who have a cystectomy (removal of bladder) due to bladder cancer. A new bladder may be created from a segment of bowel. The new bladder is connected to the urethra, allowing the person to urinate normally. This is called an orthotopic neobladder (commonly referred to as a Studer neobladder or pouch).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16705=[""].join("\n");
var outline_f16_20_16705=null;
var title_f16_20_16706="Patient information: Sex as you get older (The Basics)";
var content_f16_20_16706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sex as you get older (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10874487\">",
"      <span class=\"h1\">",
"       How does sex change as you get older?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sex can still be very satisfying as you get older, but it can change in a number of ways.",
"     </p>",
"     <p>",
"      As men get older they might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have less interest in sex",
"       </li>",
"       <li>",
"        Need more stimulation to get or stay erect or be unable to get erect",
"       </li>",
"       <li>",
"        Have trouble reaching orgasm",
"       </li>",
"       <li>",
"        Have orgasms that are less intense or satisfying than they were when they were younger",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      As women get older they might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have less interest in sex",
"       </li>",
"       <li>",
"        Have trouble getting aroused or lubricated",
"       </li>",
"       <li>",
"        Have pain or discomfort during sex (this can happen because the vagina can become dry and thin after menopause)",
"       </li>",
"       <li>",
"        Have trouble reaching orgasm",
"       </li>",
"       <li>",
"        Have orgasms that are less intense or satisfying than they were when they were younger",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10874502\">",
"      <span class=\"h1\">",
"       What causes sex problems as you get older?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many things that can lead to decreased interest or ability to have sex as you age. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lower hormones &ndash; As people age, their bodies makes less sex hormones. That&rsquo;s especially true for women who have gone through menopause (the time in a woman&rsquo;s life when she stops having monthly periods). But hormones change in men, too. In women, the decrease in hormones is more sudden, especially if they have had had their ovaries removed.",
"       </li>",
"       <li>",
"        Other medical conditions &ndash; Medical conditions, such as diabetes, heart disease, obesity, high blood pressure, and chronic pain, can decrease a person&rsquo;s interest in or ability to have sex. In men, diabetes is a major cause of problems with erections, because it damages nerves and blood vessels.",
"       </li>",
"       <li>",
"        Past surgery or medical treatment &ndash; Men who have had surgery or radiation therapy to treat prostate cancer often develop problems with erections. Men who have certain treatments for an enlarged prostate can have problems with orgasm. Women who have had surgery to treat problems with their bladder or sex organs can also have problems with sex.",
"       </li>",
"       <li>",
"        Depression or anxiety &ndash; As people get older, they sometimes have problems with depression or anxiety. These conditions can also lead to problems with sex.",
"       </li>",
"       <li>",
"        Smoking in men &ndash; Men who smoke cigarettes are more likely than men who don&rsquo;t smoke to have problems with erections.",
"       </li>",
"       <li>",
"        Medicines &ndash; Some of the medicines older people take to control diabetes, high blood pressure, heart disease, depression, and other conditions can have side effects that cause problems with sex.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10874517\">",
"      <span class=\"h1\">",
"       Should I see my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are happy with the quality and amount of sex you have, no, you do not need to see your doctor or nurse. But if you are not satisfied with your sex life, yes, see your doctor or nurse. He or she might have treatments or solutions to suggest.",
"     </p>",
"     <p>",
"      When you go, bring all the medicines you take, including any non-prescription or herbal medicines. Also, be honest about what is going on. Talking about sex can be embarrassing, but doctors and nurses are used to talking about it. Your doctor or nurse will be better able to help you if he or she understands exactly what is happening.",
"     </p>",
"     <p>",
"      To help with your problem, the doctor or nurse might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Switch you to medicines that are less likely to cause problems (or lower your dose)",
"       </li>",
"       <li>",
"        Suggest hormones or medicines to improve sex",
"       </li>",
"       <li>",
"        Suggest lubricants or devices that can improve sex or arousal",
"       </li>",
"       <li>",
"        Recommend that you speak to a counselor or therapist",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10874532\">",
"      <span class=\"h1\">",
"       What if I had a heart attack or other major health crisis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had a heart attack or other health crisis, the idea of having sex might scare you. Many people who have had a heart attack or similar crisis can have sex safely afterward. Check with your doctor and follow his or her instructions. You will probably need to wait some time after your health crisis is over before you have sex. And you might need to change what you do during sex. But chances are good you will be able to have sex safely again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10874547\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to improve my sex life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Try to stay relaxed about your situation and work around the problems that limit you. Be open to trying new things and adapting.",
"     </p>",
"     <p>",
"      If you have a condition that causes pain or stiffness, such as arthritis, try to schedule sex at a time when you are at your best and your pain medicines are most effective. If you are less flexible than you used to be, try different positions or ask your partner if he or she can help. Be open with your partner and explain what is going on with you. Also, encourage your partner to seek treatment for any physical or sexual problems he or she might have. That way the 2 of you can be at your best when you try to be intimate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10874562\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/20/16706?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85805 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16706=[""].join("\n");
var outline_f16_20_16706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874487\">",
"      How does sex change as you get older?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874502\">",
"      What causes sex problems as you get older?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874517\">",
"      Should I see my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874532\">",
"      What if I had a heart attack or other major health crisis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874547\">",
"      Is there anything I can do on my own to improve my sex life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10874562\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16707="Burch suture placement";
var content_f16_20_16707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Suture placement in endopelvic fascia for Burch procedure (retropubic colposuspension)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 299px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAErAg8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKjjmikd0jkR3Q4YKwJX60ss0cTRiWREMjbEDMBubBOB6nAJx7UAPoqNriFZvKaWMS7d2wsM4zjOPTPFSUAFFFFABRRRQAUUUUAFFM81POEWTvK7sYPT60+gAooooAKKKKACiiigAoopnnRhGYyJtU7SdwwDnGPrmgB9FFR/aIfOaLzY/NXG5Nw3DOcZHvg4+hoAkopk80cEe+eRI0yBudgBknAGT6kgfjT6ACiiigAooooAKKKjkmiiZFllRGc4UMwGfpQBJRRUH2y2+yC6+0Q/ZiARNvGwg9Du6UAT0UisGztIODg4PeloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJ4/DWsRaTq2rWaLa39tc6vLapBbFLqfzLmYrucn5lIwyqBz8hzwM29auLvVb4XE9vrX9lxa1C8WyzuElWH7GwZlUKJAN5IJA6ntXT2vjPTriCa5WG6WyjnW3+0lVKMxl8rOAxZQGPO4Kcc9Oadd+MLGGVooLe9u5d88apBGDuMG0SkFiBhS2OvUEDmgDi3tdckWKeW1vppPISON5YC0hhGpAxh8j74g2ls8jBJrq/Br3D3dwdUOrjVi0wnSdJRahRL8nlkjy/u7cbTkgndznEieONNeMuIL4b1t3gBiGbhJ2KRMgzwCwI+baR1IAqpdeOUiv7RYtPu5YDa30tzCqL58D28kKsCN23GJGPBOcLtzkZAO0orBbxXpa+Z+8lZlmghVRGcyecoZGUd1wSSe2xvSqdp4ztL7T7O+tYJktLq4iiilmxiRXBIZdhbnA+62CO4FAHVUVj+Gdft/EVl9ssoLhLVgrRSS7cSqwyGXaxxx2OGHcCtigAooooAyNQ1COz1SQOWLJYyXAG3jCMM859xxj8a0LFpXsrd7jb5zRqX2jA3Y5x7ZrndfUP4rsLeTPl3mmXtvn/azCcflu/Kug02TztOtZMAb4lbA7ZAoAs0UUUAUdQnnjvdNigKBZpmEu7GdgjY8e+7bV6sVpmm8ZpApPl2tgZHGeMySALx9In/OtqgAooooAK8bu/COqSaHq0ipJ9jm1W7vXsfKYyyTi+lEcgGOUMRRv+2aEcE17JXIan43tobHUJLa3uA8Md6LeWaMCKaa23h4wQc8FGPIAIBweDgA524k8WDVdXe3nu01JWvfs1ubWZreWMRyfZgH/wBSvIiJPDZ3KetMtLa6XXpbrTbXWZ4JJ9OJe/hl8xtvn7+ZRkAErnGAN3GBXXP4y0+21W007UA1vPcoCkjPHsY+X5hAXdvAAB+YqFyMZzimSeNbGKwhu57O+hjuWRbQTLHGbncrMCpZwFG1STvKkcZGSAQDh4v7ev4LlJLfVDbzpZTvbTQXLeRMLuMuoeXO4hcklAqYXIHGa9hrkn8faQLVLmJLye3+zrdyyRRAiCIuyFm57MjAhcnjgGnXHjnTbbfHcQXUV6s5g+ySeWkmQiybslwm3a6nJbvjrxQB1dFcsvjnSpTbvbLdT20qW0rXCRgJEtw22Itkg8twQASO4A5q/wCGddOuDUCbGe1Fpdy2oaQgrLsdk3Aj/dyRjjPU0AbVFFFABXD+N9Dutb8U6THDb2rwf2ZfxSTXlqZ4oy8lrjjIG8gMQCRkK3vXcVjat4ittN1W100w3Fxd3CGUJCF+VAwUt8zDPJHC5b2oA5axm1jT9UtNHJ1adIdVRfPeB2R7MWgGWl27eZByM53VzWn2WqHwlDY2ltrJjXTFW8guoJgBcCeLyxErgdE87ds4wFJ55r0afxfpcMDSu02V+1F0EfzILbPmkjsAcAHvuX1quPGtkJiktjqMW14VkaSJQI1mYLFI3zfdZjjAywwdwA5oA56P+0I9RlTVU1qDSzcX7xnT4ZQ7S/aP3Zby13Y2ZKk/I3O7PFelVxes+PLe20PVruytp/Nt7K8uLV7hMRXD2wbeowc8EdwMjJGcHGrb+KrKS5+zzwXdrP8AaktSk8YGGdC8bHBICsBgZ5zgEA0Ab9FczY+M9O1DVIrGwhu7h3G8uqqFRC7or4LBmUmNiCoPGCcAio9I8Z2mo3drZxQTS3UsYlk8kDbEjO6Kx3EMQTG2dqnGOcCgDqqKKKACiikbO0464oAbBKs8KSICFcZGetPrN8Nu0nh/TXc7na3QsSepKjNaVABTZZFijZ3ztXk4BJ/IU6qWuSeTouoS/wBy3kb8lJoAu0VFasz20TvjcyAnHripaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkL7wXA0OuTxyNeahqFlJaD7XsRMNkgMY0DEZx8zbmAHB5Ob1h4Us7S20qMSzs1hay2ofIzL5u3zHbIJLErnOepPWuhooA4vVvA6yWunppd5PBNarY24kdlJENvLvDD5CC+Ceo2njgVoQ+D7GNhI1xdyTm3u4JJXZd0v2l42kdsKBuzEoGAABxjpjpKKAOWj8JxL4p0/UsjydP08WkJ3nzHf5lDsMAZRGcKR/z2k4HGW2ngawt7mS5a7vJbqSeG4eYiKMs0W/bkIiqf8AWNlsbjxzgADq6KAMPw74attDu767innuLq9EYmllWNC2zdjiNFUn52yxBJ4ycAYsXWsLY3LpqFvNb2+fkusb4j/vEcp/wIAe9alFADIZY5ollhdZI3GVdDkEeoNPrIm0KFJHm0uWTTbhjuZrfGxz6tGflP1wD70z7fqGnnGqWf2iEf8AL1ZKWx/vRcsP+A7vwoAy9SuRdeOPD4AKiBrxee5EaDP/AI8a3vDxY6HYlySxhUkn6VyWnalZXfi2GZLiGS1gs76WSRGBA33EajOOhwh4ru4o0iiSONQqIAqqOgA6CgY6iiigRz2jky+MfEUhHEaWtuPwV3/9qV0NcjBcvbap4raI4dL21cn/AGDFCD+gauuoAKKKKACuJsvBCGyvo9av55Ulm1F4oo2QR26XMsrFlOwNv2SYO4sAS2OK7avI9fi12+8P6/bBNZlvpdN1JbyJo5fKZ8H7OsHG0k8ACPqpO75sUAdVZeEdGvpEvrPUp7qwe4N15UUkTwSSCMwsSwXcRjcMbsA9MYxVn/hDIGsrS2l1XU5fsTI1nJIYWa32qyYH7vDAqxB3hieD1Gad4qtZ7Twultp11exmOVMsiTTSSJuyUJizIoPTcvIrlX1TxDFp8w+x6zDJcafaC0jWKW4KSrcTeaWfZlSYzCf3m1iMdwaAOsn8H2dzbXkVzd3krXdkLGWQmNWKB3bICoFDZkPQYwBxRqHg6xvNUm1IXF3BfSTeaJo/LbZ+7WMqFdGUqQik5B5GQRXNIt9o/iHU7iOPWPLfXFnnWOCWWN7ZrcDcoVSG/ebQQuSNvIAFWdKGvaldaH9on1W1h8nUp5gUMYd1uovs6SErkAoWwOCQD2zQBvyeErOVLgTXN3I9wtqsjkoCfs8hdDgKAMk84GMdAK0NH0iPSpb429xcPFdTtceTJtKxOxLOVIUNyTnBJ9sV5tp3/CSPpExvdR1aC8aCI3cR0+7f98JF3hXGcBhvX9xwAQw6c+g+DZbmbw3ZvfW1xbT/ADqY7iR5HwHYKxZwHwQARuAYAgHnNAG1RRRQAVg+J/DNt4jESX9xcLboQTCixlWIIOcshZTx1QqffpW9RQByieEIJtW8UXd3hF1iIWy+SxykZiCO3IwrsQM4BGI06nNXLrwrY3Jui8tyPtC2qvhl4Fu5dMcdyefbpit+igDhrHwEk2j3dnrd/cz+fHfW6JEyBLeO5dixj+QHftYDLbsHOODzo+J/Cw1PTtbjtJWS71TyAZHfAgMZG2RMDO9cbh6so5A5rqKKAObu/B2n3M+lEyTR2umGE21qix7IzEQUwxQyL0UEKwBAwRgnMA8DWGdMV7u8kg0+VZ4YnERAdZDIG37N45xkKwBAwQQTnq6KAM/UZtRglSSytYbqDHzx+ZslznqpPynjscfWm2OtWd3P9n3Pb3gGTbXC+XJ+AP3h7rke9aVVr+xtdQg8m9t4p4s52uucH1HofcUAWagu7lbZYywJMkixqB3JOP0GT+FZf9n6jYHOl3n2iEf8ut8xbH+7Lyw/4Fu/Cs+416L+3NOg1aKXTDGksxFwR5bMAqja4O0/fbg4PTigDU8JZHhvT1PVIgh59OP6Vr1zfhGNxDbM54FjCcZ43OXYnH5V0lABWT4rYjw9eopw0yiAfVyE/wDZq1qyPEpJhsI+0l9AD+Dhv/ZaANZQFUAcADApaKKACiiqWr6lb6TZG6uy+zekarGhd3dmCqqgckkkCgC7RVDTdTivkOYbi1lDmPyrmPy3JABO3swwRypI69waj/t/ShqIsTqFsLowLdBC4G6Jt2GB6EfK3Q9BnpQBp0VDLd28QcyzxIEOG3OBtOM4PpxzUUepWMl2LWO9tnujGJRCsql9h6NtznHv0oAt0VW0/ULLUoWl0+7t7uJWKF4JFcBh2JB61ZoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopGYKMsQB6mqsup2ELFZb61Rh1DTKD/OgC3RVe3vrS5z9muoJsdfLkDY/I1YoAKhvJxa2ss7KziNS21Bkn2A9ampsiCRCrZ2n0OKAPMoNEW/8SXzy7re6821sTNbvsYFENzL04YFpAMEEcD0r0PTYr2FHS/uIrnB/dyLHsYj/AGhnGfcYHsK5jw9BLNpL6tADJO2qXF3sHV03vFt+vlgY9wK7MHIzQNhRRRQI4eWTbrXjjb/DBbH8fLb/AOtXcVxFoTNrfip4lLrPqFrZDaM52xRl8+wDN+Rrt6ACiiigBk0iQxPLK4SNFLMzHAAHJJqrot6dS0q2vTH5a3C+ai552HlSfcrg47Zql4oJntYNMQ/PqEogbB5EX3pD/wB8Aj6sK2QAoAUAAcACgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5zxOyxi+mIz5emyrggEEuRtGO/K10dct4gKy6jJCVB3yWUX1/fMxH5LQBHo2gtYyXf9i3b2fkskCxOvmQsFRf4Scjkn7pXrW9p1zfSSvDqFkIXUZE0UgeJ/pnDA+xH4mjRTvtHkPG+eVv/H2A/QVfoAKyPEgxFp79dl9B+rbf/Zq16yfFDbNKDjqtzbkf9/koA1qKKKACsvxLYtqWjzWq2dne7ypMF27JG2GB+8qsVIIBBAOCBWpXPeO76/07Q4Z9KmihuW1Cyg3SJuXbJdRRsCPcOR64Jxg4IAMOw8M63Y3dnexSW0rW91K8dlcX80qQRPEqELM6F2O5d20gAbiARjmivgTU00G2sA2nPL/wjsOjyys7Dy5YkbDJ8nzKxbBztIHPPStWbxZqFrdySTW9vJZw3x054Ylbz2kEPmF15xjPRcZ2/Nu7Ve8Ka9fajdxwaglo32iwh1GJ7XdtRZCRsYknPThhjdz8oxyAZkvhTUNTubmfVodM23Gq2189usjTJ5cUSoRlkXJyuRxiq7eBpxqd55kNtd2UtzNcxGS+li2eZEybDEqEEAMUyGHykcZHMN14q1LT01eOyYXd7Dd3kwgkiMn7iIJ/EZEVFBYDJJPPCmlPjHVoV1u+KwTWizWUNpb7Pmia4SDG5sjcAZGODgk4AI7AHSeCtJ1LSbe6j1OaNkZ1+zxrL5zRIqAbTJ5aFuRxkEgdz26SuJtfEXiCa/03TpNNtYLq4e48x7gmMGOLyiHVFLYJEmNpbjGc+uHqHjTUbvT7xYvkt7iyW/sb2GMwlo/OjXgF2YghwdxCd+KAPUqKKKACiiigAooooAKKKKACiiigAopH3bG2EBscEjIBrhLmWwu3eNk1DxTeBvmjh+W0Vh/CeREAPQlm9c0AdBd+KdJgkeKG4a9uV6wWMbXDg+hCA4/HFQf2xrt4caf4eaBCMiXUblIh/wB8R72/A4/Cq1jY+Jbi2jR5dM8P2w+7bWEX2iRR6b2AQfgh+tQ6pouiW648S63fXZcZ8u7vzGH+kUexT/3yaAKWp6vNZziLXfHOk6dMB81rYwRiT8PMZ2J/4D+FUTc6bdENHL441wN/FCJ7eP8ANREp/Ct7T7iy06B4/CXhaY8cMlstlGx/2mcKx+oVqtTS+IRCZr690TSYuuCrz7fYuzRj9KAPNPH19YeE/D5164+H+20gmi8+TU5YJpHjL4ZVBkc7+ciug0mwv3sYLqT4Z+HVlkXzMRTwqQCcqOY+oXGeeuayvH8ngfV4LGLxv45tJ0t5vOhSIwBRIuOcBWz7g5GCa6S31axuLeOe18S+KbuCVA8csGm70dT0ZWW2wR34oAgk0tJjuvvhdp7gHP7p7R2+o3bf51XEHg62P+m+G9Z0Qg/eFtcRrn/fgJUfnWgupbSwj8QeK0PUefohYf8ApMOPxpsnia9sVAPiHS5jnldR0+azOPd84H120wH6db6LeN/xTXje+jl6CJdSW7wfQpNvP4cGtUWPjG3ULDrmj3Y/vXOmurAevySgH8hXOx+KdJ10Y1vw/pWoEkBXsry11BWGM5AJV/yU1NFF4HtXwsl5oDvkANLc6cv4ZKofwpAXtK0XxZ4bs0g03UNN1m3DM5gvIjaMpZixCSJuAXJOAyE/7VWj4p1m0AOq+DtVRScGSxmhulH4Bg+P+A06w0qK5iD6L4u1N1H8SXUV0D9d6N/Op10fxCn3fFLuP+mthET/AOO7aAK7eP8ARoQxvoNZscf8/Ok3Kj8whB/OmTeNhdxlfDOi6rrFwR8pNu1pAD/tSzBRj/dDH2q62k+IWAB8TbfUpYRj+ZNL/YGov/r/ABTq7DGCI47aMfpFn9aAOc8Ka5eaDpS2mt+GNej1CSWS5upbe3W5ieWRy7FWjYkjJwMgHAHArcXxxp/IfTfESMOx0W6P8oyKkXwlGT++1rxBLzk51B0z/wB8baSXwxo8XNxeaoPeTWLkf+1KABPGukspZodZjAGT5mj3a4/OOox4/wDDY/1t9Nbr/fuLOeFf++nQCkXwzokufs2paqrYxmLW7kkf+RCKZP4WNlFLdQ+KvEdskaFmZrlJwoA5OJEbNAFzTtS0rVdcF/Z6xp13GkHkwJBcK5DM2XJwe4VB+Broq8Q8NafrniHXfEVvfS6fdQW9yDYf8JFoWZrqIqC0gP7v5AzbRheO/atJ/Duv6QxFv4ZQxkgmbw9rktqwH/XCXEZPtupjPXaK8uj8TXGmusd14g1DTHztVPE2lARk+gni2J/48a6Oz8Q63Eiy32iRX1iVDLe6NdLOr+/lttbH+6WpCOuorI0vxHpOqTm3tbxRdjrbTK0Mw+sbgN+la9ABRRRQAUUUUAFFFVdS1Gz0u1a51G6gtbdeDJM4Rc+mT39qALVFcvN4ourqInw7oV/qJP3ZZx9kgPvuk+Yj3VGzWfqWpanb7V13xJpGiO3S2s4xNMQfRpPvH6R0AdxUc00UClppUjUc5dgBXnvk2l1uzbeMte3ZyZXe1jP/AAFmhTH0GPSmWXh+eRtkfw/0C2jB4l1C7WZ8euFjfJ/4F+NAHcvrekxrl9UsVHqbhB/WmDxDopxjV9O56f6SnP61zA8N6ru40jwai+n2N2x+PFH/AAjmq7sPovg2VO3+jOv/ALKaY9Dq4ta0uYgRalZSEnA2zqc/rV8EEZByK85udM1BPkuPh14avUDfet7qP89skK4/OopNG0aEpJL4E1eykIOTp0iKEPt5MwP5CkI9EvFuXixZyxRS5HzSxlxjvwCP51g3tlFp82lNPO0s0+oq8s0g5kcxOqjHQAYAAHp6nNctM3h2IAS634w0fAx/pM14i+v3pQy/kadHp/grURH9s8X3GpPEwliM+ulWhcdHUIygMOxxxQB10M17ppAeCSWzikkWXYu5sM25HUDqACVIHPfmrP8AwkGll40iuhM8jqgWBWlKknA3BQSoz3bGK5q3iljAGk/EDzkHAS9Fvcge2VCMfxYmtAv4viDNbnw7qC4yOZbYv+I8wD9aAOqrG8UkGytYDjM97bpj1xIrH9FP5VktqfjY5CeGdGB6AtrL4+vFvUV3oPiXWprOfVdbt9LNnKZ4YtLh35k2lR5jyg7lwx+UKvrn0AO0orl5E8X2wUJe6BdIDy8sEsDEfg7DNV7nVfEtvyf+EWb2e/kj/XYaAOwqG8tbe9tpLa8giuLeQYeKVA6sPcHg1wE3jrWbXifS/DkjA8+T4iQcf8DjWrGnfECeditzoJGOc2mq2c4/LzVP6UAddDo2mQ3yXkOnWUd4iCJZ1gUSKgGAobGQMcYp+naXp+meb/Ztja2nnNuk+zwrHvPqcAZP1rn4vGMsill8MeISOxEULZ/KU1KviyUqS3hrxCnsbZCf0c0Aat3oOkXuPtmlWFxiRpR5tsj/ADtjc3I6nAye+Ke+i6W7yO+m2TNJB9mcmBCWi/55njleB8vSshPGNoM/a9M121A43SaZMw/NFYVf0/xLouoSCO11O1aY8eUz7JP++Gwf0oAs2Oj6bYeX9h06ztvL3bPJgVNu7G7GBxnaM+uB6VDD4d0WFpmh0fTo2mz5hS1QF8sGOeOckA89wDWpRQAUUUUAFFFFABRRRQAUUUUAFFFFAFbUba1u7KWG/jjktWGZFk+6QDnn24rLbUZVXyNE05Dbwrjz5m8i3UY/h4JYe4G33rdPI5rKvNDtr++M+otJdwgAR2khHkpjqdnRifVs47YoA55rz7exWbVrvU2zg2uiR+XGD0IaUHI/F1+lXNP03UYTnTNM0rRw4+aWTNxOf94LtBPuXaupRVRQqKFUDAAGAKWgDA/4R+4uQP7T1zUrj1SBxbJ/5DAb82NOt/CPh+BzJ/ZNpLKestwnnOf+BPk/rW7RQB5dri2998V7u0MSGHSfDEzBcDarXEmCMf7sP5Guo+FRJ+GPhInH/IKtenT/AFS1wzatYWviv4sX+o3tvaqsVtp0JmcLuK2rPtXPUlpTwMnisjwJ4vutY8D+FtI0jU9O0yC30u3W6c3kRvH2oqkIu7bECQeWO4joo60DPYPEPiXS9AWIahcD7TMcQ20fzTTH/ZX09zgDuRXmvji51nxJpM0UrS2izELDp8DjaFyMtO/WQ4/gUbB6vwRr6D4SsRcFrFS0sjBri4eUyyv7s7gM3Tg/MP51048Kx7PmuCzlvmyvDDOfXOce+PbtTEeV6D8G7S/torh0jjdEylxIBMshwBkRsDtxtAyCOOMYxXL6v4O1bQLG7a2vNT0u3VjGZrS7HyAf39pZUPPQc/hmvo7TLVtJtp0mnElrH86O5wyjHIPbAx2wOvFee3it4h8Rf2ahL29yrXN6Y2xutQf9UTkEbzhCrHGN52rgElwR5dY+G/E13PbrdarpvmXHkzJ9rsYHdYXchCWaMScorufmGOmQatnQviHpN+ZzrenRwTnyIojcXtvGDnrFH5il2xjjBHp3NereCrmHWJINThBmkW4uJZUghIjDANHCokIClVjVhgH7zg8ZroPO1h7lrqPw1ZJc7dglmvVD7fTKofyzihjPmaDxJ44a4jt7vXLtwfkb7FdTqxJTfncXfBADfKFydp4rSbSfFkFxpE/iHWvEdxBqRdYYINWkdZnSVCu0KwxmPceTyV6r29A1ux1jSryzurvRJIYrVIlS7gIlVCjAtkxASKCpkHORg4JFP1nUvtnwovdTsJBd3nhm7+32mJBJmKJiRyAMjyiy/hzRoBzDfC/VdZ8zUpLy8jsVY7om1KZ1CAnKpvZ8kEY3klcZIz1pLL4Y67AsUukb4rNWDNLdMLh5uPuqoRcJnv1PXJBr0f4Waus+p6pZO4ZX2m3IOfMWJEVz6YG9AOecH0NeksoZSrAFSMEHoaAPANHsJbLUY7XxRPbWkdw223ubrSrQxQyZ4hZigZ89pMgZ+UjOM9R420yPwb4VfV30jSNTninhi8uzhbT3cySrGCGR2wcsO1dBq2l2+pSXeluum3kUylHhQIrBSCGUqGBPHqa4TXF1nSYPDfhLxCrTadPr1klhfSOm6SGNvNMUg3E7l8tQG/iB7EcgFfUtRi0b4i2OjDw94rtNViiOoCTSNRF6ksZcKxKTdVJ4Y4DdPXNd0via4tpmDa5bQlzlbbXbF7NlGfuiXhT6cKap2i/2h+0Xfzj7mleHYrc4/vzTs/P/AAFK9MdFkQrIoZTwQRkGkBzUfiG5EAbU9Ena2cY8+wdb2Fh9Fw5H/AKzLLRvB2qXLyaDPHp+oH739mTtaSg+rxKRk/76mtqbwhoxdpbO2bTZzz5unyNbMT6kIQG/4EDVHUdD1F0VLlNP8QW6Zwt/EsVwv+7Io25/4Cv1oAbf6HrHliOeTT/EVopJWLUoVimXj+GVAVz/AMAH1p+k6hbabciK9l1LTEb5Rbai2+Ldx9ybLD8N/wCAqCykFtOtvaahf6VcscLZaqPOjY+iOSSfokhx6Vv21zfNILbUtOXa/wApmgkEkR47hsMPpg/WgDTUhgCpBB6EUtR21vDawJDbRJDCnCpGoVV+gFSUCCiiigDI8TXJtdPV/wC1I9MVnCmYxCR2/wBmNTwWPbhvoa52wsHe7F3pukXN1erkLqeuyEMvukeCy/QLGK5nxW3imx8b2cGm3R1zw/NqkF3PbROTd2GCS65HBhzg4Y57civQJtS1RoWmNpaaXbKeZdQnBYD1Kodv/j9AxDoN3e5Os6zdzITzBaf6LF9PlPmH8Xq3a2OjeH7dnggstPjPDSYWPd/vMev4mufe7nvsrFqup6kxyCulW6Qxf9/Xzj8JM0608OTtMJxpel28vJE987384PY5YjH4MaBGk/jDSGJWxln1J8ZC2ED3AP8AwJQV/M1Wv/FN3bKHOkC0jYZEmp30Nsp/AF2/StBdEllA+36rfzgf8s4nFun0/dgNj6sayvEeoeHPAmnLeSWSG6kzHbwW8XmXNywGdq/xHHUknAHJIoAxdb8dX2nadd6jcT6TaafarulmW3urtVH+8FRT14APNc1a/FS61aWUaXdXsqQqWd00eO2VcerXFyOeenWrFpLd+MJ7mTxJClywcCK1tpma2tUByrIyxtvc45kJGOgVa3rrwhb7pZJ7Oe03sMmL98pA6FnUiXcf7x6D86YzlP8AhYniJo5pF/tBCkYk8trCF2Cd5CqOcJnjJIGRxmmRfFPxSGG3TxcINxbbp6u6KvVnVLncoJ6ZQZyMZzXeab4J09vOlguxdQTOZMsEcxvnOVbbncP7zFiOwFYmu+A5bx5Zbu0EwLZXbMzMpY8t5n+tLY7knHHBAwADLtvjRLDavNqNjZhI22uzm5tSDgnHzwlM4BP3/wDGug0/4i6NrowdCub3HU2ptr4D8IpGb81FcrB4YvFVYohcPcAHal0ySNF1wQw+d/ZiCBwSWPI85+LWhQHwzqF6FiuLuJQTfzrhWYyZEduWIkdiWOXxj65zQB7u+u/D3O3UbSwsWcfMNS0trX65MsYH61Yi074b6mv+jReF5wef3DQ/+ymvEfh54X1ux0pYW8TeJLW9SUI6W982xQEVix3ZRVBbGME8YO3PG94j/tG1e3c6pDqsSyeXOdS020d5TtOAhEWeSOpLZOACetGoj1+Dwb4SMYaDTrMxnoY5Dj9DTZvCnhCAM1xZ2SK3B82Y4P5tivFLXTru/wBReG3svC0ZuIhcW8d7oEEk7hiQo2JjaoC5+Y7ueAelebw+K/HN3rl1o00fh+1msJJIYoYdGtpMMCQRENh4BBJPbv6UtRn1FPF8MrMH7R/wicYTgiRoOPrmohqnw2SYpb22izOO9rpwmz9CiHNeJ2MvxENmzRatPBgbXWAW1sIxg4lbZEOBg8Z57Z5q/o3h/wAb30MN1qviLxJcW0xyI31F7SN1Ofn3ZBVM9MjLY4UZxTsI9jj1HwPPzHoofnGR4fnP/tGpftng1VZv7CYKvU/8I/Px/wCQa8ri+FWr3MU5kn165whC3c+qyqXJ5/dRtIDgYwGkI6k7DxV/Svhq+mk3MzC2D85l1C4Ibj03KWbAGSAc9qBM7mW8+HDFTc2Wl2+7kPPpxg/NmQYrR0nTPB9//wAgK+iYnn/iX6pIP0SSvFvEEXiT4f3Vv4ot21TUPD8Ugj1G2knvUjETH/XKsjEjGQBj8sV7AfCGh+J7C11Owv3uLW5jWaCWSKG5VlI4IMqMw/Ag0hm8ugXMGfsWvarF6LKyTr/4+pb9agvdO1iVFjvYtF1mAD7lxC0LZ+vzj9BWGvhPXNKA/sq+8yNRwsFzLbkf8Ak82I/98rU39u69pQ/4mMMhjB5a7tCBj3mtzIo/FFoETxwW1gSGsdY0TGTutJDNB+CruUD6oK6jS7y3urZfs19HelRhpEZSSfcLwDWFZ+Lo7qzllFpK2xT+9tCLyMNjOMRneP8AgSrXBfBzxnrvxHsoLq+0XTrOG3MtrqlzIpEly2DhIUBygGVLFie4A7gGezUUiqEUKowoGAKWgAooooAKKKKACiiigAooooAKKKKACiiigBHdY0Z3YKijJYnAA9awIb7UNbcPpRFnpZHF5Im6Sf0MSHgL/tNnPYY5pNVH9ta0NHOfsFvGtxej/nruJ8uL6HaWb1AA6Ma1tUv7TTbMzX04ghyEB5ySeAFA5J9AOaAPENH8O6bqPx38dWGo3F5a6zJHb3lrPAVHm2xhWNwQyFT83BGOc46A11114euvDVu7yaBo3iLSEHzx2unx297Eg/uoPklwOw2H0yeKtSab4O/tL+1NWs70X/lfZxqOowzo3l7s48xgAuD9Mc+pru7EQC1jNpJ5kDDcr+YZNwPOdxJzTuBzPhWz0rU9P+2aXdw3ujzKPsxVCssBHDKZM7sg9mwykYNdRbRNDAkbytKVGN79T6Z965LXfDNzYalN4g8HLFb6u53Xdmx2QamB2fssn92TGezZHTW8L+JtO8R2pezkMV3ESlzZTYWe2kHDJInUEHv0PBBIINIA8TTqYVtB5vmP84eKQo0eCMN8uWx6kBgO4wa4H4e6K/io6lrV+qR6HeXhMECYzfRRZSMyY+Xysh3CDhixY8YWtvxEi6sL5oZXinCvFG0p8sxvg7dsgHyn/ZcZ54IFWPD2rrD8L/D0+lCNZZra1s4d4ysUrbYzuA/utnI9RimBuXWuW9rLd2lrCC1lGN7uywwRuQCkZc9CQQeAcAjPUZ4/UPHuk2GqvZ6r4pYX0bASW+mWm+KI43bS5ViTjtkH2Fcb8ZF1CQyaHN4b1K80+CSLUJtaNt9o84quG4QBVAUspBzxnCjg1wdpZabLbslpHDEina3kyrGA4HQKzqfQ85GG+tKwz6UsPEyzr9r8trrR541ntL6zheRWQ5yrqMkMMdcd+xBqDWfCukeIYDqGmyJaXlxGQL61VSJ1ZcFZV+7MhB5Vs+xB5r57+HmrW+neMtLWXVdWtfDskyRQNBcvJDFciQkxMA5RFfOD8pJ5Hy8mvp/QofIspIybUt9omZhbfcUtIzY/3ueenOeBQB4Z8FILrQb17DWTL5+i3lxYM7MEWXc67ZDyfl2F25P8NfQM8iwwvJI6IqKWLO21R9T2FeFXTCX4reKJ7Z1XTobmCaaTsZI40V+eeF5B4+8SDk4U+oCNdaukubmB5pImLQ2rsVig9GlHQv3wQdvHAOTTAo39/LNCJJr2VIXYFWtmW0jcg5/1jku491HNcn41t5PG/jjw1bto1zqfh61kunlnjQxKjNAqDcXxhlLlgR14xyprqbrX4NN1J9I8P2b6/wCKMD7QQ21IM8hriYgiMeiDLHsuK5/xxqP/AAimjvrnxB8VXbPFiSHS9IJtYmfsny/vXGcDLMF9QKQFH4U362vxV8dwajNczTXNzBYWt5OoAnNtD80eR/GFcN0G4ZI6HHs9eC+BPhjfaz8Nv7Suta1HSvEus3DayZIJS0UcztvjJibK5A28jDds8V6H8MvFd7rMF5o3iaKO18V6QwivoU4SUH7k8fqjjn2ORQB29FFFAiO4ghuYWhuYo5om4ZJFDKfqDTLK1is4BBbhhEpO1WYtjJ6DPb0Hap6KACiiigArKvtLju5TNqN1O8EeWECSGOMD/aC8t+JI9q1aKAPOfGes+IrHwLqd74B0W2iFrAZYPtKbWlHcxwj/AGckbsE4+6c1wfgMXeipYeNPE2tQ+MPD2sIjPqc0BD6TIeMhSSFi3ZRiNu04JGM19BV5Xo1vY+A/G114XukRfDPidpLjTkkAMUVyRia254w4IZR0+8KAPU1IZQVIKkZBHTFLXmVnd3Hw01e00nUGaXwVeSCHT7xyS2myE/Lbyk9YieEc/d4U9jXUeNPF1n4Zht4mC3GqXhKWdmJAhlYdWZjwkY/ic8D3JAIA/wAbeLLHwnp0c10PPvLl/Ks7NHVXuJPQFiAoHUseAOvYHzjQoZdb1O51TW9s+q3GIzLHcRlIE6rDAAC6qO5yrOck9gOj8L+Dpb+5l1zxNf219rc2Vd7dUkSBM5EUe4MFQcHAAJPLEmuy0vSxp8zhFt3iZR+8EKpJkHgHaACPTgfjTAxtCsZdOJeyWUwpgPCGOcY6BZFyPXhsZrrFO5QcEZ9aR3RNu9lXcdoycZPpVK50/M5ubSZ7e4P3iOUk/wB5eh+owfekA+40+KSbz4S1vc/89YuC3+8OjD61Bqd/JpumiWYxPMvUAEBhnk8ZI+vOKtWU8sqOtzCYZozhh1U+6nuP1HeuU1vVJLi6ZEZfLRgU3IQVOD0Ycj/eHUHtySAQQhGt8syPA2cghBGx90OYs+6shPpWP4otIL260jSkVoZtSu44WCyzRqbeM+bIPLIK7dqbflOMuKvJNbiUv5psrkruL7hHvA77hhHHsdp9zTfB1vcaxq+sazCsarbqdPsJSqhdxwZpBtGCM7QD6owzTGdRobJeT36yRRvFJIZfmUHcN7Kv4YjB/GsmXUYr3WNTtchUs9VtLaPhcFyiSsB3zhzmtPT7my0fT9XvbmUQafZNsaVgSEjijUEnHoQ2fxrjfgV4g03xBaeI7i3vLa4urnW7y8ESuGdYt4SN8dQCqjB784pCNHQdD07T/F4msLKGEl5IJSqAFuZiM+2AB9APSuds9JsIb3X9qwqrarcxtHGMPIn7tljz/DGHZsgYyccZ5Hf6WVi1NncGR55cBjztw8//AOr8a5K3VBrWuwSo6mLU55AxQbSXjibG48ZwSTkYUZJ4wpYFmztYkdZGgiWBn3usYCAE8tI5HfGCD2AH+zu6sW841CVoF+03gODc3AIitx2VF7nGM46927Vz8XnS3UUUZVP3gBkbIBG7ODnoMkcdSSC3zEBe2v2uhEiWSKZHbaXf7sY7sR1PsPU9qQGaYLPS5hdXkkt7qLZ8tmG+U8DKxqPuj6Y9z3pur+XG6ygPFNOmCsQCyseOC4yRj/Z59Ko3+pW2lxyvBP8AOzbJr6RDK7uDjZGijLt/sqNq/pWvp7hrRJJ0ktLmf5Fa42ec/HBIHGepx2/SgDkdVRGR459PtmDgo8csKEuD2Z5NxOfcKTXLfD3UD8PrqbSr14YPC0soa3RrrzH05nJyXJVcQsenXaT1IOR6lqllDBBJciNppAMHzH4PqSeOPbIFcnqWm3Go20trd22npYzcvbOjBZee6RgOy+oY4OKBHooORkUV5d4aubvwFP8AYdTe4n8KSn9xdPHMRphwBsdpM4hP8LZOw8Hggjb+Jvii70jT7TS/DYWfxRrLm306PG4R8fPO/wDsRg7j74HegZxnjS1/4WN8SItD0a4uNMsPDzefq+sWTeVMZSvyWySDnIGWbqB6ZFUfhLoviDxR4Mm1LXbuz1aG6vJUs571XjumtFO1SLiIqy5Kkjg+vetnxTpv/CE/DbT/AAXoEzS674gnNity/wDrJZJctcXLHHZd5z2+Udq9S0XTbXRtIstMsIxHaWcKQRIOyqAB/KgCn4Ygls9P+xy2t5CsBwrXN2bkuMno5JYj/ewcEVsUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcvoeR498UKVIzDZMDng5WQZ/T9KwvilrU/h+HUtRgFuJodM/0eaXJ8h3mWMvjsAJFJ9duK3ruX7B8RbEk4j1Wxkg6f8tIW3r/AOOySflVX4ieG21rRtUa3fddPaKsUDLuEjxSCZF+hZdpHcH2oGeC/wDCXeJ9AvfO0zXpL2W1kAu7e8kdklAGGQB2K5OQcggjHbNeyeFNdtL/AMPR+KPCsZFidx1PSFIJidfvlAOBIvXA4cc9SDXA3+mJrdnFqOkgmC9Tzo0bCBUZW++xViGBcAj1B/uVg6DcXXg7xLbvpczWjNHslQ7TBJtJOCuFyACccj7p5GDVMD6etLiG7tori1kWWCVQ6OhyGUjIIrmPF3gq21u7TVNPnfS/EEKhYtQgHLAdElXI3r+II7EVx1n410O2825W7PhjURceTNb3UUhsrmQ9xwACepYbWGcsCOvfJr01qiPrNibe3YAi8t5BPb4I4JOAyj3K496kRwja1qGk6tFZ+K4lsdTmzHb3ok/cXXtHMcbWP/PNyvsr9alikn03VZxZ2VtcWd6xF/pVwRDvcc+bGGAQOR1DBFfAIOck+l3EFlq+ntDcxW19Y3C/MkirJHIp9jkEVyFz4BNpEE8M6tcafApytjdRi9tAPRUc7kHsjqPagC5oc9nq+nq3hi8lsJrWRhLaXCE7GJ5SWNjkDjggj2JHXjPFnwpsvEniS31jUNJkt5oYlhZNMu4lSQKWIOHiBH3iOo7elV9Z8CaxNfw3t1o5e8hXYl1oGsSWzYznmOTH6SVaj1HUbOEQ3V/450/blf3ukC8Of9+NZc/maYHR2XgjT3FsU0Wy0xrR/MjupI47i8ZySS/msG2tkk7ssef4a5fxb8Q4IJP+EP8AhtLDPrGfLku0U3EdqSSWIAyZZeST/CDy7DpWXqdgdVw03iDx1qoDAm3k0OYRH6xmNEP45Aq94Z8KXdpbTxaZ4VvJhcOXM2uXiWkQH90wwFyy5ydrKOvbigCj4a8P2OjJFZ/2tdX1zBKzXENrKst3LMSTI0jKxS3BJOXZiwyQHToev0zUdV8b2qW3h5xpHhuP93NqtuMSXRHDJaZHyoDkecRz/CP4hZ0/4fvdwJF4nvIJrBTuGjaZALWwB/21GWl7cMdp/u11c2q2Nje22lQgvcsFVba3Td5KdAzAcIg9Tj0GaQyOwstG8IaF5VskGn6dBl2Zj1YnlmY8sxPUnJJ9TWRp6y3Kzvp+ivcRXTid7vV38sysDlMJtLALxtBVcY6d6yfHuv6f4ZlF5cq+q+JGTdZ6cJN8dufu78cBFycb2+Y52g84ryDX7jVdauxL4h1fU2upHEi2f723jSH/AGDFlQfUct8yZIJyGB9BaLM2n6kNP1CxsrS8vBJNG9kD5UoUrkHIBD/NnHORk56gc38RdN/s/wAZ+D/FtkAl1FeppN3jjzba4OwA+u2Qqw+pql8PZ9SufA3g271e4S71GPUHijuEYsJoj5qZBPJGzkHuFBrrfHhDWOk25AJn1azAH+7Msh/RCaQHTUUUUCCiiigAooooAKKKKACue8eeE9P8aeHJ9I1MyIjMJYZ4m2yQSrykiH1B/qK6GigDxaXx+sen3ngX4g6Wk3id4RawwycWusBzsWRZP4AeC2eVwccjAseEvAXjDRdNi3eItBm1byVVvtFhJcvtXhFE7Sbtq9B8uO+CSSd/4x6Fpmu2fhuDW7KO7sP7ZgjnVuPlkV0HIwQN7J0PpW/4F0C08N+HbaztrCKx8pSmwEMVQMdoLc5wCO9AHKxa9eWeqW+m+KrD+z9Xlyttd27ArcEf88pMBXPfynVWI6B67uOW7uLeG4sbm2nQoMq6FQzd+Qcr9CDima4NIvYH0zW0t5be4ABiuUzG/PAyeM5/GuPvoNV8BSNe2kk2p+Gxjzo5CXuLRP7xbrIgH8Ry6jqWA+UA7JLqG8Y2Oo2vlTOCRFLhlkA7qeh+nBHoKdFFcWMqJEWuLNjt2u2Xi9ME/eX68j36VmxR2t7pv2nSpUms2/eGCR8Kp65Vusbc5BHHf3q3p2o4KRXDsys/lrI4wyt/ckHZvQ9D+WQB2o37Hz7e2WZbqEq5CqCxT++oP3xnggEHr3xnlwqNt3KrxOpePaCykE5JQjnHqAMj+JD96trxJNHJeRQOZIJYh5kc+DgHvnHOPVh07jHWgTkst0mySQbzIqb0lx/EyL97/fTB9QvSgZzviT9xpciQRmWW5GyKNkDxys5CKOjRtlmUdRxn5RWwNSj8MaA1jppWS30mAWhYAZuLtlB2j0xy7f73sa5rWvEmjaZ4vtY9VvUYWUS3cNrbSG4mvLqQskSoiYaTaqufmBILLlsDNbun6T4nv9Is7R7HS9Kji/eNNfZvLhpSdzPsRlRSWJP326/hTA6W20Mt4HfRrpi8lxZvDMzHktIp3ZP1Y15t+yn4Nbwx8Ojf3kWzUdWlM0gI5WNSVjX+bf8AAq7O70LVorYy6v4/1G2QnBeGC0t0BPYFo2P60y38Maz9mQ6R4/1ZotvyNLbWc6H8ol4/GkImnkS11W1DRHKXskJyf78iSKfyZv1rEuGaLxn4lhRU3PcQypleSWt05J6kDyiQoGARk5wAY/EsvjDTbWNtc02HW7W0c3CX2jpsmBCsB5lu7HjkHMbMePu1UfW9M1bxje6jplyLyxu7C2dHhPziRZJEZAuMrJkp97G3rjcFoA37JfKZbiQhY0YmJXyAzr1ZuScLk59zt5YknuRtubb5gwSVORnBwR7dK4mO3klBEyL5pKxGJM4jwPlhTtn1I+6Mn73Ndjpjq9hCFdZNi7C6LtUkcHA9MjigDGgsE0+822sUM2oFSsIOdltCOBk9f6k5AwBxq21nFbSCWeTzrt/l86XGT7KOw9h+OaYxEVzLBp6K1zI3mTSvyEz0LepxwF9PQVTW1F3ePHG7uifLc3RPzMf+eaH+EeuOnTrkgAnvNTkYyJpdm19LE21iHCRq3oWPUjvgHFRaxqYsLIS3t1DZ7IvMuChDFMdfmbCqvUbmwPpVPX/E9to1xFo+kWbalrboDDptsQuxOgeVvuxR+56/whjxVC28GnUbiPVPHd1Fqt1GfNjsgNthaEd1jP32H9+TJ9AvSgDjfE3xF0kaTK0OheJdftnIUtaLOyMufvblGwAnpzyPasb4FzaTB47vYhfPqjto8c1hdXVwJZbC3SQiS1kGB5ZUuhwQDjjtXr2s+LtK0q2t7iW7tVs5mUJdtMog++qsC+cAgEnHsfQ14h41u4fiF4w06/8ADdndWnhq4nTRNS1iP9w2rRzSL+6jyMsi7Dl/qB7gHe/DtpPHXjW/8d3AzpFoJNM0GMjrGDia4/4Gw2g/3RivVarabY2umafbWOnwR29nbxrFFFGMKigYAAqzQAUUUUAFFFFABRRRQAUUUUAFFFFAATgUUUUAFFFFAHK/ERGt9HttZiVml0a6S+IQZJiGVmH/AH6eQ/gKveJjIdOttSsU+0PZSpdKqHmSPBV9vqdjMQO5ArZmiSaF4pVDxupVlIyCD1BrmPh3K8GjTaJcOWutFmNixbq0YAMLfjGyc+oNAHE6cv8AZOv3ulmVDYzz/a7CU42eTOxZfYqHJXn2BxvFc74k8M75DDdoRdQ2wg8xiJWQpH2b0yp7ZAZd2MqR6Hrvh37W13pVuY47qJWvdJeRcqA3EsDesZOMjsJFxyoxgWWoS+INCha5Lw6rao8U7uAshdQ6ZftlSWBOOxz8pbDGcLNp89sL+1uRHLbsLkKBagsB5cZJIEfbnjII5PBzViCW80m4aTRNRn08wy7hBb7REyeaUIdTgbdpXGEGCOQp67+rafHeNd7o0hlt5HBCryoNp1UkH5dw5B5TaB0wRjkX1vfyx20ioYi8rR7yDtXyWZowWwDgHgrjg4BHyhgdJ4K8Z2ss725vrHStbLDNvPG0FpfAqGBAPEc2GGQpOcg4YYx6X/b6Ww/4m9pc2BAyZGXzIfr5i5AH+9tPtXzjIlhqV+8Mnkk2l2VdhbMqg/NGThQpGQqYAJTPNWdN1bUvDxsotP1e/t40kxBHM2VeTc64KbyskZwBtQAgspFKwH0raajZXoJs7y3nA/55Sq38jVqvB7X4u6ZdWcb6z4esZ7hgEugFMZjJJGMSoARlSM7scDOO0kHxJ8Ly+UIvC94gkYKqJOgAyMjcEYhe3BxyRSsI9vubiC1iMtzNHDGOryOFA/E1kDxLaT8aXDd6m2cA2sRMZ/7aNhP/AB6vML3xnoOnvPFZeDc61GpKCaNHCdwzty2Op2j5uOgrndR8Z+Nr0yQDX7WC3ZSxmtLVQu3PBVgzMoIyCc5BHplg7Aev63qs9vamXXdWsfDlkVLEecrTsvf5m+VfwDH0IrzHU/iHKLZo/h/ara6cJUZ7yZN09yGxmXD5ZgQRjIJbK8rxniJC73hniu7yZZG2KjOJ7hnYH5vOHEqg5yCQT0BwMVt6Ro7aqyzQqk+nIw8mVImaMsuS0rR/eGegIAxlnIORRYZkaG+oyM73t4l5LflpiL+0zJyRmQtkchSVH3tihiGXPEl54eSdbRbmwmuITeW9q1sEe3e6VptzxoGPcYdxgdewHzd7aaTdWzx3guppIk/1lzBcLLGFAYKiFgdgB+b5N5BHBStHw5bbNWn1u8gaaHRoxZaarsS9xcyKoJI/vjOzP+2/uSwPRbNbO41IQW0RWLSQIkCKBErsn3VHYqmBxgAPj6UtRxf+OdKteTHp0El/J6CR8xR/oZvyrQ02GLQfD+b2ZVEEbXF3OTwW5aRz7ZyfpWf4Jjluba71y7ieKfVpROkcgw0cAG2FCOx2/MR2LmpEdLRRRQAUUUUAFFFFABRRRQAUUUUAZHi7R/7f8N3+mCTyZZ4/3Uv/ADzlUho3/Bgp/Cq3h7UT4n8IJPLGsNzNE8FzCRnyp1ykiEezAj6V0FcZEy+G/H80chEeneIsSRHOFW9RcMv1kjVSPUxN3NAHlvjbU/Eej+LrTVrXVrsxXttHNDp87M9pKI02T27IeN24biwG75u+CK9V8FeIbTVNJs72wLnSrwmONJPv2kwODC3tnOD9AOCtZPxE8NPqVhJZWiK14kp1LTC5wPOXmWHPYOpYj/eJ/hrzL4d+ILfw7qiwamssPh3Wz9ml3KT5dyDtSTgZTdtZSCAQVXOcE0xnrUunw+BtQl1C0i/4pu5O27hGcWJJ/wBao/55ZJ3L/BncMDcKn1tf7PJZ0X+zXAEcwy6Kp52PjnZnof4eoPaug0q4aaOaxvwrXcACygjiVDkK+PRgDx2II7Vy63R8G3iaPeRhvD14xTT7iQ5S2Yj/AI9n/wBjqVPp8v8ACKQGzesr+GbaaXMijY++TExQepZDnjpvXnvzzWTG5ERWNTPFgytDtEhf/aUL9/8A34+c/eUmpIGi0zS7y1s4xbQsSJrdl3i0Z/48HgwnrkcDn3AykjnsphFIu0KRJtBIU/7StnjPGGByOmT9wAEHwn8PW15qur+Ob2NZr/UriSGxdyzm3s0YoqqW5y2CxPuBxitnxtr1ytjfHRVa6hsLea4uzFJ5QZk24h87opILE7cthMcE1H8Md83w+GjiZ7bUdP8AN06ZtpDxOpO18EA8qUcZAyGFVPFnhrSr7TNGsPEV5d2EFvEI2jtFJsy2RhnLoUByOC3TPrzQI8u1H4o3+p/Zv+Ee0mCLycubu433bM7EbvKVxlUAU5yByMDjrraV43awuYLq8jNrcxSvvvLGwTyLyIx5KyqJF5RskfxEBSAMkHkfG3h3/hBdd0ex1I2ElvePK4uA7hpACCzyFhtUnPRdzZZiOBR4Z8P6vH4htdYsptNs9PhdpNPbUg6SPubLS+SyFmVuVDMFbAyOmadgPqLTJLqSHfdtAysA0bRKy5BHdW6fnXnPijRLXTfi9pmtWYeOXUtNuYr1IuPM8poijlukZ+Ygv6YGc13nhya5ube7urkyiKe5drZJV2ssQwFyMA4JBYZ5wwFedXWpN4n8XXup6csc+mWsJ02zlbmOV94aWVSMsQGVVAUZOwnOOqA25b0qo+y7CWxCmFIQKePLQdQvTJ+8fYYrsv8AjxsobeHDTEbIwx6nH8hyf09K4qwW3tLhJLuSXykUtLcrjcSMYiRV+7nJ4Tc3b5c4PSKpu0l1HVQ1lZCLLRzOF+QZJ3/3V7kZ578DFAE0TPeobazkkFsvE14DhpG7hD/Nu3Qc9Ofk1W+8QSvpHgl0s9MtiYbnWSgdUI4Mdup4kcdC5yqn+8cgVI5bj4hy+VZvNY+DITsdoyYptT4+6pGDHB78M/bC8t18k1to9tb6dpdohkVAtvZwAIqIOAT2RB6/lk8UAU9M0rSfCGmmOzilaSaXe8jMZbi8mI+87Hl2PvwAOwHGT4g1hYvMS+a3utQjAkTSo5MpHk/IZT1ZicBRjBJ4BxuGP4k1u4U30Wm3cJ1KD91f6uWAg0tW5McQbO6XGOME9Cw6LVLwR4Vg0i6l1yQyz2duubKMylzcXLkgysST5jnIUOxP3mxgYoA6S60W012G9tNQsIZ9Nu9URprZ4spujRSzZxgjfGBnHY881L4siS68S+D9EtUVY4bptRlSMACOGCNlXgdAZJIwPoa6K0EWi6GpvZlSO3iLzyseM9Xb8SSay/CWnzPcX2valG0eoakVCxv1t7Zc+VF7Hks3+05HYUAdLRRRQAUUUUAFFFFABRRRQAUUUUAFFFcLfa1fw+JJfDi3RF7c38E9s+BlbIqXk7djDMme3mJ3xQB3VFecSeP7yG4kP2aK4sri1kubG48swq22eGEZy7MVzOpLFU4U4BzxcbxLqMWox2l4YHmttZewd7dTGkqjTWugSrFiPmIGM/wg57UAd3RXn1n4z1A2O+/FnFPc2NneWvlQvJhrh2QRFdwLnIGCCo55wBmug8Jave63o9213Etpf29xNaN8oIDKcBtodgOoyNx+tAG+7rGhd2CooySTgAV514h8Q2ujeKbXXtMWS8srpV03UHiGIVYt+4kMpwnDsUPJwJB6V10fh+2kZZNUlm1OUHI+1EGMH2jGEH1xn3q7qum2mq6Vc6dfQrLZ3ERhkjI4KkY/D+lAFHUrO9vdOguPKgi1a1fzoFSQsueRsLEDhlyp4757CuK1jy9Mnj8QWcnl6Pq1wpuPMG1rK6bEYYnsjFVRx/C+GHG4Ho/AupXQF34e1qQyaxpJVDK3W6t2z5U/4gEN6Ore1Gv6Zbxre21/AZ9B1Y7LpFHNvK2B5gx0UnGSPusA3ckAzOTTWv1kWIrFLGpzCcIyuBtzGegOGIwemdvKMMcj4r8Oy3enecQyRqWEjLGV2MkOCcbuBlOQ33Sw2kjrbuftGi39ro/ihmaWNwumamvAvkxjy37CZR2PDAH8On3C8tJ7e4AYTxlBMoJbpjkZyxA687wP7w+amB5lp3hltPi1COwkmyplkQyl5HZgI5VwqhWzlmAwzEDsvatrOnOwleeI2pknWTdBscyAqHT5FyGxIq+rDPJNdvZWF2dQX7RbAJJjlCrK6tAAfLYDa4Dp0HPQ7D1qnaxva221Laa9drdWlE7ebK3kuAeD8yjBxj5Bx6GmByCG0vXupCjRq8And1lDmNdwZi0gwAyNhsBSRkjgmmX0dta2UkqXVo6Qs0QtzbMrAN6qybhE+QQ5y4zgHFdtd6Zp8tsWaK3H2G52Khi3CKA4ztjIdcgMOucbOBWJd+FpI55Y7MMZoxgot0pEkRJALb3TewBbJI67VwASSAchaQSXutxPNaRXFpbHyxuiGbRsZGSpyVweAeGB+9wWPRNoMt2ZtlqpnjG64heURZkIxmMvhhnOTgdsYBwtaui+D1kvo7yNDdRtCUge8RGWRiR+6m+fafYYJ/75ArqI4fscS2zNJaPC2yOYDDW7n+FyiIpyDwS+CDzyAaQHM6doZkk8q5jSe2MeYYizbLo4Id44wmVkUfKQH6Z5UljW9ZwQ+XEtlceZaRj5GTHmKV6o68owAH8fmOuOfWpLS2jErtNbPeTXeZJInlzEf7siBCzZBHUhiP7wxUeoeZczWui6ekMs+o5R2P8Aq1VFBZ5ME7wAAuMtkkDKdgCOLHiLXptBsh5UUqrc6je20gV1jUnYiSAZLs2Ru3YUKdoBzjrvDen280lvJahjpOn7ks97FjPKc77gk/ezlgG75du4qnYaZFuutF01pJA7A6tqJwpc4H7lccA7cDC4CKeOSK2fEmrx+H9Lhjs7dZ76dhbWFkny+bJjhf8AZUAEsegUE0gM/wATH+39Zt/DcJ3Wq7brVCOgiBykJ95GHI/uK3qK6ysbwtox0bT2W4m+06jcubi9ucY86Y4yQOygAKo7KoFbNAgooooAKKKKACiiigAooooAKKKKACue8faNJrfhi6gtABqMBW7sX7pcRnfGQe3zAA+xNdDRQBh2NzB4r8K2V9ATELuFLiJv4oZMZH4qeD9CK8W+J+hxyXseoxJFFDqqzx39qU3BbqIfvMdtrKrk8dVzkbjXrHgXFje+IdD4CWF800CgYAhnHmgD2DtIv/AayviFob6hpFzp8UZe7WV9QsMf8tWwfNh6j5irOByPvA/wmmMwPhz4muriGz0XUXRvEmnRZtJCCq6naADcobkb14BGT8yhuQTXp11b6f4k0SW3uoluLG5Uq8bjBBB/NWBH1BHqK+aYJn1W0jTTp9RgZXZ457cATQzJkbsA537sgjn7zA5HFep/DLxrJ4h/tFR5Umt6awF9BBhVvY+Qs6JnKOdpBU/ToVITAvaebnRtRh0HWpJ5JIwx06+jGJJYx1x2ZgMb4znONygjhNOVRFb7pTbGzDZB3FYM9Mo/WBuxU/Kc47mt/UbDS/FGjCK6Rbmzlw6MCVZGHRlI5R1PcYIIrkryXU/Czu2tw3epaaBgaxYxBrhFHa5hUfvAB/Gqn3VepBGXdC+0HxEdU8MiO6vJ4kivNGu5Rby3Ua52NESdhdQSAVO1gcHGARswfFDwzNI9jrgvdEumUh7XWLN4cjv8xBRh15DEGsKTxR4KvC8Z1/Q5IITiS2edUjJbs1vKQqnPdSCDnpzVqeDQZIFAu/s9u6EBobwNGVPpHLujA/3TQM3dIvfDH7r+z/FkM9nF/q7YajE8aDsv97A7Amkfxf4S0JnitL86hfXB3GKy33txMwGBnbuPbAyQB7V57q3gzRY5YpIo9HkjY7lkntIwRnHG4b85HcA9a2ND8EaXcxiaK3lkjkZlMfmXMkYXuFyIVA9sEelFhFnWL/XfGMQt5gdB0OTia3Ega7uF/uO6nbEp6FQcnpuHIrVt7KOAW9raxq8jqI4oyMIQBwMAbQoHtIB6dKuXFvZ6Dp/2jU5bHSNNhXHmTzLCqADAAxyOOAN9Y+m+IdS1S4k/4QXRprpJQM6xqqNaWYHXMaY82b64wf79AG+6WPhS2u/EHivU4FWNQFkkGEtl/uR9ySfTrwAo6Vzken638Sb2G61uCbRvBkTiSDTZBtudRI+684/5Zxg8iPqepxxW9ongdU1NNY8VajL4g1lDuheeMJb2h/6YQjIQ/wC0SzcferV1LX41t7t7KSEW9sGNzfTHEEAX73P8ZHPA4zwSKALk9zBpkUNnZQB5yuIbaLjj1P8AdX1J/U8V474p8ReJNXn1nS/DT21jBFIU1LXo7hXeTCkiG3xwhHQknK5/vVautRh1uZp7uSdNGluBALaYMk16xwBLMMbtgz8sWzbggnnCg/tCy0Tw5q5srEw6dbNKcQr5aqhVemMsMljwCg9u1AFaz8GI1zovh+NEFkrb3R9zNHFne5IJyHc9ZGAPPGeCPV7YLe3zTsscemaeTHAOis6jDP6ALyo99x9K5/w7pd7ZQ/vpPL1rVV3yJG37uxgBJIUZOW+bG7Jyx9FpJ0TxZqEvh6xiaPwtprCHUJgcC7kX/l2U9So/5aHv9zu2AC1pkkvjLVE1Jiy+GLVgbKMjH2+UH/Xt/wBM1P3B/Efn6ba7OmxosaKkaqqKMKqjAAHYCnUAFFFFABRRRQAUUUUAFFFFABRRRQAVA1pbNepeNbwm7SMxLOUG9UJBKhuoBIBx7Cp6KAMabwzpDR3n2bT7O0nuo5I5LiC1i8whyC+dykNkgEhgQcDINR6D4V0vRrVoYYEmLXBui8sUYIkMflblVFVV/djZ8oHGc5yc7tFAFCXRtMlgMEunWTwmJbcxtApUxqcqmMY2g8gdBU2n2Fnp0HkafaW9rBnd5cEYRc+uAMVZooAKKKKAOU8a6JfTTWmveHPLGv6cGCRu21LyA4L27nsDgFW/hYA9M1q+F9es/EekR39gXUFjHLDKu2SCVTh45F/hZTwR+PQg1rVxfiPRb/SdZfxN4UhE13IAupabuCrfxjgMpPCzKOhPDD5T2IAJfF2mR3NheWuvo9/oFyd7OoxNYsDkOpXnapwQw+ZCM8jpyegyXukzDSdVuxcyxANDcH/l6hH+rmUj73BAJXlD7EbvRPC/iLS/FGkR6jot0lxbuSrDo8bjqjr1Vh3BrJ1zwsktvJHaQJPZlvNFmXMZhk/vwSD/AFbdfl+6fbJyAZt3fRxWssQlRXlIJV4PPjclgN7xqQc5I+dOCTyA3AZe2NrdyJDbxKBAHSKIMZTGWGGO1iXUn/c49azbTTtbt/tVvp2orqEq/N9hvVFrdIuR1xmOUcYztAP97gYgh1+OyuhZeIxDYg5CpdSGJlI6KsTblkz0DRAj6Uxm3cWSPLKt2FkjkRAYrk/3QRu/eEfNzjgcYGMU63ikgtbY5Z3iQosx3N8vBwGQAZ4GT3xUmnalZ3luZbC7kEUTbJAZNgjJ6bl3rt9sp+BqDVdd0jTQw1LV9OyckIhS4ldx0UIsWWJ56DPoKAJ0st2mTWhtZBBLI8skYjlQMzHJbdvUHJ+brwTUPkwtKSq25vGCrHISJHDdBggyN3P8a98etZ0o1XWJzcaf4avXt3YMGvJFthnvgOfMx/vJ+FSWekjV9USw1iWB4h/rrHTGMoHB/wCPi4wuAemxQpPfcKBFi88RW1/f3NpaeZf3CuYmtLaMS78HHzhTtUe8zgD+7R4etLqa/vJLB45NUmHk3OoKd8Fin/PGEkfvHGBk4C5AzgBUres/DBltUg1SSOOxQYTTLAGC2RfRsYaT3zhT/dq3rutad4XsLeMxEySnybOwtEBknbH3I0GOnc8BRySBQMLy60zwf4fDzF0t4ztVQDJLcSseijq8jsfqSap+G9JvbnUm8Q+Io1TU5IzFbWituWwhJBKA9GkbALsPQKOBkpoWgXdxqi694ndJdUAItbSNt0GnoeCE/vSEfekIyegwvXqaQgooooAKKKKACiiigAooooAKKKKACiiigAooooA4fV530b4r6LOeLPXLOTT5OwE8JMsWfqjTD8K6jX7VrrS5vKOy4iHnQP8A3ZF5U/TsfUEisH4oW858LNqdjEZb7Rpo9ThQdX8o5dR7tGZF/Guj0nULbVtLtNQsJBLZ3cSzxOOjIwBB/I0AeAfEPTXs/FQv9F329pqtgNTlix8kcpdQx54wxdGYcDKkk5IrFsLnX9K1a11rT7uCXUon8vzdglS6iICiKV1+Yr/qsddp6DsfTPiFoF1PZXVvam2NxYWs0tv57bA1sSDjfj5WjZRgHgjGT1x5neX+n218lj9taOa4UGN3+fduX5SXHPRoyACw4OSDTGdpoPxRim1Jn1awudCFwA7y2dwLmEkgEyPGyBgOuWUHGDux1r1eDUbmGFJrlY72ykAZLuxUsNp5BKAkke6k/QV8zR6jHeTLLPLp7xqf3UhvIkm8wksY9gYO3zK4+bPVflHU07TV/Fnh7V4z4XurnTNOmUyPDsf7GjbjwokjKgNxyDnn2oA+oLibw9qEcy3UdjcJOB5qzwghwOgYMOcehrEm8AeD7W0e8s4m0WEDf5+n3slmiD1wjBQPwxXjkPxV+IrWkTwz+GpuQXBlhd1GAcNslxnnGMA5Brem+M+qWKQi5TSb+5uiUFp58EBiOcAnE7nsTtYDIxg9qQrWO+TwtbRIr2vjzX4oj0/06CQfgXjP86qzaRpJP+kfETX5ieNsWpxg/lEgP415BH8YNUfU7tbnR/BkLR/KwMDNI+ewO/B4564/Hit/w58TdY1uK7jsdQ0XS7jaWt4LTTzI0hQDep+c9+Bxzkc0Aeg6Z4a8AR38V81u2rahFzHeagZ76TI5yjSbh+K12X9uxOm6Cz1GUY4/0V4wfxfaB9TivBNV8X+JJHhgtvEWuGVomkaZraGNFI5PCoCRsIcdTgEVFpksviNoJdd1rW722QIJ7SaTMDMygSDaFAyuQwznj65oA9f1HXLa4hMuo6gskBfyl0/SpTJIzE7cO6kHrxxtA5yTXnOv6n/wkVpb29wYoNGCObbSbNVZI3QZXzcD5mGGOPuAqpwfvVqx2KWNu6w2oiupIHgeKO3Ckyw/MjnB69+PUcVV1G3sHsQ8mmFbNLgXckiDZ5cbLubqpHXeeuKYWFt57G3hku2gCqzLcBlKsvJQsd2cc4PBXr19ada7/E+sQ6cJUg0mw8vUr1Vw6BRs2xlQNgJwxGADxkdM1h6bLeaq+maRa+Ql1qNtJaRyvEyNAqjq6qcsQpBzu2n0r1vQtCsrCG30TT4Y9sISXUrhVGZpByFZurMT8xz0UY4BFAFXxTqF9p+mwx2B2eJPEVwtpa7hn7MmCSxHpFGHc+rfWur8P6RaaBo1rpmnoy21um1dxyzHOWZj3Ykkk9yTXK2X/E5+MGoXBy1t4f05LRAeguLg+Y5HuI0iH/Aq7qkAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcX44vH1K5/4RuznMSvAbrU5lYKYbYcCPJIAaUgr1GFDn0roPEmsRaFo819KjTOMJDAh+eeVjhI192YgfrXH6DoVzdrIl28U91JOLu+uQ52yzlcADByY0GFVQRwuc5yKAG2Phb7QTrvhq4Ol67GBDv2D7NcxoMLFLEoUMoHAYAMuPlJHB3/AA74tivrtdL1q2Oj+IBnNjO4IlA/jhfpKnfjkfxAGt7T7VLK0jt49gVc/dQIPXoOK53xJcaXrMEmnXulpqKK33ZR91h0ZduXB9GAGPWgDodQ0+11CNUvIFlCnKN0ZD6qw5U+4NUf7LvLcqbLVJiqtkR3aCZcemeH/Esa5Kw/4SXRvOSwuhf2kXK2mpsxZE9BcECT/vtH7fNVyPx5cwWSz6r4U1+FiM7bOD7X+ifN+a0AXtY0K41hgNU0rQ7zaQFlkLqwXPI+6T+GcUtn4duLGZjpVroOmckCaCy3SFfzXB/OoLz4i6FaRwtNHrCtIQPLOlXKsuR1IKDAqrf/ABHt4QgsNA12/eQ4Xy4FRfqS7DAoA34PDlsUuP7TnudUeeRZX+1vlAVGAFjGFUc9AOe+TzWpHHaadaERpBa2sQLEKAiIO59BXnFz408TXuUtNN0/SFP/AC1umkuWwfZVVVb6sawri1lvNRSXXf7R8QAEsguJI/JB9Psu3YcHo2M470AdlrfjwTRPD4Ogi1a4BKNevJ5djbn/AGpTgSNnoiEn1K9aT4URWep6FB4lkke81u+Qx3d1OQXR0Yq8KAcJGrg4UegJyeazdO1WUiOF75mKKUWO4hFm64/hXYfLOOnf6Gn/AA+uRpPjXWtBZGihv4xqturIqbX+WOdAFwOvlP0H3ycUxnpVFFFIQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIyhlKsAVIwQec1558NZE8L6nfeBLsNF9kZ7rSWc8XFm7btq+8TEoR6bT3r0Sue8a+FLPxVp8UU8s1pfWsnn2V/bHbNay9mQ+nYqeCODQBN4i0xrtJpIoFuRLbSWk9uzbTLE3UKx4DdcZ4Oecda838P/CjSbO8zbWOrhQwlC3lwscKEcBQIyWbpnaCF47dK27Lxh4i8NN9g8d6FeXe3iPWNEtXuIJl9ZIly8TeowV9DSt8VrG+cxeHtMvbyQStCXvB9iiDr95f3g8xiO4VGI74p6gb+keCNI0yTzoLeKK4KlS9tGISQTk/MPnPPPLE5rZj0fTkUD7HC5H8Ui72/Nsk155d614k1OQp9vOnr1C2US5I9AXWRmP8AwCOqreGtTulVtU1LUGDD5vt+pyQqenSJDg80BY7/AFDwp4avCH1DQtImKjhprSNsfiRWXB4U8ARM0cOh+GAz8MotYMt+lc8vw78MkK1xa315KGDNstyQzfV1PH41o23gDwzFG/k+GWEsnWR4od49OSaAOkXwn4fHltb6VaW5Rg6tbIIiCOhymKr6l4N0zUR/pSLOc5/0mCG4/DMiMf1rkv8AhAtPtXjKW0mn5BInR2iIYDu0chx9elPXR7u1Y/2Z4s1CMLwE/tJbg59MTj+tIC5dfCTw3dbvOiZSTnMH7jBxgEeXtxwccVy2ofClNLuB9jfXprNdxWW31FmaPKbT8jh85HHAPH0FdFNceNdPt3ltNXtNS2j5UvbDhvT54SAD9fSm6V8RNZ80W+reFZ3kX70mnSmVD643qo/DcTTA56y8A6hfWRbRdfllXykRU1O1iYgKwP8AroQBu42ncpbHBAqhqHg7xdcahNHPoglsn84PHBeQmGTcpC4Y7GUKSSBs5zg+telx6p4U1m/EF5HHaapIM+RexNazvkdBuxv/AOAkitd9Bjtzv0SY6W5GGWGNTE/uUPGfcYPrnpSA4TwP4VvdMmjjuJHtr+5TzDEqoTYRbVV23AtmR2BA5IAzjoc+mQQ22mWRWMLDbxAuxJ/EsSep6kk03TrCKxSTYzyzSndLNIcvIfUn+QGAOwrjPFV5L4xup/CmhOxsd3la1qMZ+SGP+K2Ru8rj5Tj7ikk84FAE3whSS58NXOu3CFJtfvZtTCkYIichYR/36SOu4qO3hjt4I4IEWOGNQiIowFUDAA9qkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK4j4hatPJJB4a0q4eG+vo2kuZouZLe2HDFfR3PyqTwPmb+CgCrNJP4o146jYvH9g0+U2mnM7DbJOcia4A77QDGhwed56YNdlpenpp0GPMZmx8zE4X34/qcn1NeaWGpraLbS6HbJeyRYtracM8em2vBURRbQXuGAB+4pBwTle15PCepa/ObjxG0mpg4KxaiTDaR8/wAFnGTu+srk0Abet+MfCSXKQXWrRXlwmQLOyLXLk+8cQYn8RWZL4mEEQktPCetNEGOxr+WCyjH0SWQEf98Vv2XhiGyiUSXrwWkYP+jWKLZwAe4TDce7YqS0uPC1k5Ntc6Qko6t50Zc/Uk5NAHOjxd4lu2P2LQ9GhJOMyajLOQfQ+TAw/wDHqhTxF42Zjus9EXrhfst/j/vrysfpXYDXFupCmj2sl+F+9MrBIQfTefvH/dBx3qXz9Y6nT7LHoLts/wDoumBx58ZeIbT/AI+9L0OfPIEepyW7AfSaFR/49UOpeJZ5rcz3/hrxDCjgHdbLBewDHceV5je+dtdhNrYs3CavZXFqjA/vgvmw4GOrKPl6/wAQHenjR9HvAl1b29uC3zLcWp8tm9w6YJH40gPP9N8Q6Lq8/k6XqiNejH+jSKFm+gQFZB+CV0mnHS7e8Y3zyRlCGHmgKqkd3IAyMkHMi5z3NS6v4OTULZ7e7lt9WtjkrBrFstwEz/dcYYfUkmuRvPC+saEfM0qe6itkBxY3jPqdgBj+A8XEJ91yo9DTGega+0TtHDObOSCYcRXKlVZvVZBwDjtivPPHCS6Bd6Tr8EUqJo9wJnhlZdyWzfLOEbB3qEJbaGzlQSOKZaeI3hnZNbnOliRwkd01ws9k7f8API3OPlz2SeMN2BPbprmNjDLZ3lvttbuIxvbFPMt5VIOcJk44P/LMn1K0Ad2jK6hkIZWGQQcgilrivhFqD3HhFNNupkmvNFlbTJnR9wcR48t8990ZjP1JrtaQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKo61qdto2lXOoXzMsEC7jtG5mPQKo7sSQAO5IFAGV4w1eS1SDS9NmWPV9QDLCxXeYEA+ebaOW25GB3YqOmSMCx0jR9Mtbaxit0Z4lEaM22SdsZ+8w4XkknG5jkk81nRWk+qF9R1O5uoru7yZ4rdwgVMfJblgCwVQSSB8zMWYrjGOo0MW9tE2oXEkNnp8a4Rmk8tcjjLZPzfVmP0FAzUstI8mMKHW3i/552w25/3nPzH8MVdjtILRHe2tlMmM/KBvf23HqfqayB4rsrhgNItr7VcnG+zhzH/39bah/Bqo30PiDV5UcafFYwhCPLuNRbBJPVkiX5j/ANtMe1Ai7efa53eS5mXT42+VVkuyMfgmOf8AgRqKBRE4lh1meaRewR5Y/wARk/zqKHw7qwKEarYWRAwRYaaqn/vqRn/lSt4Ru35fxf4kLdysluv6CHFAG5JqEBhfP2nG05ZLeTj3HFZbXECqrHU9T243Ye03DHvmLNVv+ESv0IaDxj4jRgc/O1tID9Q0NSrpfiiBmaDxLbXAyMLeaaCMY9Y3Tn3/AEoAhgNhdyt9n1DTZZmO7DxeVKT2OVKn9KW90ZXnFxc28yypjbNFIZcY9xtk7njJqG9j8RPHt1fQNG1mLpm0uDFIB7JKMf8Aj4qhba1p+mzGO6n1Lw+S37tdShKw5/u+ZkxFf+BBvegCx4i0Bta08WrtDKsmJ/KhkIBznB8tyQR7jHPrXATtfeD7rSlHjDVbOOa/W1ubO4jj4jlO2OSMSKwIWQqG2YG05wuMn1K5mku4YZ7uCPaEB38SwNn+JJF+ZOvUj/Gue8c6W2veEbzThfQqJUZ4TqAV0DdVKTDjggEZ5454oA2ZPCV/qCmPXfFGq3dseGt7YR2aOPRmjUSfk4rpNL06z0qwhsdNtorWzhXbHDEoVVH0FU/CesxeIfDenatCNq3UIdkPVH6Mp9wwI/CtagAooooAKKKKACiiigAooooAKKKKACiiigAoorgPF/ivUdK8T3FhZSRYS2s5IIXtHdZ5Zppo9jSghYs+WoBbuT1xigDv6K46fxzBFrlxZ/Yp3s7eZrea5QOxR1TcW2hcbB90ndnP8OOajm8Ua0X8OvDo1vHDq10I0El1lzGbaaYZwuEceWufvDBIBJOQAdrRXLp4wt2ggk+yy4livZQNw4Fs+xh/wLqKzz44uUWR59G2RwwWt5KRdAlbe4dkQgbeXBR8r0wOGOcUAdxRQTgE4J+lYw19AMyabqsf/bozf+g5oAm8Ta1aeHPD+oaxqT7LSyhaaQjqQB0HuTgD3NeQ+E9EvvF95dz6xEYZ7tkuNQR0J27gGjikB4bam0LD90Ab5AzMFG98SvEdpeXGjacbW8dfNN61vNZTKJnjKrAjDbyvnPGx/wCudd34UhtYNHSKyeWXaxM0ssTRvLKeXdgwBySc/p2oAtaXpdppkRW2Q7yAGkc7nbA4yfQdgMAdgKz01G91hm/sXyobIEr9umXeJCOD5SAjcP8AaJA9Aw5rI8R63DfaPc3LM8XhuAkXVyv3rsA7fKhUckM2F3cZ6LnORas9Gvtato5PETm0tGUbNItH2JGvZZXXBc4xkDCdsN1IBmasfDk97HDqVxf+JL+zkEotYVacRyDoWjiAjUjtvrUXxDtP7vwprm/HyAW0S7vxL4H4kV0dlaW1jbJb2VvFb26DCxxIEVfoBxU9AHKpY69rlw8+pXc+h2SriGzspUaZj/flk2kD0Crx1JJ4AePCkyztIvibxCDtwqmeMqp9QDHyfrkV09FAHGvqHiXw42NVtG8Q6Z2u9PiC3Uf/AF0gzh/96Pn/AGKqW+t+C7y6aSw12LSbxvvxCc2bk88tDJgE89SpNd7Ve9srW+h8q+toLmL+5NGHH5GgDkpPEFnBgXHjrRUUDjJhViPU5fB/ACrNrr8kdrJe2+o2Ov6dDk3D2GDNCMZztViH+gwfQE8V0FrpdhZgC0sbWADtFCq/yFeev9r0jx9ea9r2kXsVtEkltay6TaLLE1uSrb5yhMrPlemzavOM5zQM7LU9H0/xBax3cLKsksX7u6jUN5kbDO1gRiRCP4WBH0ODXCx6FqfhyX7DpEtvHDISY9GvCWsLrvi3c5e2fqdmWUdhgEjd8Magun+GrefRNRg17QLVfLZolAuIUXr04YqOq7VbjueK6u7trPW9L8uQia1uEDo6N+KurDoRwQR7UAeb+CtShPxElubae5RNVtvs15p10uJ7K8gG4CTnktGzYbncIwcsOa9WryvxRpiLq1hq99vTxJ4eZbn7XEu0ahZA7JN3YlVdiV/hbkcNz6pQDCiiigQUUUUAFFFFABRRRQAUUUUAI2cfLjPvS0UUAFFFFABXmviPV4NY8QziW48jSNBk3M7NsSW5AOWY8ErGDgAEEuTkgLmum+IXiNPC/hW71AyIk52wW5cZXzXO1cjuATkjqQMDnFc/4A8HSpp2n3PiPdM1uN9raSrjYxO4zSjJBmYktjkITxk5YgxdOttU1/DWUBsNNxtFzeR/PIvby4cABfTdhe5V+tdPZ+F9NhnS4uo31G8T7txfN5rKf9kH5U+iACtys+51NVnlt7SJ7m5jxvVTtWPIyNzHgcc45OO1AjQoJAGScAVxB8SX+qtJHocZv1QlXewUCJWBwV+0SEIffYrEe1WBYay8e5tF0mSbHBu9SlmKn3zEfyFAG4ut2kzypZebeNG21jbplQfTecLn8ahfWnSVUNqgJ/ga6iDn6DOD+dUI/DEmoSLJ4mukvolAEenwRmK0T6pkmQ/75I9FFaMXhjQYU2RaJpiJjG1bSMDH5UAWItVtWdY52NtM3AjnGwk+x6N+BNXxyOK5m88IWYRm0aR9JlPVIAGt3/34G+Q/UAN7iqUNrqmntsuPDOnXwJ5m06VYt31jkxtPsHP1oA7PIzjIzSOqujI6hlYYIIyCK4tLe0iuJrpfBepGZh8xY27E454Bm/wp8OsIwkTRkv4NRtwk0ul3sbBmhLgMyhuuBnBQkZAHJOKALM/g6C0le58L3D6HdsdzLAu62lP+3AflP1Xa3vVGHUXW+XS/ENrHpOrXOUhniPmWV+2Ogz/ERnKOA2M7SwGa7O2niuYI5rd1kikG5WXoRUGrabZavp81jqdtHc2kow8cgyD6H2IPII5B5FAHFfDR5tL1nxH4bvrWO0khuf7RtYoW3RG3n6lDgYHmrL8vBGR9a9AryWaa68KfEzw1aandPcQXXnWFpeTHMk0LqHEUh/ieORFw3UrJk8hifWqACiiigAooooAKKKKACiiigAooooAKKKKACs290PTr6S+e7tVla+t0tbjcxw8aFyq4zgYMrnIweevAxpUUAY8fhvTIrw3McdwsjFWkAu5dkrBQoaRN212wACzAk4GTxUEXhDR4oIYY4bpY4HSSAfbZ8wFVZV8s78oNrsuFwMHGMVv0UAYMfhLRo7qW4W2k3yLMhU3MpRRMcyhULbV3Hk7QOank8N6TJHMj2mVmt4bRx5j8xQszRr17F2OepzzniteigAooooA4PV4hc/FHTi65SKOFevfbcv8AzSM/lW38QLuay8HanLbEiZoxChBwQXYJke43VrLptoNQa+8lTdH/AJaHkjjbx6cVW8Q6a2q2tta5TyBdQzTBs8rG4cAfVlUfTNAzlfiH5emS+FHuYHTwtY3fm3zRIWWDy4z5DOByI1fBJxgbVJwOa7xHWRFdGDIwyrA5BHqK5bx1HeaobDw9atJb2uq+al7douWjgVcsinoHfOAT0G4jkCumtLeK0tYba2QRwQoscaDoqgYAH4UCJaKKKACiiigAooooAKKKKAOI8eWD6MG8XaHCV1CxxJfQxDH261H+sRgPvOq5ZD1BXHQkVoeHriGy1BbO2dX0rUYze6a6n5QCAzxj2+YOvszDotdM6q6MrgFCMEHoRXnngWwmufhPoohz9qs1M1gx/uo7eUPo0eFPsxoA6HxxZpLp0d46lo7UsLhR/FbupSYfgp3fVBVzwncPceH7Lz2DXESeRMc5zIh2MfxKk/jVyznh1TS4Z1Xdb3UIfa3dWGcH8DUeiaZFpNglvESxwu9z/GwULux2yFH+TQBfooooAKKKKACiiigAooooAKKKKACiiigAooooA5G/QeIvGsdhJ82maII7qdO0t02TEp9kUb/qyHtXXVy3gYNJceJrlxhp9YlGfURpHEP/AEXXQ6jO9tp9zNEjSSRxsyqFLEkDgYFAGZ4k1yHSraYmaOJoo/NllcErBH03EDkknhVHLHgd6xdJ0C51i1U62sttpUjGUaYx/eTljkvdMOpJOfLX5R0O7oH+LtMSx0O11ASwE6bdpqNyLqTYl0yqw+ZuxBYMvYMijgdOq026F9p9rdrFNCJ4llEUybJE3DOGXsRnkUASwxRwxJFCixxIAqogwFA6ADsKfRRQAUUUUAFFFFABXK39lqVl4rm1uCzXVIXtkto4lmEctsoJZwgb5W3nYTllPygc4FdVRQByHh/VLddQ1WdJpWt5pVklgeMxvYNsAw8Z5AbBbf0Jz25rrlYOoZCGUjIIOQRXM+JFFl4l8OaoMKXnfT5mA5aOVCVB9f3iJj/eNbFnp5s76WS3lKWci/8AHtt+VXzyyntn0HHegCr4q8N6d4msYrfU4d5t5lubaVXZHgmX7sispBBB/PoeKvaVc/arKNzJHJKuY5TGwIEina449GBFW653SlOmeLNTscAW9+o1CDAwA/CTD8/Lb6u1AHRUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyWRIYmkldY41GWZjgAe5p9ecfGnTLy/sNBlTTrnVtItNSjn1LT7Zd7zxAHHyfxgHB29+PTgA9Dt54bmFZbaWOWJvuvGwZT+IqSvF9Ye4jttNPhfQvEegeG5JLprmDTbEw3DXHlp5LeUoLLGSCOgGR82BzV3w3D41v9bthr97q1mttoltcSJbxqIp7vc+5GYoQTjbuVCPyoA9borw2eLx1D8O/D96b7xBcXl5LGdViMeJ7aMK2AiIgkALbd2MtwO2afDP4qFroKa9deKpdIW1uBJcaZZSJdyXAl/deam3eF8voSACeWoA9voryv4S6Ze6X4t8WjUBroa5uRcRNeRYhlRkj+feF2mTOQQDwB0r1SgCpq1kNR025szNLAs6GNpIjhwp4OD2OMjPbtU1pbw2lrDbW0axQQoscaL0VQMAD6CpaKAGxRpFGscSKkajCqowAPQCnUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADIYY4VZYUVAzFyFGMsTkn6kmn0UUAYniPQ31e50uZLmOP7DcG4EU0PmxSNtIUsoZeVJypzwecdMbdFFABUQuYDN5QmjMv9zcN35VLXiOrWTRfGDxJqWm+H79JjocsVpfR6VJt+2hXJZZNmNxX5d2fmztyc4oA9uorwjZ8QrGxJ026168u73wxDdyC7jBEF75sQkSPKgLIIzJhDySOcmr+oTasItMGny+PD4e+0zC/kkt3+3BvJXyhGNvmeXv3ZOMZ/2aAPaKK8k8Hw+NdR8SaFH4lvdWsoIdEguboQIqxTXIuG/dyMUI3GPbuVSD9KxUi8ex/DDRtQa98Qz6nd3EY1O3eLE9tAplB8tFQSDJKFurYAxgUAe60V4hBP4rFjoKa1deKZdFX7UJ7jT7KVLxn3DyRIu3zNoBYBtoyR83rWx8K9MvdO8e+KpL8eIALwRXEL30WIpVMceSzBdvmqfl2g8ANxxmgD0fXNNGqWSW/m+UUuIZw+3dgxyq+Oo67cZ7ZrQoooAKhktYZLuG5dMzwqyI2egbG4fjtH5VNRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.715.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16707=[""].join("\n");
var outline_f16_20_16707=null;
var title_f16_20_16708="Magnesium glucoheptonate: Drug information";
var content_f16_20_16708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium glucoheptonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/2/5156?source=see_link\">",
"    see \"Magnesium glucoheptonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2110224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Magnesium Glucoheptonate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2110228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2110249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum levels may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum levels in patients with normal renal function for most efficient repletion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 310 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 350 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 420 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypomagnesemia:",
"     </b>",
"     Oral: 1500-3000 mg (75-150 mg elemental magnesium) 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10952944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum levels may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum levels in patients with normal renal function for most efficient repletion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 130 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 410 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2984796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10952945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate renal impairment: Use with caution; monitor serum magnesium levels carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe renal impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, oral: 100 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10952946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2110229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2110236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2110231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment and/or lesions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2110232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart block: Hypermagnesemia may result in heart block; use with caution in patients with pre-existing heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication. Use is contraindicated in patients with severe renal impairment and/or lesions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2110241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14081298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14081299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2110628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     100 mg magnesium glucoheptonate = 0.42 mEq magnesium = 5 mg elemental magnesium",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2110250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium levels should be monitored to avoid overdose; monitor for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2110627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum total magnesium: 1.5-2.3 mg/dL (SI: 0.62-0.95 mmol/L or 1.2-1.9 mEq/L); slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Magnelium (CA);",
"     </li>",
"     <li>",
"      Magnolex (CA);",
"     </li>",
"     <li>",
"      Magnorol Sirop (CA);",
"     </li>",
"     <li>",
"      ratio-Magnesium (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2110244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2110246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Urine (as magnesium)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bohman VR and Cotton DB, &ldquo;Supralethal Magnesemia With Patient Survival,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1990, 76(5 Pt 2):984-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engel J, &ldquo;Normal Laboratory Values,&rdquo;",
"      <i>",
"       Pocket Guide to Pediatric Assessment",
"      </i>",
"      , St Louis, MO: CV Mosby, 1989, 259.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/20/16708/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaeser HE, &ldquo;Drug-Induced Myasthenia Gravis,&rdquo;",
"      <i>",
"       Acta Neurol Scand Suppl",
"      </i>",
"      , 1984, 100:39-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols B, &ldquo;Minerals,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , Norwalk, CT: Appleton &amp; Lange, 1987, 176-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/20/16708/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10201 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16708=[""].join("\n");
var outline_f16_20_16708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110228\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110249\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952944\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984796\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952945\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241424\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234056\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952946\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110229\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110236\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110231\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110232\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299632\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110241\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081299\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110628\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110250\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110627\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869467\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110244\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110246\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10201|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/2/5156?source=related_link\">",
"      Magnesium glucoheptonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16709="Hypertrophic actinic keratosis";
var content_f16_20_16709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Hypertrophic actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This hypertrophic actinic keratosis demonstrates a thick accumulation of keratin overlying an erythematous base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16709=[""].join("\n");
var outline_f16_20_16709=null;
var title_f16_20_16710="Nimodipine: Drug information";
var content_f16_20_16710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nimodipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/45/3796?source=see_link\">",
"    see \"Nimodipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nimotop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F201618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Capsules and contents are for oral/NG tube administration",
"     <b>",
"      ONLY.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Subarachnoid hemorrhage:",
"     </b>",
"     Oral: 60 mg every 4 hours for 21 days, start therapy within 96 hours after subarachnoid hemorrhage.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F201619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F201620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F201621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage to 30 mg every 4 hours in patients with liver failure.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For oral administration ONLY.  Life-threatening adverse events have occurred when administered parenterally.",
"     </b>",
"     Administer on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Nasogastric (NG) tube administration: If the capsules cannot be swallowed, the liquid may be removed by making a hole in each end of the capsule with an 18-gauge needle and extracting the contents into a syringe; transfer these contents into an oral syringe (amber-colored oral syringe preferred). It is strongly recommended that preparation be done in the pharmacy. Label oral syringe with",
"     <b>",
"      \"WARNING: For ORAL use only&rdquo;",
"     </b>",
"     or",
"     <b>",
"      &ldquo;Not for I.V. use.&rdquo;",
"     </b>",
"     Follow with a flush of 30 mL NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vasospasm following subarachnoid hemorrhage from ruptured intracranial aneurysms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NiMODipine may be confused with niCARdipine, NIFEdipine, nisoldipine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       <b>",
"        For oral administration only.",
"       </b>",
"       For patients unable to swallow a capsule, the drug should be dispensed in an oral syringe (preferably amber in color) labeled",
"       <b>",
"        \"WARNING: For ORAL use only\"",
"       </b>",
"       or",
"       <b>",
"        \"Not for I.V. use.\"",
"       </b>",
"       Nimodipine has inadvertently been administered I.V. when withdrawn from capsules into a syringe for subsequent nasogastric tube administration. Severe cardiovascular adverse events, including fatalities, have resulted. Employ precautions against such an event.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Reductions in systemic blood pressure (1% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2% to 4%), abdominal discomfort (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, CHF, deep vein thrombosis, depression, disseminated intravascular coagulation, dyspnea, ECG abnormalities, GI hemorrhage, hemorrhage, hepatitis, jaundice, neurological deterioration, rebound vasospasm, thrombocytopenia, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nimodipine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ileus/ pseudo-obstruction: Intestinal pseudo-obstruction and ileus have been reported during therapy; use caution in patients with decreased GI motility of a history of bowel obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Idiopathic hypertrophic subaortic stenosis (IHSS): Use with caution in patients with IHSS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inadvertent I.V. administration:",
"     <b>",
"      [U.S. Boxed Warning]: Nimodipine has inadvertently been administered I.V. when withdrawn from capsules into a syringe for subsequent nasogastric administration. Severe cardiovascular adverse events, including fatalities, have resulted;",
"     </b>",
"     precautions (eg, adequate labeling, use of oral syringes) should be employed against such an event.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of NiMODipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of NiMODipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F201610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nimodipine has shown a 1.5-fold increase in bioavailability when taken with grapefruit juice. Management: Avoid concurrent use of grapefruit juice and nimodipine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Dong quai has estrogenic activity. Some herbal medications may worsen hypertension (eg, ephedra); garlic may increase antihypertensive effects of nimodipine. Management: Avoid dong quai if using for hypertension. Avoid St John's wort, ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus. Teratogenic and embryotoxic effects have been demonstrated in small animals. No well-controlled studies have been conducted in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F201601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (NiMODipine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $287.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nimotop Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $310.04",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Admon (ES);",
"     </li>",
"     <li>",
"      Amocure (TW);",
"     </li>",
"     <li>",
"      Brainal (ES);",
"     </li>",
"     <li>",
"      Calnit (ES);",
"     </li>",
"     <li>",
"      Eugerial (AR, BR, CO, PE);",
"     </li>",
"     <li>",
"      Grifonimod (PE);",
"     </li>",
"     <li>",
"      Irrigor (PE);",
"     </li>",
"     <li>",
"      Kenesil (ES);",
"     </li>",
"     <li>",
"      Kenzolol (MX);",
"     </li>",
"     <li>",
"      Modip (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Modus (ES);",
"     </li>",
"     <li>",
"      Nidip (CO);",
"     </li>",
"     <li>",
"      Nimodilat (AR);",
"     </li>",
"     <li>",
"      Nimodin (PH);",
"     </li>",
"     <li>",
"      Nimodipino Bayvit (ES);",
"     </li>",
"     <li>",
"      Nimotop (AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IT, JM, KP, LU, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, RU, SE, SG, SR, SV, TH, TR, TT, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Nisom (CO);",
"     </li>",
"     <li>",
"      Periplum (IT);",
"     </li>",
"     <li>",
"      Remontal (ES);",
"     </li>",
"     <li>",
"      Tropocer (CO, VE);",
"     </li>",
"     <li>",
"      Vasoactin (EC);",
"     </li>",
"     <li>",
"      Vasoflex (CN);",
"     </li>",
"     <li>",
"      Vasotop (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nimodipine shares the pharmacology of other calcium channel blockers; animal studies indicate that nimodipine has a greater effect on cerebral arterials than other arterials; this increased specificity may be due to the drug's increased lipophilicity and cerebral distribution as compared to nifedipine; inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage sensitive areas of vascular smooth muscle and myocardium during depolarization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50%) and feces (32%) within 4 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ramoska EA, Spiller HA, and Myers A, &ldquo;Calcium Channel Blocker Toxicity,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1990, 19(6):649-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/20/16710/abstract-text/2344082/pubmed\" id=\"2344082\" target=\"_blank\">",
"        2344082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/20/16710/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9702 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16710=[""].join("\n");
var outline_f16_20_16710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709172\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201614\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201659\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201618\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201619\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201620\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201621\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201592\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201579\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201596\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201595\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201666\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201657\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201599\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201583\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201653\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201588\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201610\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201589\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201602\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201624\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201601\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201603\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201582\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201598\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9702|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/45/3796?source=related_link\">",
"      Nimodipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16711="Polymyositis interstitial lung disease";
var content_f16_20_16711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    CT scan of lung bases with interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The high resolution CT scan of the bases of the lungs in the axial projection (A) reveals bibasilar reticular pattern with traction bronchiectasis at the right base (highlighted and magnified in green with arrow in B, and blue in C); ground glass changes better seen in the left base (D, yellow arrow). Image E (magnified with red overlay) reveals a secondary lobule with thickened interlobular septa and centrally placed arteriole. While not pathognomonic, the changes are consistent with NSIP associated with polymyositis and dermatomyositis.",
"    <div class=\"footnotes\">",
"     NSIP: nonspecific interstitial pneumonia.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter LaCamera, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16711=[""].join("\n");
var outline_f16_20_16711=null;
var title_f16_20_16712="Screening laboratory tests in HIV-infected patients";
var content_f16_20_16712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening laboratory tests in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16712/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16712/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16712/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/20/16712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of HIV infection has been established, the severity of disease and rate of progression can be estimated by measurement of the CD4 count and the HIV viral load. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a number of comorbidities and complications may be encountered in the untreated HIV-infected patient with advanced immunosuppression, such as HIV-associated nephropathy or advanced liver disease secondary to viral hepatitis.",
"   </p>",
"   <p>",
"    This topic will give guidance to some of the routine laboratory testing that should be performed in the HIV-infected patient who presents for care. A discussion of the history, physical examination and other primary care issues (eg, cervical screening and tuberculosis testing) of the HIV-infected patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=see_link\">",
"     \"Primary care of HIV-infected adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual screening battery advocated for patients with established HIV infection is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef55701 \" href=\"UTD.htm?42/63/44028\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The screening tests can be divided into routine blood tests, serologic tests, skin tests, chest x-ray, and Papanicolaou smear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BLOOD TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete blood count (CBC) is important in patients with HIV infection since anemia, leukopenia, lymphopenia, and thrombocytopenia are found in 30 to 40 percent of patients who present with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/3\">",
"     3",
"    </a>",
"    ]. The CBC should be repeated at three- to six-month intervals. More frequent testing is recommended in patients with symptoms suggesting marrow suppression, those receiving marrow suppressing drugs such as the nucleoside analogues, and those with marginal or low counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SMA-12, 14 or 20 is of limited value in a general health screen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/4\">",
"     4",
"    </a>",
"    ], but is commonly advocated in the initial evaluation of HIV infection. It establishes baseline values in anticipation of medication use and can detect the presence of subclinical hepatitis, which is commonly found in HIV-infected patients. Previous studies of HIV-infected patients revealed abnormal liver function tests and elevations of serum creatinine in up to 75 percent, and severe liver function abnormalities in 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/3\">",
"     3",
"    </a>",
"    ]. Increased monitoring of aminotransferases after initiation of antiretroviral therapy (ART) is prudent if aminotransferases are elevated at baseline. Similarly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    should be used with caution in patients with elevated serum creatinine. Many patients also have elevated serum concentrations of lactate dehydrogenase (LDH) of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A routine blood glucose and lipid profile should also be performed; if either test is elevated, a fasting screen should be ordered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucose-6-phosphate dehydrogenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disease that predisposes to hemolytic anemia following exposure to oxidant drugs, including those commonly used in patients with HIV infection. Over 150 G6PD variants are inherited on the X chromosome. The most frequent are GdA-, which is found in 10 percent of black men and 1 to 2 percent of black women, and Gdmed which is found predominately in men from the Mediterranean area (Italians, Greeks, Sephardic Jews, and Arabs), India, and Southeast Asia.",
"   </p>",
"   <p>",
"    Some laboratories report G6PD levels as",
"    <span class=\"nowrap\">",
"     units/g",
"    </span>",
"    of hemoglobin while others report qualitative results. Levels below 3",
"    <span class=\"nowrap\">",
"     units/g",
"    </span>",
"    Hgb indicate severe deficiency, which is most commonly found in men and homozygous women.",
"   </p>",
"   <p>",
"    In most forms of G6PD deficiency, hemolysis is mild because only older red cells hemolyze and the bone marrow can compensate despite continued administration of the implicated drug. The important exception is Gdmed, which can cause life-threatening hemolysis.",
"   </p>",
"   <p>",
"    However, even the limited hemolysis in GdA- may be significant in patients with advanced HIV infection because of depressed bone marrow reserve and concomitant anemia from other causes. The severity of anemia also depends upon the concentration of the drug in red cells and the oxidant potential of the inducing agent. The most likely offending agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    , and occasionally sulfonamides. Partial G6PD deficiency may be a relative contraindication for oxidant drugs.",
"   </p>",
"   <p>",
"    The approach to G-6-PD screening is somewhat controversial. Three options have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain the test as baseline information on all patients",
"     </li>",
"     <li>",
"      Restrict testing to those most likely to have a defect",
"     </li>",
"     <li>",
"      Reserve testing to the occasional case of hemolytic anemia following exposure to potential offending agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typical findings in hemolysis due to G6PD deficiency are elevated serum concentrations of bilirubin and LDH, decreased serum concentrations of haptoglobin, methemoglobinemia, reticulocytosis, and a peripheral smear showing the characteristic \"bite cells\". G6PD levels are usually normal during an episode of hemolysis since the susceptible G6PD-deficient red cells have been destroyed. As a result, testing should be delayed for about 30 days following discontinuation of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SEROLOGIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of serologic tests in HIV infection may be falsely negative because of decreased antibody response to infection or falsely positive because of polyclonal B cell activation. Nevertheless, the diagnosis of several opportunistic infections in HIV infection is enhanced by serologic data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A screening test for syphilis (VDRL or reactive rapid plasma reagin) should be conducted annually in sexually active patients due to high rates of coinfection with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/5\">",
"     5",
"    </a>",
"    ]. However, HIV-infected patients are more likely than controls to have a biologic false positive (BFP) screening tests for VDRL (6.8 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/6\">",
"     6",
"    </a>",
"    ] and rapid plasma reagin (11 versus 0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/7\">",
"     7",
"    </a>",
"    ]. Other risk factors for BFP results include injection drug use and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ]. Thus, in patients with a positive serologic test, the diagnosis should be confirmed by fluorescent treponemal antibody absorption (FTA-ABS). False negative tests are rare, but have been reported with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]; furthermore, patients with symptomatic HIV infection are more likely to lose FTA-ABS reactivity to syphilis after appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Note that some laboratories now screen for T. pallidum with an antigen assay that requires confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lumbar puncture is recommended for patients with early syphilis (&lt;1 year) in the following circumstances: neurologic signs or symptoms; failure to use the standard regimen of 2.4 million units of benzathine penicillin; and when treatment has failed. A lumbar puncture is recommended for all patients with latent syphilis, regardless of the clinical findings and duration of syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/14\">",
"     14",
"    </a>",
"    ]. Interpretation of the cerebrospinal fluid (CSF) findings in the presence of HIV infection may be confounded by the presence of mononuclear cells and an elevated protein concentration.",
"   </p>",
"   <p>",
"    Following treatment for syphilis, the rate of decline in the RPR is slower in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In one report, for example, less than a fourfold decline in RPR titers at six months after therapy was seen in 56 percent of HIV-infected patients versus 38 percent of those who were HIV-negative (p = 0.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/15\">",
"     15",
"    </a>",
"    ]. However, in this and other studies, virtually all patients responded well clinically, suggesting that the significance of the diminished serologic response may be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse or serologically defined failure is common despite the use of recommended therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. In one series of 56 HIV-infected patients with syphilis, serologic or clinical relapse occurred in 10 (18 percent), 7 of whom had received high-dose intravenous or procaine penicillin therapy and 5 of whom had multiple relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, follow-up VDRL or RPR titers are particularly important. More intensive initial therapy (10 days of amoxicillin and probenecid) does not appear to reduce the frequency of serologic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatitis viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis screen advocated by the",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    guidelines is hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/1\">",
"     1",
"    </a>",
"    ]. The utility of these tests depends upon the indications for hepatitis B vaccination and interpretation of liver function tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with HIV infection should be screened for hepatitis B virus (HBV) infection with HBsAg and HBsAb. Seroprevalence is 35 to 80 percent for gay men, 60 to 80 percent for injection drug users, 60 to 80 percent for hemophiliacs, 5 to 20 percent for heterosexuals with multiple partners, and 3 to 14 percent for the general population. The CDC recommends postvaccination serology for HBsAb at one to six months after the third dose in patients with HIV infection to confirm an antigenic response. If the anti-HBV titer is &lt;10",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    the series should be repeated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected patients with abnormal liver function tests should also be tested for hepatitis C antibody (anti-HCV). Coinfection with HIV and HCV appears to accelerate the course of hepatic complications ascribed to HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    is recommended in susceptible HIV-infected persons with HCV infection, and some recommend the Hep A vaccine for all HIV-infected persons. Anti-HAV serology is often used as a screening test to avoid the expense and inconvenience of two HepA vaccine doses for a disease with a seroprevalence rate of 30 to 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis serology (IgG) is recommended to assist in the differential diagnosis of complications involving the central nervous system, to identify candidates for toxoplasmosis prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/18\">",
"     18",
"    </a>",
"    ], and to counsel seronegative patients on preventive measures. Toxoplasmosis seroprevalence among adults in the United States is 10 to 30 percent, and the seroconversion rate is as high as 1 percent per year. Relapse of latent infection occurs in 20 to 47 percent of patients with AIDS who have not received prophylactic antibiotics and have positive Toxoplasmosis serology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/19\">",
"     19",
"    </a>",
"    ]. Primary toxoplasmosis in AIDS is uncommon.",
"   </p>",
"   <p>",
"    Toxoplasmosis serology should be repeated in seronegative patients when the CD4 count is below",
"    <span class=\"nowrap\">",
"     100/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and the patient cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis for Pneumocystis carinii pneumonia. Patients who seroconvert from negative to positive should be considered for specific toxoplasmosis prophylaxis. Serology should also be repeated if toxoplasmosis encephalitis is considered and prior tests were negative.",
"   </p>",
"   <p>",
"    The preferred diagnostic method is an agglutination assay for IgG. IgM assays are not useful and the Sabin-Feldman dye test is less accurate than the agglutination assay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) serology is recommended in the",
"    <span class=\"nowrap\">",
"     USPHS/IDSA",
"    </span>",
"    Guidelines at initial evaluation to detect latent CMV infection in patients with a low risk of harboring CMV (populations other than gay men and injection drug users) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/1\">",
"     1",
"    </a>",
"    ]. Possible uses of this information are to counsel the patient on prevention through sexual exposure, in differential diagnosis of possible CMV disease in late-stage HIV infection, to identify candidates for CMV prophylaxis in whom the CD4 count is",
"    <span class=\"nowrap\">",
"     &lt;50/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (although this is not a current recommendation), and to identify persons who should have nonemergent transfusions with CMV-antibody negative blood or leukocyte-depleted blood products.",
"   </p>",
"   <p>",
"    Seroprevalence for CMV in adults in the United States is about 50 percent. The rate in gay men and injection drug users is greater than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Many authorities consider screening for CMV to be unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHEST X-RAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A routine chest x-ray is recommended by the Centers for Disease Control (CDC) in HIV-infected patients for detection of asymptomatic tuberculosis and to serve as a baseline study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the yield may be quite low. One study, for example, evaluated the results of chest radiography in 1065 patients at various stages of HIV infection who were followed for twelve months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/23\">",
"     23",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An abnormality was seen in only 2 percent",
"     </li>",
"     <li>",
"      None of the asymptomatic patients had evidence of active tuberculosis, including all 751 anergic patients",
"     </li>",
"     <li>",
"      Only 1 of 82 with a positive tuberculin (PPD) skin test had an abnormality on x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that routine chest x-ray in HIV-infected patients with a negative PPD skin test was not warranted. Despite the low frequency of subclinical active tuberculosis in the HIV population, any patient with newly discovered PPD positivity should have a chest x-ray to exclude active tuberculosis prior to initiating prophylactic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TB DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC recommends routine testing with PPD (Mantoux test, 5 tuberculin units) or the IFN gamma release assay. The criterion for a positive PPD test in the presence of HIV infection is 5 mm of induration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/24\">",
"     24",
"    </a>",
"    ]. Screening should be repeated",
"    <strong>",
"     annually",
"    </strong>",
"    in high-risk patients if the initial test is negative.",
"   </p>",
"   <p>",
"    Aggressive screening for tuberculosis in HIV-infected patients is based upon the high risk of reactivation of latent tuberculosis, even at relatively high CD4 counts. The risk of reactivation among HIV-infected patients with a positive PPD is 5 to 10 percent per year (compared to 0.4 percent per year in patients who remain PPD-negative) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/25\">",
"     25",
"    </a>",
"    ]. Similar rates of active tuberculosis have been noted in at-risk patients who are anergic in areas with high rates of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most authorities, including the revised US Public Health Service-IDSA draft guidelines, no longer recommend anergy testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link&amp;anchor=H1454273#H1454273\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\", section on 'Indications for TB preventive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PAPANICOLAOU SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC and the Agency for Health Care Policy and Research recommend a gynecologic evaluation with pelvic examination and Papanicolaou smear at the time of diagnosis in HIV-infected women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for cervical screening in HIV-infected women are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=see_link\">",
"     \"Screening for cervical cancer in HIV infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to perform a Papanicolaou smear, the cervix is scraped circumferentially using an Ayer spatula or a curved brush. A sample from the posterior fornix or the \"vaginal pool\" may also be included. The endocervical sample is taken with a saline-moistened, cotton-tipped applicator or straight ectocervical brush that is rolled on a slide and immediately fixed in ethyl ether plus 95 percent ethyl alcohol or 95 percent ethyl alcohol alone. The yield is sevenfold higher with the brush specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the Papanicolaou smear are reported using the Bethesda system. The adequacy of the specimen should be stated and the following findings are described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Within normal limits",
"     </li>",
"     <li>",
"      Benign cellular changes &mdash; eg, infection",
"     </li>",
"     <li>",
"      Reactive changes &mdash; eg, inflammation, repair, atrophy",
"     </li>",
"     <li>",
"      Epithelial cell abnormalities",
"     </li>",
"     <li>",
"      Atypical cells of undetermined significance (ACUS)",
"     </li>",
"     <li>",
"      Low-grade squamous intraepithelial lesion (LSIL) &mdash; includes HPV changes, mild",
"      <span class=\"nowrap\">",
"       dysplasia/CIN",
"      </span>",
"      1",
"     </li>",
"     <li>",
"      High-grade squamous intraepithelial lesion (HSIL) &mdash; includes moderate and severe",
"      <span class=\"nowrap\">",
"       dysplasias/CIN",
"      </span>",
"      2 and CIN 3",
"     </li>",
"     <li>",
"      Squamous cell carcinoma",
"     </li>",
"     <li>",
"      Glandular cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A gynecologist should be consulted if any abnormal cervical cytology is noted or if benign-appearing glandular cells are seen at any time other than close to the patient's menstrual period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Papanicolaou smear has a sensitivity of approximately 90 percent in diagnosing premalignant or malignant cervical lesions. Concerns have been raised, however, that cervical cytology may be less accurate as a screening tool in HIV-infected women. Thus, some experts have recommended periodic colposcopic examination even in women with normal Papanicolaou smear findings. However, controlled studies to date have found no difference in sensitivity of Papanicolaou smear in HIV-infected women compared to uninfected controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anal HPV and dysplasia are at least as common as cervical infection and dysplasia in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/32\">",
"     32",
"    </a>",
"    ]. In one report, vulvar intraepithelial neoplasia (VIN) was found in 14 of 58 (24 percent) HIV-infected women compared to only 1 of 85 (1 percent) HIV-uninfected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/33\">",
"     33",
"    </a>",
"    ]. Women with pigmented",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    raised vulvar lesions were particularly likely to have VIN on biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of abnormal Papanicolaou smears is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659726\">",
"    <span class=\"h1\">",
"     ANAL PAP SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is commonly recommended for patients with HIV infection and may be particularly important in MSM due to high rates of anal cancer despite ART [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/13,34,35\">",
"     13,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659733\">",
"    <span class=\"h2\">",
"     Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;No preparation is required. A Dacron swab is moistened with saline or non-sterile water, the anus is spread so that aroderm is exposed, and the swab is then inserted at least 2 cm beyond the anal verge. The swab is then gradually withdrawn while rotating with mild pressure against the anal wall. &nbsp;The swab is then immersed in methanol-based solution and submitted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659740\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of eight published series indicated sensitivities of 69 to 93 percent and specificity 32 to 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/36\">",
"     36",
"    </a>",
"    ]. Interpretation is the same as for cervical PAPS. Patients with abnormal tests showing ASUS, LSIL or HSIL should be referred for high resolution anoscopy, which is comparable to cervical colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659747\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotypic testing is recommended at the initial visit to assess evidence of HIV drug resistance, even if the patient will not receive ART. If genotypic testing is delayed, viral strains with resistance mutations may become undetectable, only to emerge later when the patient begins ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659754\">",
"    <span class=\"h1\">",
"     HLA-B5701 TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a necessary screening test for patients who are to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    to determine susceptibility for the abacavir-associated hypersensitivity reaction, which can be lethal. This assay has an estimated sensitivity of 100 percent and a specificity of 50 percent. Turnaround time for testing results is approximately one week and the cost is approximately $100 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/38\">",
"     38",
"    </a>",
"    ]. Although reports of false negative tests are extremely low, it is recommended that the patient with a negative test be warned of the possibility of hypersensitivity, regardless. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11659769\">",
"    <span class=\"h1\">",
"     TROPISM ASSAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tropism testing is performed in any patient who is to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , since this drug only blocks R5-tropic virus. If tropism testing detects X4-tropic virus, the drug will be ineffective. This assay is expensive (about US $1900 to $2000) and usually requires two to three weeks to perform. The probability of finding R5-tropic virus is influenced by treatment history (80 percent in treatment-naive patients; 50 percent in treatment-experienced patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16712/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The sensitivity of the Trofile test with &ldquo;enhanced sensitivity&rdquo; (that is now standard) is about 99.7 percent for detecting X4 virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=see_link\">",
"       \"Patient information: Testing for HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29176963\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of HIV infection has been established, the severity of disease and rate of progression can be estimated by measurement of the CD4 count and the HIV viral load. In addition, a number of comorbidities and complications may be encountered in the untreated HIV-infected patient with advanced immunosuppression, such as HIV-associated nephropathy or advanced liver disease secondary to viral hepatitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complete blood count (CBC) is important in patients with HIV infection since anemia, leukopenia, lymphopenia, and thrombocytopenia are found in 30 to 40 percent of patients who present with advanced disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complete blood count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A serum creatinine and urinalysis in HIV-infected patients can help determine if there is any sign of HIV-associated nephropathy. Aminotransferase elevations may be seen in HIV-infected patients who have underlying viral hepatitis, drug-induced liver injury, or hepatic steatosis. A routine blood glucose and lipid profile should also be performed to assess for any metabolic abnormalities; if either test is elevated, a fasting screen should be ordered. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Chemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A screening test for syphilis (VDRL or reactive rapid plasma reagin) should be conducted annually in sexually active HIV-infected patients due to high rates of coinfection with Treponema pallidum. Any reactive nontreponemal serology should be confirmed with a specific treponemal test. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Serologic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients should be screened for hepatitis B virus (HBV) infection with HBsAg and HBsAb, hepatitis C virus (HCV) with anti-HCV antibody and hepatitis A virus (HAV) with anti-HAV antibody. Patients who are not immune should be vaccinated against HAV and HBV. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hepatitis viruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxoplasmosis serologic testing helps to identify those patients who are at risk for reactivation disease. Immunosuppressed patients (ie, CD4 cell count &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      who are toxoplasma IgG-seropositive are candidates for prophylaxis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Toxoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with evidence of latent tuberculosis are at high risk for developing active infection in the absence of prophylaxis. A history of tuberculosis (TB) or TB exposure should be sought, and results of prior purified protein derivative (PPD) testing or an interferon-gamma release assay should be obtained. Screening should be repeated annually in high-risk patients if the initial test is negative. Anergy testing is not recommended. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'TB detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pelvic examination and Papanicolaou smear is recommended at the time of diagnosis in HIV-infected women. Anal pap smears are recommended for patients with HIV infection and may be particularly important in men who have sex with men due to high rates of anal cancer despite antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Papanicolaou smear'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11659726\">",
"       'Anal pap smear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV genotypic testing is recommended at the initial visit to assess evidence of HIV drug resistance, even if the patient will not receive antiretroviral therapy immediately. (See",
"      <a class=\"local\" href=\"#H11659747\">",
"       'Drug resistance testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HLA-B5701 testing is a necessary screening test for patients who are to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      to determine susceptibility for the abacavir-associated hypersensitivity reaction, which can be lethal. (See",
"      <a class=\"local\" href=\"#H11659754\">",
"       'HLA-B5701 testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV tropism testing is performed in any patient who is to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       maraviroc",
"      </a>",
"      , since this antiretroviral medication only blocks R5-tropic virus. If tropism testing detects X4-tropic virus, the drug will be ineffective. (See",
"      <a class=\"local\" href=\"#H11659769\">",
"       'Tropism assay'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/1\">",
"      Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Clin Infect Dis 1995; 21 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/2\">",
"      Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/3\">",
"      Freedberg KA, Malabanan A, Samet JH, Libman H. Initial assessment of patients infected with human immunodeficiency virus: the yield and cost of laboratory testing. J Acquir Immune Defic Syndr 1994; 7:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/4\">",
"      Cebul RD, Beck JR. Biochemical profiles. Applications in ambulatory screening and preadmission testing of adults. Ann Intern Med 1987; 106:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/5\">",
"      Centers for Disease Control (CDC). Recommendations for diagnosing and treating syphilis in HIV-infected patients. MMWR Morb Mortal Wkly Rep 1988; 37:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/6\">",
"      Augenbraun MH, DeHovitz JA, Feldman J, et al. Biological false-positive syphilis test results for women infected with human immunodeficiency virus. Clin Infect Dis 1994; 19:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/7\">",
"      Rompalo AM, Cannon RO, Quinn TC, Hook EW 3rd. Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection. J Infect Dis 1992; 165:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/8\">",
"      Malone JL, Wallace MR, Hendrick BB, et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med 1995; 99:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/9\">",
"      Marra CM, Handsfield HH, Kuller L, et al. Alterations in the course of experimental syphilis associated with concurrent simian immunodeficiency virus infection. J Infect Dis 1992; 165:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/10\">",
"      Hicks CB, Benson PM, Lupton GP, Tramont EC. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med 1987; 107:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/11\">",
"      Haas JS, Bolan G, Larsen SA, et al. Sensitivity of treponemal tests for detecting prior treated syphilis during human immunodeficiency virus infection. J Infect Dis 1990; 162:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/12\">",
"      Johnson PD, Graves SR, Stewart L, et al. Specific syphilis serological tests may become negative in HIV infection. AIDS 1991; 5:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/13\">",
"      Se&ntilde;a AC, White BL, Sparling PF. Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis 2010; 51:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/14\">",
"      Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med 1990; 113:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/15\">",
"      Yinnon AM, Coury-Doniger P, Polito R, Reichman RC. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med 1996; 156:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/16\">",
"      Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/17\">",
"      S&aacute;nchez-Quijano A, Andreu J, Gavil&aacute;n F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/18\">",
"      Beaman MH, Luft BJ, Remington JS. Prophylaxis for toxoplasmosis in AIDS. Ann Intern Med 1992; 117:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/19\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/20\">",
"      Pass RF. Epidemiology and transmission of cytomegalovirus. J Infect Dis 1985; 152:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/21\">",
"      Collier AC, Meyers JD, Corey L, et al. Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987; 82:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/22\">",
"      Centers for Disease Control (CDC). Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep 1986; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/23\">",
"      Schneider RF, Hansen NI, Rosen MJ, et al. Lack of usefulness of radiographic screening for pulmonary disease in asymptomatic HIV-infected adults. Pulmonary Complications of HIV Infection Study Group. Arch Intern Med 1996; 156:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/24\">",
"      Screening for tuberculosis and tuberculous infection in high-risk populations. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Recomm Rep 1990; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/25\">",
"      Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1997; 126:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/26\">",
"      Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/27\">",
"      Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/28\">",
"      Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/29\">",
"      Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1996; 153:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/30\">",
"      Korn AP, Autry M, DeRemer PA, Tan W. Sensitivity of the Papanicolaou smear in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/31\">",
"      Adachi A, Fleming I, Burk RD, et al. Women with human immunodeficiency virus infection and abnormal Papanicolaou smears: a prospective study of colposcopy and clinical outcome. Obstet Gynecol 1993; 81:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/32\">",
"      Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83:205.",
"     </a>",
"    </li>",
"    <li>",
"     Abercrombie et al. HIV and Women's Conference, Feb.1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/34\">",
"      Seaberg EC, Wiley D, Mart&iacute;nez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116:5507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/35\">",
"      Abbas A, Yang G, Fakih M. Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park) 2010; 24:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/36\">",
"      Chiao EY, Giordano TP, Palefsky JM, et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/37\">",
"      Fox P. Anal cancer screening in men who have sex with men. Curr Opin HIV AIDS 2009; 4:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/38\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/39\">",
"      Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16712/abstract/40\">",
"      Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3741 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16712=[""].join("\n");
var outline_f16_20_16712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29176963\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BLOOD TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucose-6-phosphate dehydrogenase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SEROLOGIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatitis viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHEST X-RAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TB DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PAPANICOLAOU SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11659726\">",
"      ANAL PAP SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11659733\">",
"      Method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11659740\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11659747\">",
"      DRUG RESISTANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11659754\">",
"      HLA-B5701 TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11659769\">",
"      TROPISM ASSAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29176963\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/63/44028\" title=\"table 1\">",
"      Routine labs asymptomatic HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26474?source=related_link\">",
"      Primary care of HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16713="Skin examination and clinical features of melanoma";
var content_f16_20_16713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skin examination and clinical features of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Susan Swetter, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Alan C Geller, RN, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16713/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/20/16713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6082563\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the most serious form of skin cancer and the sixth most common cancer in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/1\">",
"     1",
"    </a>",
"    ]; its incidence increases with age. Five-year survival rates for people with melanoma depend on the stage of the disease at the time of diagnosis. There are five stages: stage 0 is in situ (intraepithelial) melanoma, stage I and II are localized cutaneous disease, stage III is regional nodal disease, and stage IV is distant metastatic disease (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). Most people with thin stage I lesions can expect prolonged disease-free survival and even cure, whereas those with later stage II-IV lesions are more likely to die from metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features of melanoma and how to perform a skin examination for melanoma and other skin cancers. The rationale for performing regular screening skin examinations and the clinical presentation of nonmelanoma skin cancers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link&amp;anchor=H574559#H574559\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\", section on 'Clinical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531006\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531013\">",
"    <span class=\"h2\">",
"     Melanoma subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major subtypes of invasive cutaneous melanoma (",
"    <a class=\"graphic graphic_table graphicRef57168 \" href=\"UTD.htm?9/0/9228\">",
"     table 2",
"    </a>",
"    ): superficial spreading (",
"    <a class=\"graphic graphic_picture graphicRef57466 \" href=\"UTD.htm?28/40/29326\">",
"     picture 1D",
"    </a>",
"    ), nodular melanoma (",
"    <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"     picture 3D",
"    </a>",
"    ), lentigo maligna (",
"    <a class=\"graphic graphic_picture graphicRef62105 \" href=\"UTD.htm?4/54/4967\">",
"     picture 2D",
"    </a>",
"    ), and acral lentiginous (",
"    <a class=\"graphic graphic_picture graphicRef78826 \" href=\"UTD.htm?0/3/54\">",
"     picture 3C",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Most melanomas arise as superficial tumors that are confined to the epidermis, where they may remain for several years. During this stage, known as the horizontal or \"radial\" growth phase, the melanoma is almost always curable by surgical excision alone. Melanomas that infiltrate into the dermis are considered to be in a \"vertical\" growth phase and have metastatic potential. Nodular melanomas have no identifiable radial growth or in situ phase, and enter the vertical growth phase almost from their inception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathologic characteristics of melanoma\", section on 'Growth phases of melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The probability of metastases with invasive, vertical growth phase melanoma is most strongly predicted by measuring the thickness of the tumor (ie, Breslow depth), in millimeters, from the granular cell layer of the epidermis to the deepest malignant cell in the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/4\">",
"     4",
"    </a>",
"    ]. Other histologic factors including ulceration of the tumor, mitotic rate, presence of lymphovascular invasion, microsatellites, regression, perineural invasion, and the presence of lymphocytes infiltrating the tumor, can also affect metastatic potential of the tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531020\">",
"    <span class=\"h3\">",
"     Superficial spreading melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial spreading melanoma is the most common subtype, accounting for approximately 70 percent of all melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/5\">",
"     5",
"    </a>",
"    ]. Over 60 percent of superficial spreading melanomas are diagnosed as thin, highly curable tumors of less than 1 mm thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority arise de novo and only about one-fourth are associated with a preexisting nevus. Superficial spreading melanoma can occur in any anatomic location, but has a predilection for the back in men and women and lower extremities in women.",
"   </p>",
"   <p>",
"    Superficial spreading melanoma presents as a variably pigmented macule or plaque with an irregular border, ranging from a few millimeters to several centimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef64980 graphicRef61158 graphicRef71893 graphicRef57466 graphicRef74278 \" href=\"UTD.htm?40/20/41290\">",
"     picture 1A-E",
"    </a>",
"    ). Lesions may have multiple shades of red, blue, black, gray, and white. The pathologic features of superficial spreading melanoma are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathologic characteristics of melanoma\", section on 'Superficial spreading melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137428135\">",
"    <span class=\"h3\">",
"     Nodular melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular melanomas are the second most common type, accounting for 15 to 30 percent of all melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/5\">",
"     5",
"    </a>",
"    ]. They appear as darkly pigmented, pedunculated, or polypoid nodules (",
"    <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"     picture 3D",
"    </a>",
"    ), although amelanotic (nonpigmented) variants exist but are less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/7\">",
"     7",
"    </a>",
"    ]. Of the major histopathologic subtypes, nodular melanoma is most difficult to diagnose at an early stage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. While the great majority of superficial spreading melanomas and lentigo maligna melanomas are diagnosed at less than 1 mm of thickness, at least half of all nodular melanomas are greater than 2 mm. Likewise, more than 50 percent of melanoma lesions greater than 2 mm in thickness are nodular [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic features of nodular melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathologic characteristics of melanoma\", section on 'Nodular melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531027\">",
"    <span class=\"h3\">",
"     Lentigo maligna melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna melanoma most commonly arises in sun-damaged areas of the skin in older individuals, and begins as a tan-brown macule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/11\">",
"     11",
"    </a>",
"    ]. The lesion gradually enlarges and develops darker, asymmetric foci, color variegation, and raised areas that signify vertical growth within the precursor in situ melanoma, termed &ldquo;lentigo maligna&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef74664 graphicRef54753 graphicRef57765 graphicRef62105 \" href=\"UTD.htm?40/30/41450\">",
"     picture 2A-D",
"    </a>",
"    ). It accounts for 10 to 15 percent of all melanomas, although the incidence is rising in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. The pathologic features of lentigo maligna melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathologic characteristics of melanoma\", section on 'Lentigo maligna melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531034\">",
"    <span class=\"h3\">",
"     Acral lentiginous melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acral lentiginous subtype accounts for less than 5 percent of all melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/5\">",
"     5",
"    </a>",
"    ]. However, it is the most common type of malignant melanoma among dark-skinned individuals, who are at lower risk for more sun-related melanoma subtypes. Acral lentiginous melanomas arise most commonly on palmar, plantar, and subungual surfaces. They appear as a dark brown to black, irregularly pigmented macules or patches (",
"    <a class=\"graphic graphic_picture graphicRef51085 graphicRef63894 graphicRef78826 \" href=\"UTD.htm?29/10/29864\">",
"     picture 3A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/13\">",
"     13",
"    </a>",
"    ]. If a lesion becomes raised, develops ulceration, or is &gt;5 mm in diameter, the likelihood of invasion should be considered.",
"   </p>",
"   <p>",
"    Subungual melanoma arises from the nail matrix and usually presents as a longitudinal brown or black band, with or without nail dystrophy (",
"    <a class=\"graphic graphic_picture graphicRef64134 graphicRef52821 graphicRef75881 graphicRef51165 \" href=\"UTD.htm?22/13/22746\">",
"     picture 4A-D",
"    </a>",
"    ). Sometimes the presentation is that of a subungual mass (with or without pigmentation) with various degrees of ulceration and nail plate destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/14\">",
"     14",
"    </a>",
"    ]. Biopsy of the nail matrix may be warranted for a pigmented nail band with any of the following characteristics: dark color, solitary, dyshomogeneous pigmentation, change in shape or pigmentation, or width &gt;4mm, irregular margins. The presence of periungual pigmentation (Hutchinson sign) is an additional diagnostic clue. However, it can be observed in a number of benign nail conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic features of acral lentiginous melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathologic characteristics of melanoma\", section on 'Acral lentiginous melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137428425\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important prognostic factors for patients with localized melanoma of any subtype are tumor thickness, mitotic rate, and ulceration. These factors have been incorporated in the seventh (2010) edition of the staging system of the American Joint Committee on Cancer (AJCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/16\">",
"     16",
"    </a>",
"    ]. Tumor thickness is the single most important determinant of prognosis. Survival rates decline as tumor thickness increases.",
"   </p>",
"   <p>",
"    The AJCC used data from 27,000 patients with stage I and II disease in whom tumor thickness and follow-up information was available to define four T stage categories and calculate ten-year survival rates (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"UTD.htm?7/61/8157\">",
"     table 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/16\">",
"     16",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T1: &le;1 mm; ten year survival 92 percent",
"     </li>",
"     <li>",
"      T2: 1.01 to 2.00 mm; ten year survival 80 percent",
"     </li>",
"     <li>",
"      T3: 2.01 to 4.00 mm; ten year survival 63 percent",
"     </li>",
"     <li>",
"      T4: &gt;4 mm; ten year survival 50 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early detection of melanoma is therefore crucial to improve patient outcome and save lives. Although most melanomas are detected by patients themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], clinician detection is associated with thinner, more curable tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47495879\">",
"    <span class=\"h1\">",
"     CLINICAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical recognition of melanoma may be challenging even for the most experienced dermatologist. However, several clinical features of a skin lesion are suggestive of melanoma and prompt referral to a specialist or biopsy. Asymmetry, irregular borders, variegated color, diameter &gt;6mm, or a recent change in a lesion, are most frequently associated with a diagnosis of melanoma. These findings, especially in adults, are of utmost importance in the",
"    <span class=\"nowrap\">",
"     referral/biopsy",
"    </span>",
"    decision [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/8,23,24\">",
"     8,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three diagnostic aids have been identified to help clinicians (and lay people) identify suspicious lesions: two checklists and the &ldquo;ugly duckling&rdquo; sign. These are complementary, and all three may be used in the examination for melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3148564\">",
"    <span class=\"h2\">",
"     Diagnostic aids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several sets of criteria have been developed to identify lesions that are suspicious for melanoma, but only a few have been widely adopted. Two checklists have been developed to help clinicians and the lay public to identify skin lesions that should prompt further evaluation: the ABCDE [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/23\">",
"     23",
"    </a>",
"    ] and the revised Glasgow seven-point checklist [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/25\">",
"     25",
"    </a>",
"    ]. The seven-point checklist is used more commonly in Europe than in the United States. The ABCDE mnemonic is recommended by the American Cancer Society [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/26\">",
"     26",
"    </a>",
"    ] and by the American Academy of Dermatology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47495344\">",
"    <span class=\"h3\">",
"     ABCDE rule",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1985, dermatologists from New York University first devised the acronym ABCD (asymmetry, border irregularity, color variegation, diameter &gt;6 mm) to be used by both lay people and clinicians to identify early melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/28\">",
"     28",
"    </a>",
"    ]. The list was intended to help the diagnosis of early, superficial forms of melanoma that might be confused with benign pigmented lesions. The criteria were subsequently enhanced with the addition of E (evolving) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/23\">",
"     23",
"    </a>",
"    ] to incorporate the fundamental concept of change, including a modification over time of a preexisting nevus or the development of a new lesion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      symmetry (if a lesion is bisected, one half is not identical to the other half)",
"     </li>",
"     <li>",
"      <strong>",
"       B",
"      </strong>",
"      order irregularities",
"     </li>",
"     <li>",
"      <strong>",
"       C",
"      </strong>",
"      olor variegation (brown, red, black or",
"      <span class=\"nowrap\">",
"       blue/gray,",
"      </span>",
"      and white)",
"     </li>",
"     <li>",
"      <strong>",
"       D",
"      </strong>",
"      iameter &ge;6 mm",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      volving: a lesion that is changing in size, shape, or color, or a new lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic accuracy of the ABCD mnemonic has been assessed in a few studies, all having methodologic limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/29\">",
"     29",
"    </a>",
"    ]. The sensitivity and specificity of the ABCDE criteria vary when they are used individually or in combination, and the risks of over- and under-referral must be balanced accordingly. The use of a single criterion is sensitive but not specific, meaning that many benign lesions would be biopsied or referred, whereas using more than one criterion for referral is more specific, but increases the chance of missing malignant lesions. In the primary care setting, patients reporting a changing mole and one of the other signs noted above should be strongly considered for referral to an expert in skin cancer. Additionally, patients reporting a one month or greater duration of a changing mole that is not trauma-related should also be referred. In a retrospective study of 1140 lesions including 460 melanomas, the sensitivity in identifying a lesion as a melanoma was 97 percent when using a single criterion and 43 percent when using all five criteria jointly. By contrast, specificity was 36 percent for a single criterion and 100 percent for all five criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10374288\">",
"    <span class=\"h3\">",
"     The revised Glasgow seven-point checklist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another set of criteria for referral or biopsy was developed from a retrospective review of patients with melanoma, and subsequently revised. It includes three major and four minor features [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Major:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Change in",
"      <span class=\"nowrap\">",
"       size/new",
"      </span>",
"      lesion",
"     </li>",
"     <li>",
"      Change in shape &nbsp;",
"     </li>",
"     <li>",
"      Change in color",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diameter &ge;7mm",
"     </li>",
"     <li>",
"      Inflammation",
"     </li>",
"     <li>",
"      Crusting or bleeding",
"     </li>",
"     <li>",
"      Sensory change",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any major feature is an indication for referral; the additional presence of any of the minor criteria reinforces the need for referral [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/25,31\">",
"     25,31",
"    </a>",
"    ]. The only study to evaluate the sensitivity and specificity of the revised Glasgow seven-point check list found a sensitivity of 100 percent and specificity of 37 percent in the diagnosis of 65 melanomas and 100 benign pigmented lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/32\">",
"     32",
"    </a>",
"    ]. Another study including only melanomas found a sensitivity of 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47496022\">",
"    <span class=\"h3\">",
"     The \"ugly duckling\" sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ugly duckling sign is based upon the observation that in an individual with multiple nevi, the nevi tend to exhibit a predominant morphologic type, defining a relatively specific &ldquo;profile.&rdquo; A pigmented lesion that looks different from other surrounding lesions must be considered suspicious, even if it does not fulfill the ABCD criteria. The &ldquo;ugly duckling&rdquo; sign was proposed as an additional criterion for the clinician to identify those lesion(s) in patients with multiple nevi that deserve special attention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/34\">",
"     34",
"    </a>",
"    ]. The predictive value of the ugly duckling sign has not been systematically studied. However, the ugly duckling sign has been shown to play an important role in the overall pattern recognition process that expert clinicians use to diagnose a pigmented lesion in their daily practice [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47495758\">",
"    <span class=\"h2\">",
"     Dermoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoscopy (or epiluminescence microscopy [ELM]), requires the use of a hand-held 10x lens in combination with oil or other liquid to eliminate light reflection and provide a better view of a pigmented lesion. Newer instruments use polarized light, eliminating the need for oil or liquids. This technique is not generally used in the primary care setting, and requires training to provide an advantage over the naked eye examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dermoscopic diagnosis is a multistep process to establish whether a lesion is melanocytic, benign, or suspicious. Pigment network,",
"    <span class=\"nowrap\">",
"     globules/dots,",
"    </span>",
"    or streaks classify a pigmented lesion as melanocytic. Certain dermoscopic features are suggestive of melanoma and should prompt biopsy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A meta-analysis of studies of dermoscopy compared with naked eye examination in the diagnosis of melanoma concluded that for clinicians with at least some training in dermoscopy, the addition of dermoscopy to the unaided clinical examination increases the sensitivity in detecting melanoma (90 versus 71 percent), but has similar specificity (80 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10884070\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple melanocytic and non-melanocytic lesions may simulate melanoma. The differential diagnosis of melanoma includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Common melanocytic nevus (",
"      <a class=\"graphic graphic_picture graphicRef73384 \" href=\"UTD.htm?8/54/9062\">",
"       picture 5",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=see_link\">",
"       \"Acquired melanocytic nevi (moles)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atypical melanocytic nevus (",
"      <a class=\"graphic graphic_picture graphicRef61488 graphicRef68734 \" href=\"UTD.htm?39/0/39943\">",
"       picture 6A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41545?source=see_link\">",
"       \"Atypical (dysplastic) nevi\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Traumatized nevus",
"     </li>",
"     <li>",
"      Blue nevus (",
"      <a class=\"graphic graphic_picture graphicRef67504 \" href=\"UTD.htm?23/27/23986\">",
"       picture 7",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Lentigo (ink spot)",
"     </li>",
"     <li>",
"      Spitz nevus (",
"      <a class=\"graphic graphic_picture graphicRef68392 \" href=\"UTD.htm?33/55/34676\">",
"       picture 8",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18906?source=see_link\">",
"       \"Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Melanonychia striata (",
"      <a class=\"graphic graphic_picture graphicRef64603 \" href=\"UTD.htm?27/6/27745\">",
"       picture 9",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=see_link&amp;anchor=H549604#H549604\">",
"       \"Overview of nail disorders\", section on 'Longitudinal melanonychia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pigmented basal cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef83549 \" href=\"UTD.htm?31/58/32676\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pigmented actinic keratosis",
"     </li>",
"     <li>",
"      Seborrheic keratosis (",
"      <a class=\"graphic graphic_picture graphicRef54386 graphicRef81260 graphicRef52360 graphicRef58923 graphicRef76720 graphicRef73356 \" href=\"UTD.htm?42/42/43690\">",
"       picture 11A-F",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyogenic granuloma (",
"      <a class=\"graphic graphic_picture graphicRef67395 graphicRef60189 \" href=\"UTD.htm?29/51/30520\">",
"       picture 12A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29785?source=see_link\">",
"       \"Pyogenic granuloma (Lobular capillary hemangioma)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cherry hemangioma (",
"      <a class=\"graphic graphic_picture graphicRef63468 graphicRef54605 \" href=\"UTD.htm?32/35/33335\">",
"       picture 13A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dermatofibroma (",
"      <a class=\"graphic graphic_picture graphicRef68729 graphicRef80587 graphicRef80575 \" href=\"UTD.htm?32/9/32922\">",
"       picture 14A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Keratoacanthoma (",
"      <a class=\"graphic graphic_picture graphicRef55042 graphicRef59550 \" href=\"UTD.htm?30/42/31400\">",
"       picture 15A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subungual hematoma (",
"      <a class=\"graphic graphic_picture graphicRef67759 \" href=\"UTD.htm?32/10/32930\">",
"       picture 16",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283142762\">",
"    <span class=\"h1\">",
"     CLINICIAN SKIN EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary objective of the skin examination is to detect early melanoma that could be treated and thereby decrease mortality. Other skin cancers, including basal cell carcinoma and squamous cell carcinoma can be detected on full skin examination as well. Patient history and risk factors for melanoma can be ascertained while the skin examination is conducted. Skin examination by clinicians during examination for other purposes (termed &ldquo;opportunistic screening&rdquo;), compared to detection of lesions by patients themselves, may result in identification of thinner, more curable melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83031482\">",
"    <span class=\"h2\">",
"     History and assessment of risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for melanoma include the presence of a high number of common nevi, one or more atypical nevi, light skin phenotype, excessive sun exposure, and history of sunburns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5#H5\">",
"     \"Risk factors for the development of melanoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    History plays an important role in patient evaluation for melanoma. Patients should be asked if they have any concerns about a particular lesion or if they have noticed a new mole or a change in a preexisting mole. Patients should also be asked about a personal or family history (especially first-degree relatives) of melanoma or other skin cancers. The patient&rsquo;s tendency to sunburn, sun exposure habits, and history of blistering sunburns during childhood or teenage years should be assessed as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43034853\">",
"    <span class=\"h2\">",
"     Total body skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body skin examination (TBSE) for melanoma requires a source of bright light and, ideally, a magnifying lens. TBSE could be integrated into a routine physical examination by adequately trained primary care providers, and should be part of the dermatologist consultation.",
"   </p>",
"   <p>",
"    Clinicians should look for the characteristic features of melanoma (",
"    <a class=\"graphic graphic_picture graphicRef57466 graphicRef78826 graphicRef80955 graphicRef62105 \" href=\"UTD.htm?28/51/29497\">",
"     picture 1D, 2D, 3C-D",
"    </a>",
"    ) and other skin cancers. (See",
"    <a class=\"local\" href=\"#H81531013\">",
"     'Melanoma subtypes'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link&amp;anchor=H21299826#H21299826\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The basic tenets of the whole-body skin examination are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examine the face and rest of the head and neck while the patient is sitting on the examination table.",
"     </li>",
"     <li>",
"      Examine the scalp.",
"     </li>",
"     <li>",
"      Examine all surfaces of the arms and hands.",
"     </li>",
"     <li>",
"      Ask the patient to lie down on",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      back for viewing the chest, abdomen, anterior thighs, anterior legs, dorsal feet, soles, and toe webs.",
"     </li>",
"     <li>",
"      Ask the patient to turn over. Examine the calves, posterior thighs, buttocks, and back. The upper body could also be examined when the patient is sitting or standing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the specific order of examination, TBSE should be standardized to insure completeness. The clinician examination also serves as a model for patient skin self-examination. If a clinician ignores an area, it may convey the unintended message to the patient that this area is unimportant and that they can ignore it as well. (See",
"    <a class=\"local\" href=\"#H85360953\">",
"     'Patient skin self-examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85360811\">",
"    <span class=\"h2\">",
"     Training for skin examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medical professionals lack specific education in skin examination for the early detection of melanoma. In a study from the United States, only 25 percent of primary care residents received training in skin examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/37\">",
"     37",
"    </a>",
"    ]. The sensitivity of melanoma detection by skin examination was significantly lower for primary care clinicians in general practice compared to those practicing in skin cancer clinics in Australia (29 vs 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/38\">",
"     38",
"    </a>",
"    ]. Appropriate training can improve the skills, knowledge, confidence, and attitudes of primary care providers in diagnosing melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The INFORMED (Internet-based Program For Melanoma Early Detection)&nbsp;program is a web-based program developed to train clinicians in the early detection of melanoma. This program is available at",
"    <a class=\"external\" href=\"file://www.skinsight.com/info/for_professionals/skin-cancer-detection-informed/skin-cancer-education\">",
"     www.skinsight.com/info/for_professionals/skin-cancer-detection-informed/skin-cancer-education",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85360953\">",
"    <span class=\"h1\">",
"     PATIENT SKIN SELF-EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the principles used for the clinician skin examination are used for skin self-examination practices. One caveat for self-examination is that particular attention must be devoted to screening of the back. About one half of melanomas occur on the trunk on men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], and about one-third on the back [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/22\">",
"     22",
"    </a>",
"    ], where it is difficult to perform self-examination. Partners, friends, or family may need to participate in the examination. Recommendations for skin self-examination in high risk individuals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link&amp;anchor=H339582288#H339582288\">",
"     \"Screening and early detection of melanoma\", section on 'High-risk individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least for high-risk individuals, clinicians should be recommending monthly skin self-examinations. Skin self-examination typically involves the use of a full-length mirror to examine the entire front and back of the body and then the sides of the body (with arms raised) (",
"    <a class=\"external\" href=\"file://caonline.amcancersoc.org/content/vol60/issue5/images/large/CAAC20074fig005.jpeg\">",
"     file://caonline.amcancersoc.org/content/vol60/issue5/images/large/CAAC20074fig005.jpeg",
"    </a>",
"    ). The patient can next examine",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    palms, forearms, upper arms, and axillae, followed by the back of the legs and feet, toe web spaces, and soles. A hand mirror is helpful for closer inspection of the back of the neck and scalp as well as the back and buttocks. Several web sites describing self-examination are available for patient access:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Dermatology",
"      <span class=\"nowrap\">",
"       (www.aad.org/public/exams/self.html)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The Skin Cancer foundation",
"      <span class=\"nowrap\">",
"       (www.skincancer.org/Self-Examination/)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531898\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS WITH SUSPICIOUS SKIN LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106428122\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ABCDE rule, the revised Glasgow seven-point checklist, or the ugly duckling sign may be helpful in the identification of suspicious pigmented lesions, although they are more sensitive than specific. Primary care clinicians should have a relatively low threshold for referral to a dermatologist to determine whether biopsy is indicated, when a lesion is identified that is not clearly benign. For example, an inflamed or rapidly growing seborrheic keratosis (",
"    <a class=\"graphic graphic_picture graphicRef52360 \" href=\"UTD.htm?23/17/23827\">",
"     picture 11C",
"    </a>",
"    ) may be referred for further evaluation.",
"   </p>",
"   <p>",
"    Guidelines published in 2010 by the British Association of Dermatologists suggest the following indications for referral [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A new mole appearing after the onset of puberty which is changing in shape, color, or size",
"     </li>",
"     <li>",
"      A long-standing mole which is changing in shape, color, or size",
"     </li>",
"     <li>",
"      Any mole which has three or more colors or has lost its symmetry",
"     </li>",
"     <li>",
"      A mole which is itching or bleeding",
"     </li>",
"     <li>",
"      Any new persistent skin lesion especially if growing, if pigmented or vascular in appearance, and if the diagnosis is not clear",
"     </li>",
"     <li>",
"      A new pigmented line in a nail especially where there is associated damage to the nail",
"     </li>",
"     <li>",
"      A lesion growing under a nail",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106428130\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is necessary whenever melanoma is suspected. An excisional biopsy that includes the entire lesion with 1 to 3 mm margins of normal skin and part of the subcutaneous fat should be performed whenever possible. Narrow-margin excision allows the assessment of the entire lesion without compromising subsequent wider surgery or potential staging with the sentinel lymph node biopsy technique [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, according to the National Comprehensive Cancer Network and the American Academy of Dermatology guidelines, excisional biopsy techniques may include an elliptical or punch excision, saucerization, or deep shave biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Both guidelines recommend that shave biopsy should be limited to lesions for which the suspicion of melanoma is low, and performed to a depth below the anticipated plane of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. By contrast, the revised United Kingdom guidelines recommend that shave biopsies should be avoided, as they may lead to incorrect diagnosis due to sampling error [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/46\">",
"     46",
"    </a>",
"    ]. There is general consensus that incisional biopsy may be occasionally acceptable for very large lesions or for certain sites, including the face, palm or sole, ear, distal digit, or subungual lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed clinical information on excised lesions, including anatomic location, type of biopsy performed and intent (excisional or incisional), size of the lesion, and marking of suspicious foci, should be provided to the pathologist; additional information on ABCDE criteria, dermoscopic features, or clinical or dermoscopic images, if available, would also be useful, especially for incisional or punch biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. When a suspicious nail lesion (melanonychia striata, diffuse pigmentation, or amelanotic changes such as ulceration) is biopsied, the nail matrix should be sampled [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/49\">",
"     49",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81531913\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of skin examination in asymptomatic individuals is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at increased risk of melanoma (patients with a previous melanoma, patients with a large number of nevi",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    many clinically atypical nevi, and organ transplant recipients) should have regular examinations once or twice a year, and be seen sooner if a change in a pigmented lesion or a new lesion is noted. Patients with large or giant congenital nevi are also at increased risk, although this is a relatively rare risk factor. The optimum frequency with which skin examination should be performed in individuals at increased risk is uncertain, as there are no randomized trials to inform that determination. Several expert groups endorse recommendations that patients at increased risk of developing melanoma should be educated regarding the need for regular clinician examinations, skin self-examination, and sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients at greatly increased risk include individuals with a strong family history of melanoma (melanoma in more than one first-degree relative), or multiple primary melanomas, or the familial atypical multiple mole melanoma syndrome. The Melanoma Genetics Consortium recommends that members of high-risk families have a baseline skin examination by a trained health care provider beginning at the age of 10, with follow-up every six months until the nevus pattern is stable and the patient is judged competent at self-surveillance, and then annual follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/51\">",
"     51",
"    </a>",
"    ]. The Australian Cancer Network recommends monthly skin self-examination and biannual full body skin examination by a clinician for high risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16713/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283143748\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are four main types of cutaneous melanoma: superficial spreading melanoma (",
"      <a class=\"graphic graphic_picture graphicRef57466 \" href=\"UTD.htm?28/40/29326\">",
"       picture 1D",
"      </a>",
"      ), lentigo maligna melanoma (",
"      <a class=\"graphic graphic_picture graphicRef62105 \" href=\"UTD.htm?4/54/4967\">",
"       picture 2D",
"      </a>",
"      ), acral lentiginous melanoma (",
"      <a class=\"graphic graphic_picture graphicRef78826 \" href=\"UTD.htm?0/3/54\">",
"       picture 3C",
"      </a>",
"      ), and nodular melanoma (",
"      <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"       picture 3D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H81531013\">",
"       'Melanoma subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumor thickness is the single most important prognostic factor for patients with localized melanoma; the 10-year survival is 92 percent for patients with melanomas &le;1mm thick, and declines to 50 percent for patients with tumors &gt;4mm thick. Histologic findings of ulceration and mitotic rate are also significant features. (See",
"      <a class=\"local\" href=\"#H137428425\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early signs of melanoma include asymmetry, irregular borders, variegated color, diameter &gt;6mm, and a recent change in or development of a new lesion, particularly in adults. A pigmented lesion that looks different from other surrounding lesions (&ldquo;ugly duckling&rdquo; sign) is an important finding in patients with multiple nevi. (See",
"      <a class=\"local\" href=\"#H3148564\">",
"       'Diagnostic aids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of dermoscopy, after adequate training, can substantially improve the recognition of suspicious lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=see_link\">",
"       \"Overview of dermoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient&rsquo;s history, including personal and family history of melanoma, sun exposure habits, and history of sunburns is an important aspect of the clinical evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5#H5\">",
"       \"Risk factors for the development of melanoma\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The primary objective of the skin examination is to detect early melanoma and other skin cancers. Total body skin examination should be performed in a standardized sequence to avoid omissions, and should include the scalp. (See",
"      <a class=\"local\" href=\"#H43034853\">",
"       'Total body skin examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A changing or a new lesion is the most important criterion for referral. Additional indications include any mole which has three or more colors or has lost its symmetry, or is itching or bleeding; a new pigmented line in a nail, particularly if associated with nail plate damage; a lesion growing under the nail. (See",
"      <a class=\"local\" href=\"#H106428122\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest excisional biopsy with 1 to 3 mm margins of normal skin, for initial excision of suspicious lesions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Incisional biopsy may be acceptable for very large lesions or for certain sites, including the face, palm or sole, ear, distal digit, or subungual lesions. (See",
"      <a class=\"local\" href=\"#H106428130\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients determined to be at increased risk of developing melanoma, based on a personal history of melanoma, the presence of multiple atypical nevi, or history suggesting a familial melanoma syndrome should be educated on the importance of skin self-examination and sun protection, and strongly encouraged to receive regular clinician examinations. (See",
"      <a class=\"local\" href=\"#H81531913\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/2\">",
"      Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/3\">",
"      Geller AC, Miller DR, Annas GD, et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/4\">",
"      Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.",
"     </a>",
"    </li>",
"    <li>",
"     Paek SC, Sober AJ, Tsao H, et al. Cutaneous melanoma. In: Fitzpatrick's Dermatology in General Medicine, 7th, Wolff K, Goldsmith LA, Katz SI, et al.  (Eds), McGraw Hill Medical, New York 2008. Vol I, p.1134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/6\">",
"      Lasithiotakis KG, Leiter U, Gorkievicz R, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 2006; 107:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/7\">",
"      Plotnick H, Rachmaninoff N, VandenBerg HJ Jr. Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. J Am Acad Dermatol 1990; 23:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/8\">",
"      Geller AC, Elwood M, Swetter SM, et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/9\">",
"      Warycha MA, Christos PJ, Mazumdar M, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008; 113:3341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/10\">",
"      Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005; 141:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/11\">",
"      Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/12\">",
"      Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/13\">",
"      Coleman WP 3rd, Loria PR, Reed RJ, Krementz ET. Acral lentiginous melanoma. Arch Dermatol 1980; 116:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/14\">",
"      Buka R, Friedman KA, Phelps RG, et al. Childhood longitudinal melanonychia: case reports and review of the literature. Mt Sinai J Med 2001; 68:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/15\">",
"      Ruben BS. Pigmented lesions of the nail unit: clinical and histopathologic features. Semin Cutan Med Surg 2010; 29:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/16\">",
"      Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/17\">",
"      Brady MS, Oliveria SA, Christos PJ, et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000; 89:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/18\">",
"      Carli P, De Giorgi V, Palli D, et al. Self-detected cutaneous melanomas in Italian patients. Clin Exp Dermatol 2004; 29:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/19\">",
"      Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/20\">",
"      Epstein DS, Lange JR, Gruber SB, et al. Is physician detection associated with thinner melanomas? JAMA 1999; 281:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/21\">",
"      Schwartz JL, Wang TS, Hamilton TA, et al. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002; 95:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/22\">",
"      Swetter SM, Johnson TM, Miller DR, et al. Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol 2009; 145:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/23\">",
"      Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004; 292:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/24\">",
"      Kalkhoran S, Milne O, Zalaudek I, et al. Historical, clinical, and dermoscopic characteristics of thin nodular melanoma. Arch Dermatol 2010; 146:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/25\">",
"      MacKie RM. Clinical recognition of early invasive malignant melanoma. BMJ 1990; 301:1005.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Melanoma skin cancer overview. file://www.cancer.org/Cancer/SkinCancer-Melanoma/OverviewGuide/melanoma-skin-cancer-overview-diagnosed (Accessed on December 17, 2010).",
"    </li>",
"    <li>",
"     file://www.aad.org/public/publications/pamphlets/sun_malignant.html (Accessed on March 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/28\">",
"      Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/29\">",
"      Whited JD, Grichnik JM. The rational clinical examination. Does this patient have a mole or a melanoma? JAMA 1998; 279:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/30\">",
"      Thomas L, Tranchand P, Berard F, et al. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 1998; 197:11.",
"     </a>",
"    </li>",
"    <li>",
"     Scottish Intercollegioate Guidelines Network. Cutaneous Melanoma. A national clinical guideline.  file://www.sign.ac.uk/pdf/sign72.pdf (Accessed on December 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/32\">",
"      Healsmith MF, Bourke JF, Osborne JE, Graham-Brown RA. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994; 130:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/33\">",
"      du Vivier AW, Williams HC, Brett JV, Higgins EM. How do malignant melanomas present and does this correlate with the seven-point check-list? Clin Exp Dermatol 1991; 16:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/34\">",
"      Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/35\">",
"      Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005; 141:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/36\">",
"      Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008; 159:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/37\">",
"      Wise E, Singh D, Moore M, et al. Rates of skin cancer screening and prevention counseling by US medical residents. Arch Dermatol 2009; 145:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/38\">",
"      Youl PH, Baade PD, Janda M, et al. Diagnosing skin cancer in primary care: how do mainstream general practitioners compare with primary care skin cancer clinic doctors? Med J Aust 2007; 187:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/39\">",
"      Mikkilineni R, Weinstock MA, Goldstein MG, et al. The impact of the basic skin cancer triage curriculum on provider's skin cancer control practices. J Gen Intern Med 2001; 16:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/40\">",
"      Mikkilineni R, Weinstock MA, Goldstein MG, et al. The impact of the basic skin cancer triage curriculum on providers' skills, confidence, and knowledge in skin cancer control. Prev Med 2002; 34:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/41\">",
"      Pruthi DK, Guilfoyle R, Nugent Z, et al. Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. J Am Acad Dermatol 2009; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/42\">",
"      Juhl AL, Byers TE, Robinson WA, et al. The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado. Melanoma Res 2009; 19:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/43\">",
"      Harman KE, Fuller LC, Salisbury JR, et al. Trends in the presentation of cutaneous malignant melanoma over three decades at King's College Hospital, London. Clin Exp Dermatol 2004; 29:563.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Dermatology. How to perform a skin self-exam. www.aad.org/public/exams/self.html.",
"    </li>",
"    <li>",
"     Skin Cancer Foundation. Self Examination. www.skincancer.org/self-examination.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/46\">",
"      Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/47\">",
"      Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/48\">",
"      Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw 2009; 7:250.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aad.org/education-and-quality-care/clinical-guidelines/current-and-upcoming-guidelines/current-guidelines-and-guidelines-in-development (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/50\">",
"      Marghoob AA, Terushkin V, Dusza SW, et al. Dermatologists, general practitioners, and the best method to biopsy suspect melanocytic neoplasms. Arch Dermatol 2010; 146:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16713/abstract/51\">",
"      Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245.",
"     </a>",
"    </li>",
"    <li>",
"     Australian Cancer Network. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. National Health and Medical Research Council (NHMRC), Canberra, 2008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15806 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16713=[""].join("\n");
var outline_f16_20_16713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H283143748\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6082563\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81531006\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81531013\">",
"      Melanoma subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81531020\">",
"      - Superficial spreading melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H137428135\">",
"      - Nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81531027\">",
"      - Lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81531034\">",
"      - Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H137428425\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47495879\">",
"      CLINICAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3148564\">",
"      Diagnostic aids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47495344\">",
"      - ABCDE rule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10374288\">",
"      - The revised Glasgow seven-point checklist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47496022\">",
"      - The \"ugly duckling\" sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47495758\">",
"      Dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10884070\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283142762\">",
"      CLINICIAN SKIN EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83031482\">",
"      History and assessment of risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43034853\">",
"      Total body skin examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85360811\">",
"      Training for skin examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85360953\">",
"      PATIENT SKIN SELF-EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81531898\">",
"      MANAGEMENT OF PATIENTS WITH SUSPICIOUS SKIN LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106428122\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106428130\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81531913\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283143748\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15806|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/37/24147\" title=\"picture 1A\">",
"      Superficial spreading melanoma 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/28/17860\" title=\"picture 1B\">",
"      Superficial spreading melanoma 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/3/37939\" title=\"picture 1C\">",
"      Superficial spreading melanoma 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29326\" title=\"picture 1D\">",
"      Superficial spreading melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/61/18389\" title=\"picture 1E\">",
"      Melanoma- superficial spreading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18211\" title=\"picture 2A\">",
"      Lentigo maligna melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34866\" title=\"picture 2B\">",
"      Lentigo maligna melanoma 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/19/27957\" title=\"picture 2C\">",
"      Lentigo maligna melanoma 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/54/4967\" title=\"picture 2D\">",
"      New lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/63/25586\" title=\"picture 3A\">",
"      Acral lentiginous melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/4/1091\" title=\"picture 3B\">",
"      Acral lentiginous melanoma 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/3/54\" title=\"picture 3C\">",
"      Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30110\" title=\"picture 3D\">",
"      Nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/33/43536\" title=\"picture 4A\">",
"      Subungual melanoma - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/43/36531\" title=\"picture 4B\">",
"      Subungual melanoma - advanced on thumb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/31/26098\" title=\"picture 4C\">",
"      Subungual melanoma - advanced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/19/39231\" title=\"picture 4D\">",
"      Acral lentiginous melanoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/54/9062\" title=\"picture 5\">",
"      Common melanocytic nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/56/36739\" title=\"picture 6A\">",
"      Atypical nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/39/23153\" title=\"picture 6B\">",
"      Atypical nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23986\" title=\"picture 7\">",
"      Common blue nevus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/55/34676\" title=\"picture 8\">",
"      Spitz nevus pigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/6/27745\" title=\"picture 9\">",
"      Longitudinal melanonychia - thumbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/58/32676\" title=\"picture 10\">",
"      Pigmented basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21636\" title=\"picture 11A\">",
"      Seborrheic keratosis hyperpigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/40/39557\" title=\"picture 11B\">",
"      Seborrheic keratosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/17/23827\" title=\"picture 11C\">",
"      Seborrheic keratosis inflamed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/60/963\" title=\"picture 11D\">",
"      Seborrheic keratosis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/13/38097\" title=\"picture 11E\">",
"      Seborrheic keratosis temple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/25/6545\" title=\"picture 11F\">",
"      Seborrheic keratosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23859\" title=\"picture 12A\">",
"      Pyogenic granuloma - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/49/37651\" title=\"picture 12B\">",
"      Pyogenic granuloma lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41841\" title=\"picture 13A\">",
"      Cherry angioma2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/37/3667\" title=\"picture 13B\">",
"      Cherry angiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/7/17527\" title=\"picture 14A\">",
"      Dermatofibroma - dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/12/29892\" title=\"picture 14B\">",
"      Dermatofibroma - shin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/36/36417\" title=\"picture 14C\">",
"      Dermatofibroma dimple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35347\" title=\"picture 15A\">",
"      Keratoacanthoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/25/28051\" title=\"picture 15B\">",
"      Keratoacanthoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/10/32930\" title=\"picture 16\">",
"      Subungual hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/0/9228\" title=\"table 2\">",
"      Compare melanoma subtypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41545?source=related_link\">",
"      Atypical (dysplastic) nevi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36090?source=related_link\">",
"      Overview of nail disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29785?source=related_link\">",
"      Pyogenic granuloma (Lobular capillary hemangioma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18906?source=related_link\">",
"      Spitzoid melanocytic neoplasms (Spitz nevus and atypical Spitz tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16714="Pineal gland masses";
var content_f16_20_16714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pineal gland masses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Maria Moschovi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     George P Chrousos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/20/16714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/20/16714/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/20/16714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors involving the pineal gland or body are uncommon (",
"    <a class=\"graphic graphic_figure graphicRef74410 \" href=\"UTD.htm?38/9/39063\">",
"     figure 1",
"    </a>",
"    ). The classification, presentation, and general approach to lesions involving the pineal gland will be presented here, focusing on the management of pineal parenchymal tumors.",
"   </p>",
"   <p>",
"    Germ cell tumors, the most frequent tumor type found in the pineal region, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"     \"Pediatric intracranial germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe and North America, pineal tumors account for less than 1 percent of all primary brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/1\">",
"     1",
"    </a>",
"    ]. Pineal tumors are more common in children aged 1 to 12 years where these constitute about 3 percent of brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pineal tumors are more common in Asian countries than in Western countries [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This increased frequency is due largely to an increase in germ cell tumors, which comprise 70 to 80 percent of all pineal region tumors in Japan and Korea.",
"   </p>",
"   <p>",
"    Pineal tumors are substantially more common in males. In an analysis of 633 cases from the Surveillance, Epidemiology and End Results (SEER) database over a 32 year period, pineal tumors were three times more common in males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/1\">",
"     1",
"    </a>",
"    ]. In those with germ cell tumors, the male predominance was approximately 12:1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three histologic tumors that account for most neoplasms arising within the pineal gland are germ cell tumors (GCTs), pineal parenchymal tumors, and gliomas (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"UTD.htm?14/49/15134\">",
"     table 1",
"    </a>",
"    ). In a series of 633 cases from the SEER database, these comprised 59, 30, and 5 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/1\">",
"     1",
"    </a>",
"    ]. Other pineal tumors reported included meningiomas, gangliogliomas, ependymomas, lipomas, trilateral retinoblastomas and metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/5\">",
"     5",
"    </a>",
"    ]. Benign lesions arising within the pineal gland that can be confused with neoplasms include pineal cysts, vascular malformations, and vein of Galen aneurysms.",
"   </p>",
"   <p>",
"    GCTs are divided into germinomas and nongerminomatous GCTs in the World Health Organization (WHO) classification system (",
"    <a class=\"graphic graphic_table graphicRef82711 \" href=\"UTD.htm?8/29/8667\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/6\">",
"     6",
"    </a>",
"    ]. The nongerminomatous GCTs include embryonal carcinoma, endodermal sinus tumor (also known as yolk sac tumor), choriocarcinoma, teratoma (immature and mature), and mixed tumors with more than one element. Germinomas comprise approximately three-quarters of all GCTs in the SEER series and approximately 45 to 50 percent of all pineal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link&amp;anchor=H6#H6\">",
"     \"Pediatric intracranial germ cell tumors\", section on 'Histologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 WHO classification of central nervous system tumors divides pineal gland tumors into four groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pineocytoma (grade I)",
"     </li>",
"     <li>",
"      Pineal parenchymal tumors of intermediate differentiation (grade II or III)",
"     </li>",
"     <li>",
"      Papillary tumor of the pineal region (grade II or III)",
"     </li>",
"     <li>",
"      Pineoblastoma (grade IV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumors that contain areas histopathologically like both pineocytoma and pineoblastoma (mixed",
"    <span class=\"nowrap\">",
"     pineocytoma/pineoblastoma)",
"    </span>",
"    are often included within the intermediate differentiation group.",
"   </p>",
"   <p>",
"    The potentially aggressive behavior of pineoblastoma and the",
"    <span class=\"nowrap\">",
"     intermediate/mixed-group",
"    </span>",
"    tumors and the tendency for CSF seeding justified grouping these histologic subtypes together. This explains the absence of pineal parenchymal tumors of intermediate differentiation and of the pineal papillary tumor from the registry before 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative prevalence of histologic types depends on the age of the patient population under study. As an example, among patients with a pineal GCTs, germinoma is most frequent among those between 10 and 19 years of age, and there are some patients aged &gt;30 years. Choriocarcinoma, embryonal carcinoma, and yolk sac tumor are rare in those over age 30 years. Pineoblastoma is most frequent among patients under five years of age, while pineocytoma is evenly distributed in patients between 10 and 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/7\">",
"     7",
"    </a>",
"    ]. Astrocytomas tend to occur in two separate age groups: two to six-year-olds, and 12 to 18-year-olds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTING FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal gland tumors share some common clinical and radiographic features based upon their anatomic location. The initial diagnostic approach is similar, and the treatment and prognosis depend upon establishing a histologic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal tumors cause neurologic dysfunction by direct invasion, compression, or obstruction of cerebrospinal fluid (CSF) flow. The rate of tumor growth determines the rapidity of symptom onset and is an important prognostic factor.",
"   </p>",
"   <p>",
"    Common signs and symptoms are summarized in the following table (",
"    <a class=\"graphic graphic_table graphicRef71731 \" href=\"UTD.htm?15/0/15371\">",
"     table 3",
"    </a>",
"    ). Hydrocephalus is common, manifested by headaches, lethargy, and signs of increased intracranial pressure. Up to 75 percent of patients with pineal tumors have Parinaud's syndrome, a constellation of neuroocular symptoms that result from pressure on the pretectal region (the dorsal aspect of the rostral or upper midbrain) (",
"    <a class=\"graphic graphic_table graphicRef81227 \" href=\"UTD.htm?11/52/12107\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H9#H9\">",
"     \"Supranuclear disorders of gaze in children\", section on 'Parinaud syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive local tumor growth may result in cranial neuropathies or hypothalamic dysfunction. While extracranial metastases are rare, patients may have symptoms of leptomeningeal dissemination, which is present at diagnosis in up to 19 percent of pineoblastomas and approximately 12 percent of GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the most useful initial study to identify the tumor and delineate its relationship to adjacent structures. As an example, obstructive hydrocephalus from aqueductal stenosis is common; in the majority of cases, this is due to the tumor extending into the third ventricle (",
"    <a class=\"graphic graphic_figure graphicRef74410 \" href=\"UTD.htm?38/9/39063\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In some cases, the imaging findings may suggest certain tumor types. While germ cell tumors and malignant gliomas characteristically \"invade\" through the wall of the third ventricle, expansive compression is more common with pineal parenchymal tumors, low-grade astrocytomas, and meningiomas. However, imaging alone is generally not reliable enough to establish a histologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell tumors (GCTs) typically are seen as a homogeneous hyperdense mass. In contrast, teratomas are multilocular heterogeneous masses containing lipid areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pineal calcification on skull radiographs, uncommon in children younger than 10 years, is a useful clue to the diagnosis of a GCT because approximately 70 percent of patients with GCTs have calcifications that are seen within the mass rather than calcifications \"exploding\" to the periphery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracranial GCTs typically appear hypointense or isointense on T1-weighted imaging and hyperintense on T2-weighted imaging; their contrast enhancement pattern can be homogeneous or heterogeneous. Cystic areas are common and may be multiple. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link&amp;anchor=H11#H11\">",
"     \"Pediatric intracranial germ cell tumors\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pineal parenchymal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal parenchymal tumors (PPTs) include pineocytomas, pineoblastomas, PPTs of intermediate differentiation, and papillary tumor of the pineal region.",
"   </p>",
"   <p>",
"    Pineocytomas are typically isodense and enhance homogeneously with contrast. Cysts and calcifications are present in up to one-half of cases, with peripheral calcifications more suggestive of pineocytoma than germinoma as the PPTs classically result in preexisting pineal calcifications dispersing to the periphery of the lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Benign pineal cysts may present similarly (see",
"    <a class=\"local\" href=\"#H40\">",
"     'Pineal cysts'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    On MRI, pineocytomas are typically &le;3 cm, sharply demarcated lesions with a high degree of cytoplasm that are hypointense on T1-weighted images and hyperintense on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. They enhance homogeneously with contrast, and only one-third have associated hydrocephalus.",
"   </p>",
"   <p>",
"    Pineoblastomas are hyperdense and have no associated calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/11\">",
"     11",
"    </a>",
"    ]. They tend to be larger than 3 cm, lobulated, and poorly demarcated on MRI, and they are essentially isointense to gray matter on T2-weighted images, possibly related to the known paucity of cytoplasm in these tumor cells and overall dense cellularity seen in these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. These tumors enhance heterogeneously with contrast and 90 percent have associated hydrocephalus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glial tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal glial tumors typically arise from the neighboring tectal plate and have a similar appearance on CT and MRI as when encountered elsewhere in the brain. Given their location of origin, pineal calcifications are displaced superiorly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/12\">",
"     12",
"    </a>",
"    ]. Calcifications can be identified in about two-thirds of pineal gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. Low-grade pilocytic astrocytomas may be cystic, and unlike other low-grade gliomas, they enhance with contrast. The typical appearance of high-grade gliomas (eg, glioblastoma multiforme) is a multilobular solid tumor with indistinct margins and heterogeneous contrast enhancement. Enhancing tumor can be distinguished from the surrounding hypointense signal of edema on T1-weighted images. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=see_link\">",
"     \"Diagnosis and classification of low-grade gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other tumors may be suspected based upon neuroimaging results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningiomas &mdash; Pineal meningiomas are small tumors (&lt;2 cm) that have well-defined margins. Attachments to the falx often can be identified on sagittal images. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link&amp;anchor=H22#H22\">",
"       \"Meningioma: Clinical presentation and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipomas &mdash; Lipomas have low attenuation on CT, increased signal on T1-weighted images, and lack contrast enhancement.",
"     </li>",
"     <li>",
"      Pineal metastases &mdash; The MRI features of metastases to the pineal gland are nonspecific. As in other areas of the brain, metastases are accompanied by more edema than would be expected based upon lesion size. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Imaging studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nonneoplastic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonneoplastic pineal lesions in the differential diagnosis of pineal masses include vascular malformations, arachnoid cysts, and pineal cysts, which must commonly be distinguished from cystic germ cell tumors, pineal parenchymal tumors, or gliomas (see",
"    <a class=\"local\" href=\"#H40\">",
"     'Pineal cysts'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal tumors are a challenge to the neurosurgeon because the pineal gland is a deep structure, surrounded by important vascular and neural structures. However, advances in microsurgery and neuroanesthesia have improved accessibility to the pineal region, and there is less hesitancy to approach this region surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Staging work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging work-up for patients with suspected pineal tumors must include a contrast-enhanced MRI of the brain and the entire spine. The cerebrospinal fluid (CSF) should be examined cytologically only if the patient is considered safe for a lumbar puncture. If CSF cannot be obtained by lumbar puncture then CSF can be obtained at the time of surgery and sent for the appropriate studies.",
"   </p>",
"   <p>",
"    Both serum and CSF should be assayed for alpha-fetoprotein and beta human chorionic gonadotropin (beta-hCG) to help diagnose a germ cell tumor. Once tissue is obtained, immunohistochemistry may be of additional value in detecting these markers or placental alkaline phosphatase. There are no serum markers for other pineal tumors.",
"   </p>",
"   <p>",
"    Measurement of daily variation in serum melatonin levels does not have an established role but remains an area of interest for patients with tumors of the pineal region. In a series of 29 patients with a histologically well-defined pineal tumor and 24-hour melatonin profile determination before",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after surgery, melatonin rhythm was dramatically reduced for undifferentiated or invasive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/21\">",
"     21",
"    </a>",
"    ]. An abnormal melatonin profile following surgery could be a reflection of either residual tumor or surgical damage to the pineal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tissue diagnosis is generally needed prior to therapy, since treatment is histology-dependent. Empiric therapy for a nongerminomatous GCT may be considered in a patient with characteristic neuroimaging studies and elevated serum or CSF levels of the tumor markers alpha-fetoprotein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the beta subunit of human chorionic gonadotropin. Similarly empiric therapy for patient with germinoma can be initiated based upon the imaging presence of &ldquo;bi focal&rdquo; tumors, CSF beta-hCG &lt;50",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    and no elevation of alpha-fetoprotein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"     \"Pediatric intracranial germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Stereotactic biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct, visually guided biopsy of the pineal gland mass with open or neuroendoscopic surgery has been preferred due to concerns about injury to the deep cerebral veins. An open procedure also allows CSF to be obtained for tumor marker studies, permits direct visualization of the third ventricle for staging purposes, and allows a third ventriculostomy to be performed for CSF diversion if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these concerns, contemporary series suggest that stereotactic biopsy is reasonably safe and well tolerated, provided a low frontal approach is used to access the tumor below the level of the internal cerebral veins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. CSF sampling is possible because the biopsy trajectory often traverses the lateral ventricle.",
"   </p>",
"   <p>",
"    The diagnostic yield of stereotactic biopsy ranges from 94 to 100 percent when multiple target biopsies are obtained, but sampling error may be an issue due to the heterogeneity of some pineal tumors (particularly mixed germ cell tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/20\">",
"     20",
"    </a>",
"    ]. Procedure-related morbidity is generally limited to transient worsening of ocular symptoms, although fatal complications have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/24\">",
"     24",
"    </a>",
"    ]. A frameless stereotactic robot has been successfully used for brain biopsies over the past few years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the biopsy is nondiagnostic, equivocal, or suggests a benign tumor such as mature teratoma or meningioma, surgery is recommended to establish a definitive diagnosis or to identify focal areas of malignant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open surgery, including an attempt at gross total resection, is an alternative to stereotactic biopsy that is favored by some as the initial approach to patients with pineal tumors. Since approximately one-third of pineal lesions are benign, open surgery may be potentially curative as well as diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/19,30-32\">",
"     19,30-32",
"    </a>",
"    ]. Furthermore, an open procedure minimizes sampling error and tumor debulking may obviate the need for CSF diversion if obstructive hydrocephalus is present [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an attempt at gross total resection is not widely accepted for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Except for well-encapsulated teratomas, few pineal region tumors are amenable to complete resection because of local or regional extension [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many tumors require multimodality therapy once a diagnosis is established. As an example, germ cell tumors are highly sensitive to both chemotherapy and radiation therapy, and the best results have been achieved with these modalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link&amp;anchor=H15#H15\">",
"       \"Pediatric intracranial germ cell tumors\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CSF seeding, as evidenced by positive cytology, requires craniospinal radiation and adjuvant chemotherapy regardless of tumor type. In this setting, the use of radiation therapy and chemotherapy may obviate the need for an extensive resection.",
"     </li>",
"     <li>",
"      Any potential benefit from open resection must be balanced against procedural risks. New or worsening visual deficits may occur in up to one-third of patients, although most improve over time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/19\">",
"       19",
"      </a>",
"      ]. Depending upon surgical expertise, the risk of permanent morbidity from open pineal gland surgery is 3 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/19,30\">",
"       19,30",
"      </a>",
"      ], while operative mortality rates range from 4 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/33\">",
"       33",
"      </a>",
"      ]. The most serious complications are related to postoperative hemorrhage in a subtotally resected malignant tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contemporary microsurgical techniques may provide a more effective and relatively safe approach to pineal region tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/34\">",
"     34",
"    </a>",
"    ]. These techniques provide an alternative to stereotactic biopsy in some cases.",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) may be useful technique following surgery to determine whether viable tumor is still present and to assist in further treatment planning. In this setting, imaging with 11C-methionine appears to be more specific and possibly more sensitive than contrast-enhance MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. PET imaging with 11C-methionine also appears to be more specific that 18-fluorodeoxyglucose PET [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PINEAL PARENCHYMAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pineal gland is composed of parenchymal (epithelial) and interstitial cells. Approximately 20 percent of pineal tumors arise from the epithelial cells and are termed pineal parenchymal tumors (PPTs). PPTs classically result in preexisting pineal calcification at the periphery of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/12\">",
"     12",
"    </a>",
"    ]. They are classified histologically into pineocytomas (grade I), pineoblastomas (grade IV), PPT of intermediate differentiation, and papillary tumor of the pineal region (grade II-III) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Histogenesis and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pinealocytes are specially modified neuronal cells similar to the photoreceptor cells in the retina, and phylogenetic studies have shown the evolution of the pineal from a photoreceptor organ to a secretory gland. PPTs share morphologic and immunohistochemical features of cells from both the developing human pineal gland and the retina. Clinical evidence of their shared histogenesis is the occurrence of bilateral familial retinoblastoma with pineoblastoma (the trilateral retinoblastoma syndrome) (see",
"    <a class=\"local\" href=\"#H33\">",
"     'Trilateral retinoblastoma'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Using immunohistochemistry, parenchymal cells (pinealocytes) are positive for neuron specific enolase (NSE) and synaptophysin, supporting their neuroendocrine nature. Both pineocytomas and pineoblastomas stain for NSE, and IHC may be used to distinguish PPT from astrocytic tumors. In contrast, interstitial cells show immunoreactivity to glial fibrillary acidic protein (GFAP), S-100 and vimentin, supporting their glial origin.",
"   </p>",
"   <p>",
"    Pineocytomas and pineoblastomas each account for a little less than one-half of all PPTs. The remainder are comprised of PPTs with intermediate differentiation and papillary tumors of the pineal region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pineocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineocytomas are classified as grade I on the World Health Organization (WHO) grading scale for brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/38\">",
"     38",
"    </a>",
"    ]. Pineocytomas are well circumscribed and generally do not seed the CSF.",
"   </p>",
"   <p>",
"    Microscopically, pineocytomas are composed of sheets of mature-appearing cells arranged in lobules, with rare or absent mitotic figures, and no pleomorphism, hyperchromatic nuclei, or necrosis. The cells are separated by a connective tissue stroma, giving a pseudolobular appearance reminiscent of normal pineal gland architecture. Characteristic pineocytomatous rosettes are arranged around central areas of eosinophilic fibrillar material. The absence of these rosettes (ie, lack of neuronal differentiation) is associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pineoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineoblastomas correspond to WHO grade IV tumors. These are highly malignant, infiltrative tumors, with a significant potential for dissemination and a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pineoblastomas are less cellular than pineocytomas; they are composed of patternless sheets of densely packed, mitotically active small cells with round to irregular nuclei, and scant cytoplasm. Necrosis is common. Pineoblastomas lack pineocytomatous rosettes, but can have Homer-Wright or Flexner-Wintersteiner rosettes, which are indicative of retinoblastic differentiation.",
"   </p>",
"   <p>",
"    Pineoblastomas are considered by some to be a variant of supratentorial primitive neuroectodermal tumors (PNETs). Like supratentorial PNETs, pineoblastomas are poorly differentiated, infiltrative, and have a significant potential for leptomeningeal and extracranial dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/10,39,40\">",
"     10,39,40",
"    </a>",
"    ]. Extraneuronal metastases after surgery have also been described, although they are distinctly rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     PPTs of intermediate differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal parenchymal tumors (PPTs) of intermediate differentiation are classified as grade II-III according to the WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/6\">",
"     6",
"    </a>",
"    ]. These tumors seem to exist along a continuum, as approximately 10 percent of PPTs are classified as mixed pineocytoma-pineoblastoma. PPTs have moderately high cellularity, mild nuclear atypia, occasional mitoses, and lack pineocytomatous rosettes. Their clinical behavior is variable, although CNS and extraneural metastases are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/10,24,30,44-46\">",
"     10,24,30,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Papillary tumor of the pineal region",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary tumor of the pineal region (PTPR) is a rare neuroepithelial tumor that was added to the 2007 WHO classification of CNS tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/6\">",
"     6",
"    </a>",
"    ]. The biological behavior of PTPR is variable and appears to correspond to WHO grade II or III.",
"   </p>",
"   <p>",
"    Histologically, PTPRs are characterized by a papillary architecture and epithelial cytology, with immunoreactivity for cytokeratin and glial fibrillary acidic protein (GFAP). Precise histologic criteria have not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/47\">",
"     47",
"    </a>",
"    ]. Although microscopically indistinguishable from pineocytoma, the histology is incompatible with a pineal parenchymal tumor. Ultrastructural features suggest ependymal differentiation and a possible origin from specialized ependymal cells of the subcommissural organ. Although it is difficult to speculate on the origin of PTPRs, cells from both pineal parenchymal tumor of intermediate differentiation (PPTID) and PTPR have neurosecretory features, suggesting the possibility of a common precursor. Indeed, a recent report documented for the first time a PPTID with transition to a papillary tumor of the pineal region (PTPR), highlighting the continuum with which primary pineal tumors exist [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/46\">",
"     46",
"    </a>",
"    ]. Overall, histologic diagnosis of PTPRs is difficult due to similarities with the two main differential diagnoses, papillary ependymoma and choroid plexus tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Presentation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of PPTs is similar to that of other tumors arising in the pineal gland area (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Presenting features'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The interval between symptom onset and diagnosis may be as short as one month in patients with pineoblastoma, while symptom duration can be as long as several years in those with pineocytomas. Pineocytomas have a peak incidence at age 30 to 35, and there is a slight male predominance. In contrast, the median age at diagnosis for pineoblastomas is 8 years of age with a higher predominance in children younger than five years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Neuroradiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging features of PPTs are non-specific. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Neuroimaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A PPT with a cystic or partially cystic appearance can mimic a typical pineal cyst in imaging appearance. This can be problematic, since benign cystic lesions are identified by MRI in 1 to 4 percent of healthy subjects. Surgical intervention may be required to obtain a definite diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Pineal cysts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Papillary tumors of the pineal region (PTPRs) have been described predominantly in adults. Unlike other PPTs, there is a slight female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Papillary tumors of the pineal region appear to be mildly lobulated, partially cystic, heterogeneously enhanced masses, and usually cause obstructive hydrocephalus. They are relatively large (2.5 to 4 cm), and well circumscribed, with low T1 and increased T2 signal as well as contrast enhancement on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main prognostic indicators are disease extent and histologic subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/54\">",
"     54",
"    </a>",
"    ]. Tumors with leptomeningeal or spinal metastases have a poor prognosis regardless of treatment.",
"   </p>",
"   <p>",
"    Pineocytomas have the best prognosis, followed by PPTs of intermediate differentiation, and then pineoblastomas. Tumor biology may be more aggressive in younger children with pineoblastoma, who also present more frequently with high-risk features at diagnosis and have poorer response rates to neoadjuvant postoperative chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/55\">",
"     55",
"    </a>",
"    ]. Nonetheless, a subset of pineocytomas can behave aggressively and show a proclivity for symptomatic recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTPRs constitute a rare entity, and the data are too limited to provide accurate guidance regarding prognosis. In the four reports that have been published to date, 15 of 21 patients experienced recurrences even after total resection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/53,57\">",
"     53,57",
"    </a>",
"    ]. There has been a case report of PTPR in a young boy that was noteworthy for early CSF dissemination and relentless progression; the outcome was fatal despite the aggressive chemotherapy and RT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/51\">",
"     51",
"    </a>",
"    ]. The only prognostic factor currently identified in the literature is whether or not surgical resection was complete [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expression of the protooncogene Bcl-2 was detected in the tumor cells of a patient with PTPR of high proliferation index, suggesting that Bcl-2 might be related to the malignancy of this neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PPTs must be guided by the histologic subtype. Successful treatment of pineocytomas requires surgery with or without RT, while the best results with pineoblastomas are seen with multimodality approaches that include chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     CSF diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surgical strategy to treat acute hydrocephalus in patients with pineal tumors is uncertain. CSF diversion (ventriculoperitoneal [VP] shunt or third ventriculostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]) may be necessary in symptomatic patients, although debulking surgery may obviate the need for this procedure (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Initial approach'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    When CSF diversion is necessary, endoscopic third ventriculostomy can be carried out at the same time as the biopsy and is preferred over VP shunts, which can be complicated by infection, shunt malfunction, subdural hematoma, and rarely, tumor seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/25,61-63\">",
"     25,61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some series report long-term survival with surgery alone, even in patients with pineoblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/13,19,54\">",
"     13,19,54",
"    </a>",
"    ]. Indeed, for pineoblastomas, gross total surgical resection appears to correlate with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients with symptomatic recurrent pineocytomas should also be considered for surgical resection of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative adjuvant RT is frequently (but not universally) recommended, and local control is dose-dependent. This was illustrated in a series of 30 patients with PPT (9 pineocytomas, 15 pineoblastomas, 4 intermediate, and 2 mixed), 22 of whom received adjuvant RT. Among those treated with RT, there were fewer local failures among patients treated to &ge;50 Gy compared to those receiving lesser doses (0 of 12 versus 6 of 7, respectively).",
"   </p>",
"   <p>",
"    The importance of craniospinal irradiation (CSI) for patients with metastatic involvement or the potential to seed CSF (ie, all non-pineocytomatous PPTs) was demonstrated in a series of 135 patients with histologically confirmed pineal tumors and other germ cell tumors. The incidence of leptomeningeal recurrence was significantly lower among patients receiving CSI compared with those who did not. The five-year survival rates were 86 and 49 percent for pineocytomas and non-pineocytoma PPTs, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant RT is not universally recommended after gross total resection of a pineocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. Some authors advocate adjuvant RT for only those pineocytomas that lack neuronal differentiation and which behave more like pineoblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery (SRS) is emerging as a useful treatment alternative for pineocytomas, although experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/26,66,67\">",
"     26,66,67",
"    </a>",
"    ]. The precise radiation fields that are defined by MRI or CT-computerized treatment planning minimize damage to the surrounding brain, and the risks of general anesthesia and craniotomy are avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SRS is increasingly being used to treat pineal region tumors, either as an additional therapy after conventional treatments or as a primary treatment. This was illustrated by a series of 49 patients with pineal tumors, including nine with PPTs, who were treated with SRS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/68\">",
"     68",
"    </a>",
"    ]. Survival rates at five and ten years were 100 and 67 percent, respectively, in those with PPTs.",
"   </p>",
"   <p>",
"    In another more recent series, the efficacy of interstitial radiosurgery (IRS) was evaluated in 18 patients with PPTs (8 pineocytomas, 10 malignant PPTs) who were treated with IRS using stereotactically guided iodine-125 seed implantation (125I-IRS) as either primary or salvage therapy. Overall actuarial five- and eight-year survival rates after IRS were 100 and 86 percent, respectively, for pineocytomas, and the overall actuarial five-year survival rate was 78 percent for high-grade PPTs. Follow-up magnetic resonance imaging showed complete remission in 72 percent (13 of 18) and partial remission in 28 percent (5 of 18) of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/69\">",
"     69",
"    </a>",
"    ]. Due to the low rate of side effects, IRS may develop into an attractive alternative to microsurgery in de novo diagnosed pineocytomas. In malignant PPTs, IRS may be routinely applied in a multimodality treatment schedule supplementary to conventional irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Chemotherapy as part of multimodality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The similarity of pineoblastomas to medulloblastomas in terms of their clinical behavior and tendency for leptomeningeal seeding has led to the use of similar chemotherapy regimens in patients with pineoblastoma as part of a multimodality approach [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/30,70-75\">",
"     30,70-75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy has been used to delay radiation therapy in very young children, for whom the long-term neurocognitive and developmental side effects of craniospinal irradiation (CSI) are a major concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results with this approach have been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/76\">",
"     76",
"    </a>",
"    ], and the optimal approach remains uncertain, as is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series, 25 children with pineal pineoblastomas were treated as part of a Children's Cancer Group trial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/74\">",
"       74",
"      </a>",
"      ]. Infants received the eight-in-one chemotherapy regimen only (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , CCNU or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , all administered within 12 hours on day 1), while the other 17 patients received CSI, and were randomly assigned to either vincristine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"       lomustine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , or the eight-in-one regimen. All infants developed progressive disease within four months. In contrast, 61 percent of the older children who received both CSI and chemotherapy remained progression-free at three years. Outcome was not better with the more toxic eight-in-one chemotherapy regimen compared to the three-drug regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Pediatric Oncology Group (POG) study, 11 children with pineoblastoma under three years of age were treated with chemotherapy (alternating cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      for up to 23 months) and delayed RT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/76\">",
"       76",
"      </a>",
"      ]. Only one child had a partial response after two months of chemotherapy, and all died of progressive disease, most within one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of radiation therapy as a component of the initial treatment of supratentorial primitive neuroendocrine tumors (PNETs) is also supported by the German HIT-SKK87 and HIT-SKK92 protocols, as well as the Canadian pediatric brain tumor protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an effort to improve overall survival and event-free survival and to decrease radiation exposure, more intensive approaches to chemotherapy are being investigated.",
"   </p>",
"   <p>",
"    As an example, the Head Start protocols treated children with newly diagnosed pineoblastoma utilizing intensified induction chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic rescue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/80\">",
"     80",
"    </a>",
"    ]. The five-year event-free and overall survival rates were 39 and 49 percent, respectively, and non-pineal supratentorial PNET patients fared significantly better than those patients with pineal PNETs. Metastasis at diagnosis, age, and extent of resection were not significant prognostic factors. Sixty percent of survivors (12 out of 20) are alive without exposure to radiation therapy.",
"   </p>",
"   <p>",
"    A recently published pilot study for supratentorial PNET patients that used risk adapted craniospinal irradiation (23.4 Gy craniospinal irradiation for patients with gross tumor resection and no metastatic disease; 36 to 39.6 Gy for patients with &gt;1.5 cm",
"    <sup>",
"     2",
"    </sup>",
"    residual disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease) and a radiation therapy boost to the primary site to 55.8 Gy followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based dose intensive chemotherapy has demonstrated very encouraging results: five-year event-free survival rates for standard and high risk patients of 75&plusmn;17 and 60&plusmn;19 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Trilateral retinoblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trilateral retinoblastoma consists of unilateral or bilateral retinoblastoma associated with an intracranial neuroblastic tumor. The intracranial tumors are typically located in the pineal region, but can also exist in the suprasellar or parasellar regions. The term trilateral retinoblastoma is used because the pineal is considered a photosensitive organ (third eye) in lower vertebrates.",
"   </p>",
"   <p>",
"    Approximately three-fourths of cases of trilateral retinoblastoma arise in the pineal gland. The mean age at diagnosis is 31 months, and the average interval between diagnosis of retinoblastoma and the intracranial tumor is 21 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/82\">",
"     82",
"    </a>",
"    ]. Data from large centers estimate the chance of developing an intracranial neuroblastic tumor among patients with sporadic retinoblastoma, sporadic bilateral retinoblastoma, and familial bilateral retinoblastoma to be &lt;0.5, 5 to 13, and 5 to 15 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link\">",
"     \"Overview of retinoblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, treatment for patients with an intracranial neuroblastic tumor associated with a retinoblastoma has been neurosurgical resection followed by chemotherapy and cranial or craniospinal radiation therapy. Despite aggressive therapy, trilateral retinoblastoma was generally considered to be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. However, the use of intensive chemotherapy regimens combined with autologous hematopoietic stem cell rescue has been associated with prolonged disease-free survival in small series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine screening in patients with retinoblastoma using cranial MRI is controversial, and there are no formal guidelines. Although prospective trials are not available, the value of screening neuroimaging was evaluated in a meta-analysis that included individual data from 106 children with trilateral retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/82\">",
"     82",
"    </a>",
"    ]. Although intracranial tumors were detected earlier (1 versus 22 months) and the children survived longer (16 versus 8 months) if neuroimaging was routinely performed (ie, tumors were detected by screening rather at a symptomatic stage), the age at death was similar (36 versus 37 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     INTRACRANIAL GERM CELL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial germ cell tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"     \"Pediatric intracranial germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     GLIOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients with glioma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=see_link\">",
"     \"Diagnosis and classification of low-grade gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PINEAL MENINGIOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas are relatively common tumors in adults and account for approximately 20 percent of all intracranial tumors. Meningiomas constitute about 8 percent of pineal region tumors, and pineal meningiomas account for less than 1 percent of all meningiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link\">",
"     \"Meningioma: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pineal meningiomas are most commonly encountered after the second decade of life. However, they may occur at any age or even during fetal development. In children they are uncommon but not rare lesions with a slight male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/89\">",
"     89",
"    </a>",
"    ]. Most meningiomas are benign (WHO grade I), slow-growing lesions, but some are classified as atypical (WHO grade II) or malignant (WHO grade III).",
"   </p>",
"   <p>",
"    Meningiomas in the pineal region may originate either from the velum interpositum or from the falcotentorial junction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/90\">",
"     90",
"    </a>",
"    ]. In children, meningiomas arising from velum interpositum with no dural attachment are more prevalent than those arising from the falcotentorial junction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual clinical presentation for a patient with a pineal meningioma is with headaches and other signs of elevated intracranial pressure, ataxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/92\">",
"     92",
"    </a>",
"    ], but not the typical Parinaud's syndrome that is associated with other pineal region tumors (",
"    <a class=\"graphic graphic_table graphicRef81227 \" href=\"UTD.htm?11/52/12107\">",
"     table 4",
"    </a>",
"    ). Tinnitus or hearing loss can be observed in up to 30 percent at diagnosis. Overall, the commonest presenting symptoms are seizures, increased intracranial pressure, and focal neurological deficits (76, 71, and 39 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal meningiomas may present with dural attachment and compromise of the venous system or, less commonly, as free-lying masses without dural attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/93\">",
"     93",
"    </a>",
"    ]. Calcification is common and is characteristically located at the lesion margins rather than in the center. On MRI, meningiomas have well-defined margins, and attachments to the falx can be appreciated on sagittal images.",
"   </p>",
"   <p>",
"    Cerebral angiography may be needed to delineate the relationship between the tumor and the surrounding vessels, particularly before any surgery or embolization. Attention to the venous phase of the study is important because if the major basal veins fail to opacify preoperatively, the patient may be able to tolerate the venous occlusion that is usually required for a major resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the primary form of therapy for pineal meningiomas. Tumors are usually excised in a piecemeal fashion, as identification and preservation of the vein of Galen may prove difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/88\">",
"     88",
"    </a>",
"    ]. Incompletely resected tumors and high-grade lesions are frequently treated with fractionated radiotherapy or stereotactic radiosurgery.",
"   </p>",
"   <p>",
"    The overall therapeutic approach to meningiomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link\">",
"     \"Treatment of benign (WHO grade I) meningioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PINEAL CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic pineal cysts are usually an incidental neuroimaging finding. In a retrospective study of 1000 consecutive MRIs, true pineal cysts (5 mm or larger in diameter) were found in 0, 1.8, and 2.6 percent of children &le;12 years of age, teenagers, and adults, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/94\">",
"     94",
"    </a>",
"    ]. Their main importance is in their differentiation from cystic tumors such as pineocytomas, low grade astrocytomas, and teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pineal cysts are hypodense with respect to CSF, and occasionally there is evidence of recent intra-cyst hemorrhage. Cyst walls may or may not show contrast enhancement, and calcifications within the wall are found in about one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/96\">",
"     96",
"    </a>",
"    ]. To be considered a typical pineal cyst, an area of signal-intensity abnormality must be centered on the pineal recess, demonstrating internal homogeneity on T2-weighted imaging, following CSF signal intensity on T1- and T2-weighted images, without any marginal lobularity or nodular contrast enhancement, and a wall thickness of &lt;2 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On MRI, pineal cysts are typically sharply delineated ovoid-shaped lesions, without intracystic trabeculations. They have low signal intensity on both T1-weighted imaging and T2-weighted imaging, and contrast enhancement is usually nodular and irregular. Like pineal cysts, pineocytomas may be isointense with CSF, but they usually have intratumoral trabeculations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pineal cysts are silent and remain so for years; some may even spontaneously collapse. In one report of 32 patients with pineal cysts who underwent serial MRIs, 75 percent of cysts remained stable over time, while 16 percent decreased in size or regressed completely and 8 percent increased [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/49\">",
"     49",
"    </a>",
"    ]. In another study of 26 patients with incidentally found indeterminate pineal lesions ranging from probable benign cysts to pineal masses with follow-up MRI imaging from seven months to eight years, all lesions were stable over time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/97\">",
"     97",
"    </a>",
"    ]. In a third study of 106 children and young adults with pineal cysts followed for a mean interval of three years, 98 had no increase in size and no change in imaging appearance, six increased in size, and two others had a change in imaging characteristics without associated growth. The mean age of patients with cysts that changed or grew was 5.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Symptomatic cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic pineal cysts are usually larger than those ones found incidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/96,99\">",
"     96,99",
"    </a>",
"    ]. The incidence of symptomatic pineal cysts is highest in young women between 21 and 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/100\">",
"     100",
"    </a>",
"    ], leading to the hypothesis that hormonal influences contribute to their etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Symptoms may be caused by aqueductal compression resulting in hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/102\">",
"     102",
"    </a>",
"    ], obstruction of the vein of Galen, or compression of the collicular plate, leading to Parinaud syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small, asymptomatic pineal cysts require no therapy. If cysts become symptomatic by causing hydrocephalus, several treatment options can be considered. CSF diversion is not routinely recommended as sole therapy because of the lack of histological confirmation and the fact that symptoms associated with direct mass effect may not improve [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/104\">",
"     104",
"    </a>",
"    ]. Open or stereotactic cyst resection is considered by some the only guarantee of permanent cure and can obviate the need for CSF shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/44,105\">",
"     44,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stereotactic cyst aspiration relieves the mass effect while at the same time providing a histologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/99\">",
"     99",
"    </a>",
"    ]. In general, the morbidity is lower than with open procedures, although the risk of recurrence after aspiration alone is unknown. Instillation of radioactive phosphorus 32 (P32) into the cyst cavity may be considered for recurrent cysts.",
"   </p>",
"   <p>",
"    Some authors advocate imaging follow-up for typical pineal cysts to document stability with time, particularly for cysts larger than 10 to 14mm, under the assumption that they may enlarge or become symptomatic, whereas others advocate clinical follow-up only if there are no atypical features or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/106\">",
"     106",
"    </a>",
"    ]. Others suggest that pineal cysts can be followed clinically rather than with serial imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/20/16714/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. However, the preference for follow-up imaging of individual clinicians and patients may vary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal gland tumors are rare, the most common of which are germ cell tumors and pineal parenchymal tumors. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pineal tumors can cause neurologic dysfunction by direct invasion, compression, or obstruction of cerebrospinal fluid (CSF) flow. Common signs and symptoms are headaches, lethargy, and signs of increased intracranial pressure. Up to 75 percent of patients with pineal tumors have Parinaud's syndrome, a constellation of neuroocular symptoms that result from pressure on the pretectal region (the dorsal aspect of the rostral or upper midbrain). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Presenting features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The initial evaluation should include imaging of the entire neuraxis and cytology examination of the cerebrospinal fluid, to rule out leptomeningeal spread of the tumor. Serum and cerebrospinal fluid should also be assessed for elevated tumor markers (alpha-fetoprotein and beta human chorionic gonadotropin) to detect a possible germ cell tumor. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Staging work-up'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although features on neuroradiologic imaging may suggest a specific histologic diagnosis, a biopsy is necessary in most cases to establish the diagnosis and to permit appropriate treatment. Tissue may be obtained either by stereotactic biopsy or open surgery. When the patient's condition permits, we suggest an open surgical approach, rather than a stereotactic biopsy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Open biopsy may allow gross total resection in some cases, and this may constitute adequate therapy for low-grade lesions. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tissue diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pineal parenchymal tumors, we recommend surgical resection if technically feasible without causing severe neurologic dysfunction, rather than radiation therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with evidence of leptomeningeal tumor spread, and for those thought to be at high risk for leptomeningeal spread based upon tumor histology, we recommend craniospinal irradiation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with high-grade lesions (ie, pineoblastomas), we suggest the addition of intensive chemotherapy to surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy as part of a multimodality approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with intracranial germ cell tumors, the most frequent tumor arising in the pineal gland, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=see_link\">",
"       \"Pediatric intracranial germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/1\">",
"      Al-Hussaini M, Sultan I, Abuirmileh N, et al. Pineal gland tumors: experience from the SEER database. J Neurooncol 2009; 94:351.",
"     </a>",
"    </li>",
"    <li>",
"     CBTRUS (2005). Statistical Report: primary brain tumors in the United States - PbtCBTRotUS.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/3\">",
"      Konovalov AN, Pitskhelauri DI. Principles of treatment of the pineal region tumors. Surg Neurol 2003; 59:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/4\">",
"      Kanamori M, Kumabe T, Tominaga T. Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region? J Clin Neurosci 2008; 15:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/5\">",
"      Lassman AB, Bruce JN, Fetell MR. Metastases to the pineal gland. Neurology 2006; 67:1303.",
"     </a>",
"    </li>",
"    <li>",
"     Chapter 7 - Tumours of the pineal region. In: WHO Classification of Tumours of the Central Nervous System, 3rd, Louis D, Ohgaki H, Wiestler O, Cavenee WK (Eds), WHO Publication Center, Albany, NY 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/7\">",
"      Shibui S, Nomura K. Statistical analysis of pineal tumors based on the data of Brain Tumor Registry of Japan. Prog Neurol Surg 2009; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/8\">",
"      Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, et al. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 2008; 132:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/9\">",
"      Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 1996; 14:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/10\">",
"      Luther N, Stetler WR Jr, Dunkel IJ, et al. Subarachnoid dissemination of intraventricular tumors following simultaneous endoscopic biopsy and third ventriculostomy. J Neurosurg Pediatr 2010; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/11\">",
"      Chiechi MV, Smirniotopoulos JG, Mena H. Pineal parenchymal tumors: CT and MR features. J Comput Assist Tomogr 1995; 19:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/12\">",
"      Banks KP, Brown SJ. AJR teaching file: solid masses of the pineal region. AJR Am J Roentgenol 2006; 186:S233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/13\">",
"      Vaquero J, Ramiro J, Mart&iacute;nez R, et al. Clinicopathological experience with pineocytomas: report of five surgically treated cases. Neurosurgery 1990; 27:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/14\">",
"      Ganti SR, Hilal SK, Stein BM, et al. CT of pineal region tumors. AJR Am J Roentgenol 1986; 146:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/15\">",
"      Korogi Y, Takahashi M, Ushio Y. MRI of pineal region tumors. J Neurooncol 2001; 54:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/16\">",
"      Nakamura M, Saeki N, Iwadate Y, et al. Neuroradiological characteristics of pineocytoma and pineoblastoma. Neuroradiology 2000; 42:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/17\">",
"      Lambrinides K, Reichert M. MR imaging of pineoblastomas. Radiol Technol 1994; 66:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/18\">",
"      Shin HJ, Cho BK, Jung HW, Wang KC. Pediatric pineal tumors: need for a direct surgical approach and complications of the occipital transtentorial approach. Childs Nerv Syst 1998; 14:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/19\">",
"      Bruce JN, Stein BM. Surgical management of pineal region tumors. Acta Neurochir (Wien) 1995; 134:130.",
"     </a>",
"    </li>",
"    <li>",
"     Apuzzo MLJ, Chandrasoma PT. mage-directed stereotactic biopsy: Methods utilization and strategies. In: Neurosurgery state of the art reviews: Stereotactic surgery, Tasker RR (Ed), Hanley and Belfus, Philadelphia  p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/21\">",
"      Leston J, Mottolese C, Champier J, et al. Contribution of the daily melatonin profile to diagnosis of tumors of the pineal region. J Neurooncol 2009; 93:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/22\">",
"      Reddy AT, Wellons JC 3rd, Allen JC, et al. Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus. Neuro Oncol 2004; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/23\">",
"      Kreth FW, Sch&auml;tz CR, Pagenstecher A, et al. Stereotactic management of lesions of the pineal region. Neurosurgery 1996; 39:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/24\">",
"      Regis J, Bouillot P, Rouby-Volot F, et al. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. Neurosurgery 1996; 39:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/25\">",
"      Popovic EA, Kelly PJ. Stereotactic procedures for lesions of the pineal region. Mayo Clin Proc 1993; 68:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/26\">",
"      Dempsey PK, Lunsford LD. Stereotactic radiosurgery for pineal region tumors. Neurosurg Clin N Am 1992; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/27\">",
"      Haegelen C, Touzet G, Reyns N, et al. Stereotactic robot-guided biopsies of brain stem lesions: Experience with 15 cases. Neurochirurgie 2010; 56:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/28\">",
"      Choi JU, Kim DS, Chung SS, Kim TS. Treatment of germ cell tumors in the pineal region. Childs Nerv Syst 1998; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/29\">",
"      Balmaceda C, Modak S, Finlay J. Central nervous system germ cell tumors. Semin Oncol 1998; 25:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/30\">",
"      Edwards MS, Hudgins RJ, Wilson CB, et al. Pineal region tumors in children. J Neurosurg 1988; 68:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/31\">",
"      Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/32\">",
"      Sawamura Y, de Tribolet N, Ishii N, Abe H. Management of primary intracranial germinomas: diagnostic surgery or radical resection? J Neurosurg 1997; 87:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/33\">",
"      Herrmann HD, Westphal M, Winkler K, et al. Treatment of nongerminomatous germ-cell tumors of the pineal region. Neurosurgery 1994; 34:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/34\">",
"      Hernesniemi J, Romani R, Albayrak BS, et al. Microsurgical management of pineal region lesions: personal experience with 119 patients. Surg Neurol 2008; 70:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/35\">",
"      Kawai N, Miyake K, Yamamoto Y, et al. Use of 11C-methionine positron emission tomography in basal germinoma: assessment of treatment response and residual tumor. Childs Nerv Syst 2009; 25:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/36\">",
"      Nakamura H, Makino K, Kuratsu J. Carbon 11-labeled methionine positron emission tomography for detection of residual viable tumor cells after adjuvant therapy in nongerminomatous malignant germ cell tumors in 2 cases including an autopsy case. Surg Neurol 2009; 71:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/37\">",
"      Pirotte B, Acerbi F, Lubansu A, et al. PET imaging in the surgical management of pediatric brain tumors. Childs Nerv Syst 2007; 23:739.",
"     </a>",
"    </li>",
"    <li>",
"     Mena H, Nakazato Y, Jouvet A, Scheithauer BW. Pineocytoma. In: Pathology and Genetics - Tumors of the Nervous System, Kleihues P, CaveneeWK (Eds), International Agency for Research on Cancer, Lyon, France 2000. p.118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/39\">",
"      Borit A, Blackwood W, Mair WG. The separation of pineocytoma from pineoblastoma. Cancer 1980; 45:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/40\">",
"      Jouvet A, Saint-Pierre G, Fauchon F, et al. Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases. Brain Pathol 2000; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     Mena H, Nakazato Y, Jouvet A, Scheithauer BW. Pineoblastoma. In: Pathology and Genetics - Tumors of the Nervous System, Kleihues P, Cavenee WK (Eds), IARC, Lyon, France 2000. p.116.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/42\">",
"      Tate M, Sughrue ME, Rutkowski MJ, et al. The long-term postsurgical prognosis of patients with pineoblastoma. Cancer 2012; 118:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/43\">",
"      Charafe-Jauffret E, Lehmann G, Fauchon F, et al. Vertebral metastases from pineoblastoma. Arch Pathol Lab Med 2001; 125:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/44\">",
"      Bruce JN, Stein BM. Pineal tumors. Neurosurg Clin N Am 1990; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/45\">",
"      Mena H, Rushing EJ, Ribas JL, et al. Tumors of pineal parenchymal cells: a correlation of histological features, including nucleolar organizer regions, with survival in 35 cases. Hum Pathol 1995; 26:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/46\">",
"      Cohan JN, Moliterno JA, Mok CL, et al. Pineal parenchymal tumor of intermediate differentiation with papillary features: a continuum of primary pineal tumors? J Neurooncol 2011; 101:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/47\">",
"      Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/48\">",
"      Fakhran S, Escott EJ. Pineocytoma mimicking a pineal cyst on imaging: true diagnostic dilemma or a case of incomplete imaging? AJNR Am J Neuroradiol 2008; 29:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/49\">",
"      Barboriak DP, Lee L, Provenzale JM. Serial MR imaging of pineal cysts: implications for natural history and follow-up. AJR Am J Roentgenol 2001; 176:737.",
"     </a>",
"    </li>",
"    <li>",
"     Taveras JM, Pile-Spellman J. Neuroradiology, 3rd, Lippincott, Williams and Wilkins, 1996. p.617.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/51\">",
"      Sato TS, Kirby PA, Buatti JM, Moritani T. Papillary tumor of the pineal region: report of a rapidly progressive tumor with possible multicentric origin. Pediatr Radiol 2009; 39:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/52\">",
"      Buffenoir K, Rigoard P, Wager M, et al. Papillary tumor of the pineal region in a child: case report and review of the literature. Childs Nerv Syst 2008; 24:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/53\">",
"      Amemiya S, Shibahara J, Aoki S, et al. Recently established entities of central nervous system tumors: review of radiological findings. J Comput Assist Tomogr 2008; 32:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/54\">",
"      Chang SM, Lillis-Hearne PK, Larson DA, et al. Pineoblastoma in adults. Neurosurgery 1995; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/55\">",
"      Hinkes BG, von Hoff K, Deinlein F, et al. Childhood pineoblastoma: experiences from the prospective multicenter trials HIT-SKK87, HIT-SKK92 and HIT91. J Neurooncol 2007; 81:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/56\">",
"      Deshmukh VR, Smith KA, Rekate HL, et al. Diagnosis and management of pineocytomas. Neurosurgery 2004; 55:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/57\">",
"      F&egrave;vre-Montange M, Hasselblatt M, Figarella-Branger D, et al. Prognosis and histopathologic features in papillary tumors of the pineal region: a retrospective multicenter study of 31 cases. J Neuropathol Exp Neurol 2006; 65:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/58\">",
"      F&egrave;vre-Montange M, Grand S, Champier J, et al. Bcl-2 expression in a papillary tumor of the pineal region. Neuropathology 2008; 28:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/59\">",
"      Rieger A, Rainov NG, Brucke M, et al. Endoscopic third ventriculostomy is the treatment of choice for obstructive hydrocephalus due to pediatric pineal tumors. Minim Invasive Neurosurg 2000; 43:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/60\">",
"      Pople IK, Athanasiou TC, Sandeman DR, Coakham HB. The role of endoscopic biopsy and third ventriculostomy in the management of pineal region tumours. Br J Neurosurg 2001; 15:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/61\">",
"      Shima H, Nishizaki T, Ishihara H, et al. Recurrent intracranial germinoma with dissemination along the ventricular catheter: a case report. J Clin Neurosci 2002; 9:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/62\">",
"      Bamberg M, Kortmann RD, Calaminus G, et al. Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 1999; 17:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/63\">",
"      Gururangan S, Heideman RL, Kovnar EH, et al. Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts. Med Pediatr Oncol 1994; 22:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/64\">",
"      Gilheeney SW, Saad A, Chi S, et al. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol 2008; 89:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/65\">",
"      Schild SE, Scheithauer BW, Haddock MG, et al. Histologically confirmed pineal tumors and other germ cell tumors of the brain. Cancer 1996; 78:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/66\">",
"      Kobayashi T, Kida Y, Mori Y. Stereotactic gamma radiosurgery for pineal and related tumors. J Neurooncol 2001; 54:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/67\">",
"      Hasegawa T, Kondziolka D, Hadjipanayis CG, et al. The role of radiosurgery for the treatment of pineal parenchymal tumors. Neurosurgery 2002; 51:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/68\">",
"      Mori Y, Kobayashi T, Hasegawa T, et al. Stereotactic radiosurgery for pineal and related tumors. Prog Neurol Surg 2009; 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/69\">",
"      Maarouf M, El Majdoub F, B&uuml;hrle C, et al. Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery. Strahlenther Onkol 2010; 186:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/70\">",
"      Ghim TT, Davis P, Seo JJ, et al. Response to neoadjuvant chemotherapy in children with pineoblastoma. Cancer 1993; 72:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/71\">",
"      Ashley DM, Longee D, Tien R, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Med Pediatr Oncol 1996; 26:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/72\">",
"      Kurisaka M, Arisawa M, Mori T, et al. Combination chemotherapy (cisplatin, vinblastin) and low-dose irradiation in the treatment of pineal parenchymal cell tumors. Childs Nerv Syst 1998; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/73\">",
"      Jakacki RI. Pineal and nonpineal supratentorial primitive neuroectodermal tumors. Childs Nerv Syst 1999; 15:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/74\">",
"      Jakacki RI, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group. J Clin Oncol 1995; 13:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/75\">",
"      Reddy AT, Janss AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000; 88:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/76\">",
"      Duffner PK, Cohen ME, Sanford RA, et al. Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol 1995; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/77\">",
"      Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol 1995; 13:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/78\">",
"      Timmermann B, Kortmann RD, K&uuml;hl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006; 24:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/79\">",
"      Johnston DL, Keene DL, Lafay-Cousin L, et al. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. J Neurooncol 2008; 86:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/80\">",
"      Fangusaro J, Finlay J, Sposto R, et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 2008; 50:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/81\">",
"      Chintagumpala M, Hassall T, Palmer S, et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 2009; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/82\">",
"      Kivel&auml; T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/83\">",
"      Ibarra MS, O'Brien JM. Is screening for primitive neuroectodermal tumors in patients with unilateral retinoblastoma necessary? J AAPOS 2000; 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/84\">",
"      Holladay DA, Holladay A, Montebello JF, Redmond KP. Clinical presentation, treatment, and outcome of trilateral retinoblastoma. Cancer 1991; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/85\">",
"      Malik RK, Friedman HS, Djang WT, et al. Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide. Am J Ophthalmol 1986; 102:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/86\">",
"      Dunkel IJ, Jubran RF, Gururangan S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer 2010; 54:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/87\">",
"      Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/88\">",
"      Konovalov AN, Spallone A, Pitzkhelauri DI. Meningioma of the pineal region: a surgical series of 10 cases. J Neurosurg 1996; 85:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/89\">",
"      Menon G, Nair S, Sudhir J, et al. Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir (Wien) 2009; 151:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/90\">",
"      Rushing EJ, Olsen C, Mena H, et al. Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 2005; 103:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/91\">",
"      Matushita H, Pinto FC, Plese JP. Meningiomas of pineal region in children. Arq Neuropsiquiatr 2007; 65:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/92\">",
"      Miyazawa T, Fukui S, Otani N, et al. Peduncular hallucinosis due to a pineal meningioma. Case report. J Neurosurg 2001; 95:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/93\">",
"      Madawi AA, Crockard HA, Stevens JM. Pineal region meningioma without dural attachment. Br J Neurosurg 1996; 10:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/94\">",
"      Sener RN. The pineal gland: a comparative MR imaging study in children and adults with respect to normal anatomical variations and pineal cysts. Pediatr Radiol 1995; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/95\">",
"      Engel U, Gottschalk S, Niehaus L, et al. Cystic lesions of the pineal region--MRI and pathology. Neuroradiology 2000; 42:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/96\">",
"      Fleege MA, Miller GM, Fletcher GP, et al. Benign glial cysts of the pineal gland: unusual imaging characteristics with histologic correlation. AJNR Am J Neuroradiol 1994; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/97\">",
"      Cauley KA, Linnell GJ, Braff SP, Filippi CG. Serial follow-up MRI of indeterminate cystic lesions of the pineal region: experience at a rural tertiary care referral center. AJR Am J Roentgenol 2009; 193:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/98\">",
"      Al-Holou WN, Maher CO, Muraszko KM, Garton HJ. The natural history of pineal cysts in children and young adults. J Neurosurg Pediatr 2010; 5:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/99\">",
"      Musolino A, Cambria S, Rizzo G, Cambria M. Symptomatic cysts of the pineal gland: stereotactic diagnosis and treatment of two cases and review of the literature. Neurosurgery 1993; 32:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/100\">",
"      Sawamura Y, Ikeda J, Ozawa M, et al. Magnetic resonance images reveal a high incidence of asymptomatic pineal cysts in young women. Neurosurgery 1995; 37:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/101\">",
"      Hajdu SI, Porro RS, Lieberman PH, Foote FW Jr. Degeneration of the pineal gland of patients with cancer. Cancer 1972; 29:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/102\">",
"      Fetell MR, Bruce JN, Burke AM, et al. Non-neoplastic pineal cysts. Neurology 1991; 41:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/103\">",
"      Wisoff JH, Epstein F. Surgical management of symptomatic pineal cysts. J Neurosurg 1992; 77:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/104\">",
"      Vaquero J, Ramiro J, Mart&iacute;nez R, Bravo G. Neurosurgical experience with tumours of the pineal region at Clinica Puerta de Hierro. Acta Neurochir (Wien) 1992; 116:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/20/16714/abstract/105\">",
"      Hellwig D, Bauer BL, List-Hellwig E. Stereotactic endoscopic interventions in cystic brain lesions. Acta Neurochir Suppl 1995; 64:59.",
"     </a>",
"    </li>",
"    <li>",
"     Neuroradiology, Taveras JM, Pile-Spellman J (Eds), Lippincott, Williams and Wilkins, Baltimore 1996. p.617.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5192 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16714=[""].join("\n");
var outline_f16_20_16714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTING FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pineal parenchymal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glial tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nonneoplastic lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Staging work-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Stereotactic biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Open surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PINEAL PARENCHYMAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Histogenesis and histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pineocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pineoblastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - PPTs of intermediate differentiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Papillary tumor of the pineal region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Neuroradiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - CSF diversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Chemotherapy as part of multimodality therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Trilateral retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      INTRACRANIAL GERM CELL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      GLIOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PINEAL MENINGIOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PINEAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Symptomatic cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5192|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/9/39063\" title=\"figure 1\">",
"      Subarachnoid spaces and cisterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/49/15134\" title=\"table 1\">",
"      WHO nervous system tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/29/8667\" title=\"table 2\">",
"      WHO IGCTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/0/15371\" title=\"table 3\">",
"      Symptoms pineal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/52/12107\" title=\"table 4\">",
"      Parinaud syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2071?source=related_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30105?source=related_link\">",
"      Pediatric intracranial germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_20_16715="Lab practices to avoid Brucella exposure";
var content_f16_20_16715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for safe laboratory practices to avoid exposure to",
"    <em>",
"     Brucella",
"    </em>",
"    spp.",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       When brucellosis is suspected, clinicians or forwarding laboratories should note on the laboratory submission: \"Suspect or rule out brucellosis.\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Review laboratory containment methods and microbiologic procedures to ensure compliance with recommendations in the",
"       <em>",
"        Biosafety in Microbiological and Biomedical Laboratories, Fifth Edition",
"       </em>",
"       .",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use primary barriers (ie, safety centrifuge cups, personal protective equipment, and Class II or higher biological safety cabinets [BSCs]) for procedures with a high likelihood of producing droplet splashes or aerosols.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use secondary barriers: restrict access to the laboratory when work is being performed and maintain the integrity of the laboratory air-handling system by keeping external doors and windows closed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avoid causing splashes or aerosols when performing procedures on unidentified isolates.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prohibit sniffing of open culture plates to assist in the identification of isolates.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Manipulate isolates of small gram-negative or gram-variable rods initially inside a BSC.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: MMWR Surveill Summ 2008; 57:39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16715=[""].join("\n");
var outline_f16_20_16715=null;
var title_f16_20_16716="Headache causes in children";
var content_f16_20_16716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Life-threatening and common causes of headache in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Bacterial meningitis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Viral encephalitis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Orbital or cerebral abscess",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Viral infection, including viral meningitis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Pharyngitis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Otitis media",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Sinusitis",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Dental infection",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Increased intracranial pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Tumor",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Hydrocephalus",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Intracranial hemorrhage",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic intracranial hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Carbon monoxide poisoning",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        Hypertensive encephalopathy",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temporomandibular joint dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cluster headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary headache",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Migraine",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"green\">",
"        Tension-type headache",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic daily headache",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <span class=\"red\">",
"     Red:",
"    </span>",
"    life-threatening conditions.",
"    <br>",
"     <span class=\"green\">",
"      Green:",
"     </span>",
"     common conditions.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16716=[""].join("\n");
var outline_f16_20_16716=null;
var title_f16_20_16717="Major language milestones";
var content_f16_20_16717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major speech, language, and communication milestones*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expressive language skill",
"       </td>",
"       <td class=\"subtitle1\">",
"        Receptive language skill",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gestural communication skill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth to 2 months",
"       </td>",
"       <td>",
"        Cries",
"       </td>",
"       <td>",
"        Turns toward sound",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        2 to 4 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Coos (makes open vowel sounds: \"ooh\"; \"aah\")",
"       </td>",
"       <td>",
"        Social smile",
"       </td>",
"       <td rowspan=\"2\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Watches faces intently",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        Babbles (repetitive consonant-vowel combinations (\"bababa\"; \"mamama\")",
"       </td>",
"       <td>",
"        Responds to name",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        12 months",
"       </td>",
"       <td>",
"        Says first word/word approximation",
"       </td>",
"       <td>",
"        Follows one-step verbal command with gesture (eg, \"Give me the ball\")",
"       </td>",
"       <td>",
"        Visually follows adult's pointing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uses jargon/babbles with inflection",
"       </td>",
"       <td rowspan=\"2\">",
"        Responds to \"no\" (eg, stops activity)",
"       </td>",
"       <td>",
"        Points to request (12-14 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeats sounds or gestures to get attention",
"       </td>",
"       <td>",
"        Starts to use gestures (eg, shaking head \"no\")",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        15 to 18 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Points to common body parts when named",
"       </td>",
"       <td rowspan=\"2\">",
"        Follows one-step verbal command without gesture",
"       </td>",
"       <td>",
"        Points to share attention/enjoyment with another person (not just to request things)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shows objects to another person",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        18 to 24 months",
"       </td>",
"       <td>",
"        Uses&bull; two-word phrases (\"Mommy milk\"; \"go outside\")",
"       </td>",
"       <td>",
"        Points to objects or people when named",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        24 to 36 months",
"       </td>",
"       <td>",
"        Answers simple questions (\"What's your name?\"; \"Who's that?\")",
"       </td>",
"       <td rowspan=\"2\">",
"        Follows two-step verbal command",
"       </td>",
"       <td rowspan=\"2\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 percent intelligible",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        36 to 48 months",
"       </td>",
"       <td>",
"        Uses four- to five-word sentences",
"       </td>",
"       <td rowspan=\"3\">",
"        Understands placement in space (on, in, under)",
"       </td>",
"       <td rowspan=\"3\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uses pronouns and some plurals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 percent intelligible",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        48 to 72 months",
"       </td>",
"       <td>",
"        Uses full sentences with grammatical markings (eg, plurals, verb endings)",
"       </td>",
"       <td rowspan=\"2\">",
"        Follows three-step verbal command",
"       </td>",
"       <td rowspan=\"2\">",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 percent intelligible",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A general knowledge of skills that are typical for age (milestones/50th percentile skills) is important in order to conduct general developmental surveillance in primary care. However, milestones are not particularly helpful in making decisions about which children may require more formal evaluation or closer monitoring. This is because of the significant variability in the normal range of development of different skills in young children. Red flags (usually the 90th percentile for skill attainment) are more helpful in clinical decision-making",
"     <sup>",
"      [1]",
"     </sup>",
"     .",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Young children's use of words implies spontaneous expression of words or word approximation to communicate a request or to interact with another person. Echoing or immediately repeating words spoken by a caregiver does not constitute having or using words in the meaning of the milestone.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Sices, L. Use of developmental milestones in pediatric residency training and practice: time to rethink the meaning of the mean. J Dev Behav Pediatr 2007; 28:47.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16717=[""].join("\n");
var outline_f16_20_16717=null;
var title_f16_20_16718="Pulmonary complications of allogeneic HCT - Postengraftment";
var content_f16_20_16718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary complications of allogeneic hematopoietic cell transplantation: Postengraftment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease process",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Useful diagnostic tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lung biopsy needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bacterial pneumonia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Focal or patchy consolidation, may be peribronchial",
"        </p>",
"        <p>",
"         Occasionally mass-like \"round-pneumonia\"",
"        </p>",
"       </td>",
"       <td>",
"        Legionella urinary antigen, blood and BAL cultures, special stains/cultures for Actinomycosis and Nocardia",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mycobacterial pneumonia",
"       </td>",
"       <td>",
"        Total body irradiation, chronic GVHD",
"       </td>",
"       <td>",
"        M. haemophilum is associated with skin nodules and/or joint inflammation",
"       </td>",
"       <td>",
"        Miliary pattern",
"       </td>",
"       <td>",
"        PPD after HCT not helpful; cultures of sputum and BAL are helpful",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        CMV pneumonitis",
"       </td>",
"       <td>",
"        Seropositive recipient with seronegative donor; delayed reconstitution, prior treatment for CMV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        CT: patchy or diffuse ground-glass opacities, patchy consolidation, small nodular opacities; rarely tree-in-bud pattern",
"       </td>",
"       <td>",
"        Serology, blood test for pp65 antigen or CMV PCR, BAL and endobronchial brush&nbsp;for inclusion bodies and BAL cultures for CMV",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Respiratory viruses",
"       </td>",
"       <td>",
"        Exposure to someone with active viral infection",
"       </td>",
"       <td>",
"        URI symptoms prior to onset of lower respiratory tract symptoms",
"       </td>",
"       <td>",
"        Diffuse ground glass opacities are the most common",
"       </td>",
"       <td>",
"        Culture or rapid immunofluorescence of nasopharyngeal lavage or swab and BAL fluid",
"       </td>",
"       <td>",
"        Sometimes to completely exclude other possibilities",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fungal infection (eg, invasive aspergillosis, Fusarium, Zygomycetes, Candida, Scedosporium, Pneumocystis)",
"       </td>",
"       <td>",
"        Presence and severity GVHD, older patient age, cytopenia, CMV infection",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Focal nodular and consolidative opacities, \"halo sign\", sometimes subpleural wedge-shaped densities",
"       </td>",
"       <td>",
"        Broad based cultures of blood and BAL; blood tests for &beta;-D-glucan and Aspergillus galactomannan and BAL for galactomannan",
"       </td>",
"       <td>",
"        Sometimes when cultures are negative and no response to initial therapy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Idiopathic pneumonia syndrome",
"       </td>",
"       <td>",
"        Busulfan, high dose cyclophosphamide, radiation, nonmyeloablative conditioning regimen",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Extensive opacities",
"       </td>",
"       <td>",
"        Negative blood and BAL cultures",
"       </td>",
"       <td>",
"        Yes, either transbronchial or surgical",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diffuse alveolar hemorrhage",
"       </td>",
"       <td>",
"        Underlying mucopolysaccharidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        CT: patchy or diffuse opacities with air bronchograms",
"       </td>",
"       <td>",
"        BAL showing increasingly bloody return in sequential lavages and &gt;20 percent hemosiderin-laden macrophages",
"       </td>",
"       <td>",
"        Not usually",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Connective tissue disease",
"       </td>",
"       <td>",
"        Myeloablative conditioning regimen",
"       </td>",
"       <td>",
"        Extrapulmonary manifestations such as dry mouth/dry eyes, joint pain/swelling, muscle weakness",
"       </td>",
"       <td>",
"        CT: subpleural, ground-glass opacities; septal thickening",
"       </td>",
"       <td>",
"        Autoantibody tests positive",
"       </td>",
"       <td>",
"        Often to identify specific type of interstitial pneumonitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Organizing pneumonia",
"       </td>",
"       <td>",
"        Irradiation, CMV infection, HCT associated connective tissue disease, chronic GVHD",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        CT: patchy air-space consolidation, ground-glass opacities, small nodular opacities",
"       </td>",
"       <td>",
"        Lung biopsy",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Underlying lymphoma, EBV infection in posttransplant lymphoproliferative disorder",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Nodular opacities, lymphangitic pattern",
"       </td>",
"       <td>",
"        BAL cytology and flow cytometry, biopsy",
"       </td>",
"       <td>",
"        Biopsy usually needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pulmonary alveolar proteinosis",
"       </td>",
"       <td>",
"        HCT for myeloid disorder",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Perihilar opacities in a \"bat-wing\" distribution often with air bronchograms",
"       </td>",
"       <td>",
"        Bronchoalveolar lavage showing characteristic milky appearance and positive stain for lipoproteins",
"       </td>",
"       <td>",
"        Not usually",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pulmonary cytolytic thrombi",
"       </td>",
"       <td>",
"        Chronic GVHD is a risk factor",
"       </td>",
"       <td>",
"        Low grade fever, cough",
"       </td>",
"       <td>",
"        CT: peripheral nodules",
"       </td>",
"       <td>",
"        BAL to rule out infection; lung biopsy",
"       </td>",
"       <td>",
"        Yes, findings are basophilic cytolytic thrombi in the small to medium distal pulmonary vessels with entrapped monocytes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pulmonary veno-occlusive disease",
"       </td>",
"       <td>",
"        Onset after first 100 days, chronic GVHD",
"       </td>",
"       <td>",
"        Reduced DLCO",
"       </td>",
"       <td>",
"        CXR: pleural effusion and Kerley B lines; CT chest: centrilobular ground glass opacities; no emboli on CTPA",
"       </td>",
"       <td>",
"        Right heart catheterization; BAL showing occult hemorrhage",
"       </td>",
"       <td>",
"        For definitive diagnosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Drug toxicity",
"       </td>",
"       <td>",
"        History of pneumotoxic drug use (eg, busulfan, cyclophosphamide)",
"       </td>",
"       <td>",
"        May be associated with rash, peripheral eosinophilia",
"       </td>",
"       <td>",
"        Varied",
"       </td>",
"       <td>",
"        Increased BAL eosinophils may be seen; other processes excluded by negative blood and BAL stains and cultures, negative fungal studies",
"       </td>",
"       <td>",
"        Sometimes to completely exclude other possibilities",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Radiation pneumonitis",
"       </td>",
"       <td>",
"        History of radiation therapy involving lungs",
"       </td>",
"       <td>",
"        <p>",
"         Acute: onset usually 4 to 12 weeks following irradiation",
"        </p>",
"        <p>",
"         Late: onset after 6 to 12 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Acute CT: ground-glass attenuation within the area of irradiated lung",
"        </p>",
"        <p>",
"         Late CT: linear opacities (scarring) or an area of dense consolidation and volume loss",
"        </p>",
"       </td>",
"       <td>",
"        Other processes excluded by negative blood and BAL stains and cultures, negative fungal studies",
"       </td>",
"       <td>",
"        Sometimes to completely exclude other possibilities",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bronchiolitis obliterans",
"       </td>",
"       <td>",
"        Chronic GVHD, postviral",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Initially clear, as progresses, may have mosaic ground glass opacities on CT and bronchiectasis",
"       </td>",
"       <td>",
"        <p>",
"         Spirometry",
"        </p>",
"        <p>",
"         Skin biopsy for GVHD",
"        </p>",
"       </td>",
"       <td>",
"        Sometimes if diagnosis uncertain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage; GVHD: graft-versus-host disease; PPD: purified protein derivative skin test; HCT: hematopoietic cell transplantation; CMV: cytomegalovirus; PCR: polymerase chain reaction; URI: upper respiratory infection; CT: computed tomography; EBV: Epstein-Barr virus; DLCO: diffusing capacity for carbon monoxide; CXR: chest radiograph.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16718=[""].join("\n");
var outline_f16_20_16718=null;
var title_f16_20_16719="The Philadelphia chromosome";
var content_f16_20_16719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    The Philadelphia chromosome in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    G-band ideograms (left) and partial karyotype (right) of the CML-associated chromosome translocation t(9;22)(q34;q11.2). Breakpoints are indicated with arrows on the normal chromosome homologs. Translocated segments are framed on the der(9) and Ph ideograms. The translocation results in a slightly longer chromosome 9 [der(9)] and a shorter chromosome 22 [der(22)], which is termed the Philadelphia (Ph) chromosome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Athena Cherry, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_20_16719=[""].join("\n");
var outline_f16_20_16719=null;
